
<html lang="en"     class="pb-page"  data-request-id="c2810e29-4535-41fe-9c4c-e7b544800268"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2018.61.issue-20;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.7b01843;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors" /></meta><meta name="dc.Creator" content="Yuming  Wang" /></meta><meta name="dc.Creator" content="Lijun  Li" /></meta><meta name="dc.Creator" content="Jun  Fan" /></meta><meta name="dc.Creator" content="Yang  Dai" /></meta><meta name="dc.Creator" content="Alan  Jiang" /></meta><meta name="dc.Creator" content="Meiyu  Geng" /></meta><meta name="dc.Creator" content="Jing  Ai" /></meta><meta name="dc.Creator" content="Wenhu  Duan" /></meta><meta name="dc.Description" content="Fibroblast growth factor receptors (FGFR1–4) are promising therapeutic targets in many cancers. With the resurgence of interest in irreversible inhibitors, efforts have been directed to the discove..." /></meta><meta name="Description" content="Fibroblast growth factor receptors (FGFR1–4) are promising therapeutic targets in many cancers. With the resurgence of interest in irreversible inhibitors, efforts have been directed to the discove..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 9, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01843" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01843" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01843" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01843" /></link>
        
    
    

<title>Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01843" /></meta><meta property="og:title" content="Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0020.jpeg" /></meta><meta property="og:description" content="Fibroblast growth factor receptors (FGFR1–4) are promising therapeutic targets in many cancers. With the resurgence of interest in irreversible inhibitors, efforts have been directed to the discovery of irreversible FGFR inhibitors. Currently, several selective irreversible inhibitors are being evaluated in clinical trials that could covalently target a conserved cysteine in the P-loop of FGFR. In this article, we used a structure-guided approach that is rationalized by a computer-aided simulation to discover the novel and irreversible pan-FGFR inhibitor, 9g, which provided superior FGFR in vitro activities and decent selectivity over VEGFR2 (vascular endothelia growth factor receptor 2). In in vivo studies, 9g displayed clear antitumor activities in NCI-H1581 and SNU-16 xenograft mice models. Additionally, the diluting method confirmed the irreversible binding of 9g to FGFR." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01843"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01843">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01843&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01843&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01843&amp;href=/doi/10.1021/acs.jmedchem.7b01843" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 9085-9104</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00951" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00049" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/acs.jmedchem.8b01414"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yuming Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuming Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuming++Wang">Yuming Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lijun Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lijun Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lijun++Li">Lijun Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jun Fan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jun Fan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jun++Fan">Jun Fan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yang Dai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yang Dai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yang++Dai">Yang Dai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alan Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alan Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alan++Jiang">Alan Jiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Meiyu Geng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Meiyu Geng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Meiyu++Geng">Meiyu Geng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jing Ai</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jing Ai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>For J.A.: phone, +86-21-50806600-2413; E-mail, <a href="/cdn-cgi/l/email-protection#dab0bbb39aa9b3b7b7f4bbb9f4b9b4"><span class="__cf_email__" data-cfemail="402a21290033292d2d6e21236e232e">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Ai">Jing Ai</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Wenhu Duan</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenhu Duan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>For W.D.: phone, +86-21-50806032; E-mail, <a href="/cdn-cgi/l/email-protection#3c4b5458495d527c4f555151125d5f125f52"><span class="__cf_email__" data-cfemail="88ffe0ecfde9e6c8fbe1e5e5a6e9eba6ebe6">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenhu++Duan">Wenhu Duan</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5084-6026" title="Orcid link">http://orcid.org/0000-0002-5084-6026</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01843&amp;href=/doi/10.1021%2Facs.jmedchem.7b01843" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 9085–9104</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 9, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 December 2017</li><li><span class="item_label"><b>Published</b> online</span>9 March 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 October 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01843" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01843</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9085%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYuming%2BWang%252C%2BLijun%2BLi%252C%2BJun%2BFan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D20%26contentID%3Dacs.jmedchem.7b01843%26title%3DDiscovery%2Bof%2BPotent%2BIrreversible%2BPan-Fibroblast%2BGrowth%2BFactor%2BReceptor%2B%2528FGFR%2529%2BInhibitors%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9104%26publicationDate%3DOctober%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01843"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4676</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01843" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yuming&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Lijun&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;Fan&quot;},{&quot;first_name&quot;:&quot;Yang&quot;,&quot;last_name&quot;:&quot;Dai&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Meiyu&quot;,&quot;last_name&quot;:&quot;Geng&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Ai&quot;},{&quot;first_name&quot;:&quot;Wenhu&quot;,&quot;last_name&quot;:&quot;Duan&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;9085-9104&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01843&quot;},&quot;abstract&quot;:&quot;Fibroblast growth factor receptors (FGFR1–4) are promising therapeutic targets in many cancers. With the resurgence of interest in irreversible inhibitors, efforts have been directed to the discovery of irreversible FGFR inhibitors. Currently, several selective irreversible inhibitors are being evaluated in clinical trials that could covalently target a conserved cysteine in the P-loop of FGFR. In this article, we used a structure-guided approach that is rationalized by a computer-aided simulation to discover the novel and irreversible pan-FGFR inhibitor, 9g, which provided superior FGFR in vitro activities and decent selectivity over VEGFR2 (vascular endothelia growth factor receptor 2). In in vivo studies, 9g displayed clear antitumor activities in NCI-H1581 and SNU-16 xenograft mice models. Additionally, the diluting method confirmed the irreversible binding of 9g to FGFR.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01843&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01843" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01843&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01843" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01843&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01843" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01843&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01843&amp;href=/doi/10.1021/acs.jmedchem.7b01843" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01843" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01843" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01843%26sid%3Dliteratum%253Aachs%26pmid%3D29522671%26genre%3Darticle%26aulast%3DWang%26date%3D2018%26atitle%3DDiscovery%2Bof%2BPotent%2BIrreversible%2BPan-Fibroblast%2BGrowth%2BFactor%2BReceptor%2B%2528FGFR%2529%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D20%26spage%3D9085%26epage%3D9104%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=291120" title="Hydrophobicity">Hydrophobicity</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/jmcmar.2018.61.issue-20/20181025/jmcmar.2018.61.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Fibroblast growth factor receptors (FGFR1–4) are promising therapeutic targets in many cancers. With the resurgence of interest in irreversible inhibitors, efforts have been directed to the discovery of irreversible FGFR inhibitors. Currently, several selective irreversible inhibitors are being evaluated in clinical trials that could covalently target a conserved cysteine in the P-loop of FGFR. In this article, we used a structure-guided approach that is rationalized by a computer-aided simulation to discover the novel and irreversible pan-FGFR inhibitor, <b>9g</b>, which provided superior FGFR in vitro activities and decent selectivity over VEGFR2 (vascular endothelia growth factor receptor 2). In in vivo studies, <b>9g</b> displayed clear antitumor activities in NCI-H1581 and SNU-16 xenograft mice models. Additionally, the diluting method confirmed the irreversible binding of <b>9g</b> to FGFR.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44462" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44462" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Fibroblast growth factor receptors (FGFR1–4) are a family of transmembrane receptor tyrosine kinases (RTKs) that serve as high affinity receptors for fibroblast growth factors (FGFs).<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> Ligand binding to the receptors induces FGFR dimerization, initiating the activations of a cascade of downstream signaling pathways such as Ras-MAPK, PI3K-Akt, STATs, and PLCγ.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> FGFR signaling has been demonstrated to mediate crucial physiological processes such as embryogenesis, tissue repair, wound healing, and angiogenesis.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Recently, accumulative evidence has indicated that aberrant signaling of the FGF/FGFR pathway has the potential to drive the pathogenesis of a broad range of human malignancies, including urothelial cancers, breast cancers, endometrial cancers, squamous lung cancers, ovarian cancers, and cholangiocarcinomas.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Additionally, the dysregulation of FGFR has also been implicated in the poor prognosis, metastatic progression, and resistance to both cytotoxic and targeted agents during clinical treatment.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9 ref10">(6−10)</a> Therefore, the inhibition of FGF/FGFR signaling pathway presents a promising option for cancer therapeutics.</div><div class="NLM_p">Several multitargeting tyrosine kinase inhibitors (TKIs) were originally adopted for the treatment of cancers that harbor aberrant FGFR such as dovitinib (TKI-258),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> lucitanib (E-3810),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> nintedanib (BIBF-1120),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and ponatinib (AP-24534);<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> however, the efficacies of these are quite variable. Although some benefits have emerged in early stage clinical trials, it is uncertain whether these multitargeting TKIs can achieve efficacious concentrations that will inhibit FGFR in clinical trials due to the dose-limiting adverse effects (in particular, the hypertension that occurs as a result of VEGFR2 inhibition).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> On the basis of these considerations, there has been an increasing interest in developing selective FGFR TKIs.</div><div class="NLM_p">More recently, several selective FGFR TKIs that bear various scaffolds have been developed; some TKIs have been evaluated in clinical trials at different stages such as <b>1</b> (AZD-4547,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> phase III), <b>2</b> (BGJ-398,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> phase II), <b>3</b> (JNJ-42756493,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> phase II), <b>4</b> (Debio-1347,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> phase I), and <b>5</b> (LY-2874455,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> phase II) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A). Most selective FGFR inhibitors are ATP-competitive inhibitors that bind to active forms of FGFRs.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Given the diverse binding modes with FGFR, the ATP-binding pocket is divided into five regions<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B and <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>C): (i) hydrophobic region I, (ii) the adenine region, (iii) hydrophobic region II, (iv) the nucleotide domain, and (v) the phosphate region. Hydrophobic region I is a selective pocket that forms van der Waals interactions and crucial H bonds with hydrophobic groups (colored in blue, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A);<a onclick="showRef(event, 'ref16 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref16 ref22 ref23 ref24">(16,22−24)</a> the adenine region is rendered as the major binding site in which heterocycle templates (colored in orange, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A) are anchored through several H bonds with a hinge;<a onclick="showRef(event, 'ref16 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref16 ref22 ref23 ref24">(16,22−24)</a> hydrophobic region II is another hydrophobic area that plays an important role in binding small molecules by interacting with lipophilic moieties (colored in gray, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A);<a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref22 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref22 ref24 ref25">(16−19,22,24,25)</a> the nucleotide domain is rarely used in binding inhibitors, whereas compound <b>5</b> has been reported to bond to this region via a H bond between the pyridine N atom (colored in yellow, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A) and Asn568 (FGFR1 residue numbering) by adapting a chairlike conformation,<a onclick="showRef(event, 'ref19 ref26'); return false;" href="javascript:void(0);" class="ref ref19 ref26">(19,26)</a> and the phosphate region forms a H bond with the amino side chain (colored in green, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A) of <b>3</b>, which may considerably contribute to the overall binding affinity and specificity.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structural analysis of the FGFR and FGFR inhibitors. (A) Representative FGFR inhibitors. (B) X-ray crystal structure of FGFR1 in complex with AMP (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GQI">3GQI</a>). (C) Five regions of the ATP binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Most clinical FGFR inhibitors present strong bioactivities against FGFR1–3 due to the high structural similarity of the three kinase domains while sparing FGFR4 as a result of its structural distinction. However, aberrations of the four FGFR paralogues have been identified in a variety of cancers. For instance, FGFR1 amplifications predominate in squamous cell lung, breast, ovarian, and urothelial cancers; FGFR2 alterations have been identified in 3.7% of gastric cancers and 7.5% of endometrial adenocarcinomas, mutations in FGFR3 are known in approximately 15% of urothelial tumors, and aberrant FGF19/FGFR4 are associated with hepatocellular carcinomas (HCCs).<a onclick="showRef(event, 'ref5 ref27'); return false;" href="javascript:void(0);" class="ref ref5 ref27">(5,27)</a> More importantly, FGFR1–4 can easily compensate for each other when one of the single pathways is blocked. Taken together, it is reasonable to infer that a molecule targeting all FGFR paralogues would provide an opportunity to satisfy the broadest medical needs for cancer therapeutics. Because suitably designed irreversible inhibitors may have higher selectivity and better efficacy than reversible ones, the first irreversible inhibitor of FGFR1–4 (FIIN-1, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) originated via a structure-guided approach, which could covalently engage a conserved cysteine in all four FGFR paralogues.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> On the basis of the same mode, FIIN-2, -3, and -4<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> and PRN1371<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> have also been reported as promising irreversible pan-FGFR inhibitors for the treatment of tumors with FGFR alterations (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). These successful covalent applications provided great inspiration for our pan-FGFR inhibitor design. First, the inhibitors covalently targeting the cysteine within FGFR1–4 could substantially and consistently suppress the activation of the four paralogues. Second, the irreversible binding mechanism is considered to be a practical solution for cases in which reversible inhibitors are less effective against drug-resistant mutants as well as tyrosine kinases with a high affinity for ATP.<a onclick="showRef(event, 'ref29 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref31">(29,31)</a> In addition, the great successes of the irreversible inhibitors, ibrutinib<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> (BTK inhibitor) and osimertinib<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (EGFR inhibitor), also encouraged us to identify a new set of irreversible inhibitors that are attractive for anti-FGFR therapies in the future. In this paper, we describe our efforts to apply a structure-guided design to discover pyrrolopyrimidine-based, potent, and irreversible pan-FGFR inhibitors.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of reported irreversible FGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00546" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00546" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design and SAR (Structure–Activity Relationship) Exploration</h3><div class="NLM_p">Commonly, covalent inhibitors have been developed by structure-guided attachment of an electrophilic moiety to a reversible inhibitor.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> To identify an appropriate chemical scaffold for our covalent design, a set of clinical molecules with various binding modes were inspected, which emphasized the adenine region and hydrophobic region I (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C) as the two pivotal binding sites that played important roles in binding FGFR inhibitors. It was reasonable to assume that chemical entities capable of occupying the two regions would provide acceptable binding affinity that is beneficial for covalent design.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> We initiated our study of the pyrrolopyrimidine fragment as the hinge-binding moiety due to its structural resemblance to purine (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Analysis of the ATP-binding pocket suggested that introducing an appropriate aromatic moiety at the C-3 position of pyrrolopyrimidine would provide considerable interactions with hydrophobic region I; thus, we directed our attention to the 3,5-dimethoxyphenyl moiety because it was the optimal aromatic group that could interact productively with this hydrophobic pocket to provide selectivity and potency.<a onclick="showRef(event, 'ref16 ref27 ref28 ref29 ref36 ref37 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref16 ref27 ref28 ref29 ref36 ref37 ref38 ref39 ref40">(16,27−29,36−40)</a> On the basis of our assumption, two motifs (pyrrolopyrimidine and 3,5-dimethoxyphenyl) formed our basic molecular scaffold (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), which was expected to fill the two pivotal regions and provide the reversible (noncovalent) binding affinity to FGFR. To determine how to best align the electrophile, the X-ray crystal structure of FGFR1 in complex with AMP (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GQI">3GQI</a>) was analyzed; we determined that the ribose moiety (5-membered ring) of AMP was in close proximity to the P-loop, which was reported to be a flexible region where Cys488 (FGFR1 residue numbering) resided.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> On the basis of this observation, we envisioned that a pyrrolidine-based linker attached to the pyrrolopyrimidine core at the N-1 position may provide a suitable length for a Michael acceptor to engage the cysteine. Compound <b>6a</b>, as the early product, was first prepared based on the design hypothesis (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design of covalent FGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To identify the pan-FGFR inhibitors, an activity-based assay was carried out by evaluating the inhibitory activities of pyrrolopyrimidines on FGFR1 and FGFR4. Compounds with acceptable biochemical activities were further profiled in a FGFR1-amplified NCI-H1581 proliferation assay. Due to the fact that covalent inhibitors interact with their target proteins time dependently, IC<sub>50</sub> values for FGFRs were carried out based on the same incubation time (60 min). As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, compound <b>6a</b> elicited promising potency in the biochemical assay of FGFR1 (IC<sub>50</sub> = 30.9 nM). Moderate impacts on the FGFR4 kinase and NCI-H1581 cell line were also observed with IC<sub>50</sub> values of 327.3 and 90.2 nM, respectively. Further analysis of hydrophobic region I suggested that an increased potency could be achieved by extending the aromatic moiety more deeply into this region. To test this hypothesis, a set of analogues with aromatic extensions were synthesized.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SARs in the Modification of Hydrophobic Region I</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0012.gif" alt="" id="GRAPHIC-d7e533-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0013.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Values are the mean ± SD of two independent assays.</p></div></div><div></div></div><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, incorporating the 5,7-dimethoxybenzo[<i>b</i>]thiophene group at the C-3 position of pyrrolopyrimidine (<b>6b</b>) noticeably improved the FGFR1/4 inhibitory activities compared with <b>6a</b> with IC<sub>50</sub> values of 2.6 and 33.2 nM, respectively; a significant increase in the cellular potency was also observed with <b>6b</b> when it was tested against the NCI-H1581 cell line (IC<sub>50</sub> < 0.3 nM). The sharp increase in inhibiting FGFR strongly supported our aforementioned hypothesis; thus, we then surveyed the influences of substituents on the benzo[<i>b</i>]thiophene ring. We found that removal of the 5-methoxy at benzo[<i>b</i>]thiophene (<b>6b</b>) to give compound <b>6c</b> further increased the biochemical potencies against FGFRs; the corresponding monomethoxy analogue, <b>6d</b>, with a lower molecular weight, was equipotent to <b>6c</b> in FGFR suppression, which indicated the similar impacts of pyrrolidine and azetidine on FGFR potencies. A comparison of <b>6d</b>–<b>f</b> revealed that introducing a methoxy at different positions in benzo[<i>b</i>]thiophene was tolerated for the biochemical activities toward FGFR1, whereas the phenomenon was variable with FGFR4. Reduced potencies on FGFR4 were observed when the methoxy group shifted from the 7-position (<b>6d</b>) to other positions (<b>6e</b>,<b>f</b>). To further understand the substitution pattern, compound <b>6g</b> with the 7-methyl at the benzo[<i>b</i>]thiophene and <b>6h</b> with no substituents were subsequently assessed. Both compounds displayed modest inhibitory activities against FGFR4, and a substantial drop in cellular potency with <b>6h</b> was observed. The obvious preference for 7-methoxy implied that a H bond may be involved within hydrophobic region I, which was supported by molecular modeling (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). However, the substantial losses in cellular potencies of <b>6e</b>–<b>f</b> indicated that an improper introduction of the methoxy may cause unfavorable interactions with hydrophobic region I and weaken the potency against FGFR. Intrigued by the 7-methoxy substitution pattern, we conducted further investigation on dimethoxy-substituted <b>6i</b>; the resulting compound displayed no highlights but moderate inactivation of FGFR4 with an IC<sub>50</sub> of 145.0 nM, which was 4-fold less potent than <b>6b</b>. Given the similar impact of pyrrolidine and azetidine on FGFR inhibition, the observed increase in <b>6b</b> was directly linked to the effect of the methoxy substituents. According to the molecular modeling (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B), we rationalized that the improved potency for FGFR4 was presumably provoked by the interaction between the 5-methoxy at the benzo[<i>b</i>]thiophene (<b>6b</b>) and Met524 (FGFR4 residue numbering) within hydrophobic region I. Considering that <b>6c</b> was almost 2-fold better than <b>6b</b> against FGFR4, we proposed that further improving the potency could be feasible by switching the 5-methoxy (<b>6b</b>) to a smaller methyl; this improvement may not only retain the interaction with Met524 but also cripple the possible steric interference between the spatially demanding methionine and the 5-methoxy. Interestingly, the replacement of 5-methoxy with 5-methyl to give <b>6j</b> considerably improved the FGFR1/4 inhibitory activities with IC<sub>50</sub> values of less than 0.3 and 6.2 nM, respectively, thus underscoring the importance of the interaction between the 5-methyl and methionine. A similar methyl–methionine interaction was also observed in compound <b>4</b>, which not only contributed to the potency to FGFR but also improved the specificity over VEGFR2.<a onclick="showRef(event, 'ref18 ref24'); return false;" href="javascript:void(0);" class="ref ref18 ref24">(18,24)</a> Attempts to alter benzo[<i>b</i>]thiophene with benzofuran caused considerable losses of FGFR inhibitory activities (<b>6k</b>–<b>l</b>). Therefore, the 5-methyl-7-methoxybenzo[<i>b</i>]thiophene segment of <b>6j</b> represented the optimal aromatic motif and formed the basis for further structural optimization.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Modeled interactions of benzo[<i>b</i>]thiophene motifs with hydrophobic region I in FGFR4 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R6V">4R6V</a>): (A) <b>6c</b> with hydrophobic region I, (B) <b>6b</b> with hydrophobic region I.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Having produced an optimized aromatic group, we turned our attention to the 4-amino pyrrolo[2,3-<i>d</i>]pyrimidine core. As summarized in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, any addition to the pyrrolopyrimidine ring (<b>7a</b>–<b>c</b>) suffered losses in biochemical and cellular assays, which indicated that even minor modifications in pyrrolopyrimidine would impair H bonding with the hinge and result in attenuated potencies. Compared to <b>6j</b>, the methylated analogue, <b>7d</b>, completely lost potencies for FGFR despite losing one hydrogen, which emphasized the critical nature of the amino group.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Effects of Substitutions on Pyrrolo[2,3-<i>d</i>]pyrimidine</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0014.gif" alt="" id="GRAPHIC-d7e740-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0015.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Values are the mean ± SD of two independent assays.</p></div></div><div></div></div><div class="NLM_p">Then, the SARs with respect to the electrophiles were investigated (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). For propylamide <b>8a</b>, notable losses in activities were observed compared with the irreversible counterpart, <b>6j</b>, indicating the significance of covalent binding for FGFR inhibition. However, the reasonable biochemical/cellular activities with <b>8a</b> reflected a considerable reversible binding affinity to FGFR, which strongly confirmed our design. Vinylsulfonamide <b>8b</b> and propiolamide <b>8c</b> exhibited inspiring inhibitions on FGFR kinases; however, their biochemical impacts translated into poor cellular potencies in the NCI-H1581 cell line. Attachments of water-solubilizing groups at the terminal position of the electrophiles (<b>8d</b>,<b>e</b>) provided good biochemical and cellular activities that were relevant to FGFR1, whereas FGFR4 was less addressed.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Activity Data for Varying the Electrophilic Motifs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0016.gif" alt="" id="GRAPHIC-d7e782-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0017.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Values are the mean ± SD of two independent assays.</p></div></div><div></div></div><div class="NLM_p">To further systematically optimize the electrophilic system, compounds containing various linkers were tested. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, increasing the size of the linker (<b>9a</b>–<b>c</b>) led to moderate potencies against FGFR4, and the cellular impacts of <b>9b</b>–<b>c</b> were also attenuated. Compounds with a flexible linker (<b>9d</b>,<b>e</b>) were unfavorable for the suppression of FGFR; in contrast, the more constrained analogue, <b>9f</b>, demonstrated improved potencies in both biochemical and cellular evaluations. This phenomenon was observed with other irreversible inhibitors and was attributed to the conformational flexibility, which may impede the formation of the covalent bond between the protein and the acrylamide moieties.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> In accordance with <b>6c</b> and <b>6d</b>, the pyrrolidine- and azetidine-based linkers (<b>6j</b> and <b>9i</b>) were well tolerated according to the excellent activities in both biochemical and cellular evaluations. Our investigation also revealed that the <i>S</i> configuration (<b>9g</b>) was more favorable than the <i>R</i> configuration (<b>9h</b>) due to the higher potencies observed with <b>9g</b>. With superior biochemical and cellular potencies, <b>9g</b> and <b>9i</b> were chosen for a pharmacokinetic study.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SARs for Optimization of the Linker Region</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0018.gif" alt="" id="GRAPHIC-d7e865-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0019.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Values are the mean ± SD of two independent assays.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Pharmacokinetic Study for Compound Selection</h3><div class="NLM_p">The preliminary pharmacokinetic evaluations were conducted in Sprague–Dawley (SD) rats. Compounds <b>9g</b> and <b>9i</b> were orally administered by gavage at a 10 mg/kg dose to male SD rats, and the pharmacokinetic parameters are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. Both compounds displayed moderate maximum concentrations and oral exposures; however, <b>9g</b> was more favorable. Therefore, compound <b>9g</b> was selected for further evaluation.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Data of <b>9g</b> and <b>9i</b> in Rats<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9g</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">2.75</td><td class="colsep0 rowsep0" align="char" char=".">77.7</td><td class="colsep0 rowsep0" align="center">277</td><td class="colsep0 rowsep0" align="char" char=".">1.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9i</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">1.67</td><td class="colsep0 rowsep0" align="char" char=".">12.0</td><td class="colsep0 rowsep0" align="center">46.4</td><td class="colsep0 rowsep0" align="char" char=".">2.11</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last"><i>T</i><sub>max</sub>, time of maximum concentration; <i>C</i><sub>max</sub>, maximum concentration; <i>T</i><sub>1/2</sub>, elimination half-life; AUC, area under the plasma concentration time curve. Experiments were carried out in male Sprague–Dawley rats (<i>n</i> = 3). Data are the mean values.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Selectivity Profile of <b>9g</b></h3><div class="NLM_p">Compound <b>9g</b> was tested against a panel of tyrosine kinases to determine its kinase selectivity. As summarized in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, <b>9g</b> effectively inhibited the activities of FGFR1–4 with IC<sub>50</sub> values of less than 0.3, 0.8, 9.4, and 5.3 nM, respectively, indicating that <b>9g</b> is a potent pan-FGFR inhibitor. Compared with <b>1</b> (FGFR4 IC<sub>50</sub> = 165 nM, literature reported data<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a>), <b>9g</b> was significantly more potent in inhibiting FGFR4, suggesting its potential use for the treatment of FGFR4-driven cancer types, such as FGF19/FGFR4-driven hepatocellular carcinoma. Moreover, <b>9g</b> displayed a more than 350-fold selectivity over recombinant VEGFR2 relative to FGFR1, and no obvious inhibitory effects were observed with the other closely related tyrosine kinases (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). These data indicated that <b>9g</b> was a selective pan-FGFR kinase inhibitor.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Kinase Selectivity Profile of <b>9g</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">tyrosine kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">tyrosine kinase</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR1</td><td class="colsep0 rowsep0" align="center"><0.3</td><td class="colsep0 rowsep0" align="center">c-Src</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR2</td><td class="colsep0 rowsep0" align="center">0.8 ± 0.1</td><td class="colsep0 rowsep0" align="center">ErbB2</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR3</td><td class="colsep0 rowsep0" align="center">9.4 ± 1.6</td><td class="colsep0 rowsep0" align="center">c-Met</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR4</td><td class="colsep0 rowsep0" align="center">5.3 ± 1.2</td><td class="colsep0 rowsep0" align="center">ABL</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR2</td><td class="colsep0 rowsep0" align="center">113.4 ± 0.6</td><td class="colsep0 rowsep0" align="center">EGFR</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR-α</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">EPH-A2</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR-β</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">ErbB4</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">IGF1R</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt-1</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">BTK</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Values are the mean ± SD of two or more independent assays.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> In Vitro Activity of Compound <b>9g</b></h3><div class="NLM_p">To assess the cellular potency of <b>9g</b>, we profiled its efficacies on FGFR-mediated cancer cell lines. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, <b>9g</b> significantly inhibited the proliferation of FGFR-driven cancer cell lines with IC<sub>50</sub> values of less than 1 nM against NCI-H1581, SNU-16, OPM-2, and RT-112, respectively. Moreover, the potent impact of <b>9g</b> on FGFR4 translated into pronounced antiproliferative effects on the Huh-7 and BaF3/TEL-FGFR4 cell lines, affording IC<sub>50</sub>s of less than 1.5 nM and less than 4.6 nM, respectively; this outcome further confirmed the potential for treatment of cancers that harbor FGF19/FGFR4 alterations. Moreover, <b>9g</b> demonstrated substantially weaker activity against the BaF3/TEL-KDR cell line (293.5 nM). Collectively, these results highlighted the antiproliferative activities of <b>9g</b> on FGFR-altered cancer cell lines and the selectivity over VEGFR2 on the cellular level.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Antiproliferative Activity of <b>9g</b> on FGFR-Addicted Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell lines</th><th class="colsep0 rowsep0" align="center">FGFR alteration</th><th class="colsep0 rowsep0" align="center"><b>9g</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>1</b></th><th class="colsep0 rowsep0" align="center"><b>2</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCI-H1581</td><td class="colsep0 rowsep0" align="left">FGFR1 amplification</td><td class="colsep0 rowsep0" align="center"><0.5</td><td class="colsep0 rowsep0" align="char" char="±">37.9 ± 2.8</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SNU-16</td><td class="colsep0 rowsep0" align="left">FGFR2 amplification</td><td class="colsep0 rowsep0" align="center"><0.1</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.2</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">OPM-2</td><td class="colsep0 rowsep0" align="left">FGFR3 amplification</td><td class="colsep0 rowsep0" align="center"><0.5</td><td class="colsep0 rowsep0" align="char" char="±">83.6 ± 5.2</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RT-112</td><td class="colsep0 rowsep0" align="left">FGFR3 amplification</td><td class="colsep0 rowsep0" align="center"><0.5</td><td class="colsep0 rowsep0" align="char" char="±">36.4 ± 3.2</td><td class="colsep0 rowsep0" align="center"><0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Huh-7</td><td class="colsep0 rowsep0" align="left">FGF19/FGFR4</td><td class="colsep0 rowsep0" align="center"><1.5</td><td class="colsep0 rowsep0" align="char" char="±">284.3 ± 22.6</td><td class="colsep0 rowsep0" align="center">57.2 ± 4.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3/TEL-FGFR4</td><td class="colsep0 rowsep0" align="left">TEL-FGFR4</td><td class="colsep0 rowsep0" align="center"><4.6</td><td class="colsep0 rowsep0" align="char" char="±">339.2 ± 30.0</td><td class="colsep0 rowsep0" align="center">132.6 ± 9.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3/TEL-KDR</td><td class="colsep0 rowsep0" align="left">TEL-KDR</td><td class="colsep0 rowsep0" align="center">293.5 ± 32.9</td><td class="colsep0 rowsep0" align="char" char="±">543.5 ± 140.2</td><td class="colsep0 rowsep0" align="center">3343.8 ± 33.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Values are the mean ± SD of two or more independent assays.</p></div></div></div><div class="NLM_p">To further elucidate the impact of <b>9g</b> on FGFR signaling, we analyzed its effects on the phosphorylation of FGFR and the major downstream signaling molecules, PLCγ and Erk. Three representative human cancer cell lines with different mechanisms of FGFR activation were used, including FGFR1-translocated myeloid leukemia cancer cells (KG-1), FGFR2-amplified gastric cancer cells (SNU-16), and FGFR3-mutated bladder cancer cells (UMUC-14). As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, <b>9g</b> significantly inhibited the phosphorylation of FGFR1 in the KG-1 cell line. In accordance with the suppressed FGFR1 phosphorylation, the phosphorylation of PLCγ and Erk (two key downstream effectors of FGFR signaling) were also substantially inhibited. Similar results were obtained in <b>9g</b>-treated SNU-16 and UMUC-14 cells. These results suggested that <b>9g</b> effectively blocked FGFR signaling, regardless of the mechanistic complexity of the FGFR activation.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>9g</b> effectively inhibits the phosphorylation of FGFR and the downstream effectors PLCγ and Erk in KG-1 (A), SNU-16 (B), and UMUC-14 (C). Cells treated with <b>9g</b> for 2 h at the indicated concentrations were lysed and subjected to Western blot analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Irreversible Assay of <b>9g</b></h3><div class="NLM_p">To ascertain if compound <b>9g</b> inhibited FGFR via irreversible binding, we used a diluting method<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> to assess this intrinsic property of <b>9g</b>. In this assay, FGFR1 kinase was preincubated with excess <b>9g</b> (or <b>1</b>) at a final concentration of 100-fold IC<sub>50</sub> at room temperature for 30 min. Then, the enzyme/inhibitor mixture was diluted to 100-fold with a reaction buffer containing ATP and peptide, and the FGFR1 kinase activity was continuously measured. The enzyme activity was determined by the percentage of peptide converted (phosphorylated) from substrate to product. After incubation with FGFR1, the recovery curve of reversible inhibitor <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) coincided with the nonpreincubation control, whereas the recovery curve of <b>9g</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) considerably decreased compared with the nonpreincubation control and was almost comparable with the control group. This assay suggested that <b>9g</b> could irreversibly bind to FGFR1 and suppress kinase activity.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>9g</b> irreversibly binds to FGFR1. Enzyme activity of FGFR1 was assayed by a Caliper EZ Reader under three different conditions: without the enzyme (background), without the compound (nonpreincubation control), and preincubated with the compound. “Conversion” here represents the enzyme activity and means “the percent of conversion of the substrate peptide”.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> In Vivo Antitumor Efficacy of Compound <b>9g</b></h3><div class="NLM_p">We assessed the in vivo efficacies of <b>9g</b> on tumors with FGFR alterations. Mice bearing xenograft tumors derived from NCI-H1581 (FGFR1-amplified) and SNU-16 (FGFR2-amplified) cells were treated orally with <b>9g</b> once daily for 14 consecutive days in the NCI-H1581 model and for 21 consecutive days in the SNU-16 model. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, <b>9g</b> dose-dependently suppressed the tumor progression in both xenograft models with a maximum tumor growth inhibition rate (TGI) of 98.9% at a dose of 100 mg/kg in the NCI-H1581 model and 85.8% at a dose of 50 mg/kg in the SNU-16 model. No severe weight loss was observed during the treatment. These results demonstrated that inhibitor <b>9g</b> was effective against tumors with FGFR genetic alterations, exhibiting potential for further study.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <b>9g</b> significantly inhibited FGFR-mediated tumor growth in vivo. (A) Tumor growth was inhibited upon <b>9g</b> treatment in NCI-H1581 xenografts. The RTVs are expressed as the mean ± SEM. Significant difference from the vehicle group was determined using a <i>t</i>-test, * <i>P</i> < 0.05, ** <i>P</i> < 0.01, *** <i>P</i> < 0.001. (B) Tumor weights are shown for day 14 after the mice were administered <b>9g</b>. (C) Body weight measurements during treatment. (D) Tumor growth was inhibited upon <b>9g</b> treatment in the SNU-16 xenografts. The RTVs are expressed as the mean ± SEM. Significant difference from the vehicle group was determined using a <i>t</i>-test, * <i>P</i> < 0.05, ** <i>P</i> < 0.01, *** <i>P</i> < 0.001. Tumor weights (E) are shown for day 21 after the mice were administered <b>9g</b>. (F) Body weight measurements during treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Molecular Docking of Compound <b>9g</b> to FGFR4</h3><div class="NLM_p">To investigate the binding modes of our inhibitors, representative compound <b>9g</b> was docked into the ATP-binding pocket of FGFR4 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R6V">4R6V</a>). As depicted in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, the 5-methyl-7-methoxybenzo[<i>b</i>]thiophene motif was anchored to hydrophobic region I via van der Waals interactions by adopting the perpendicular orientation with respect to the plane of the pyrrolopyrimidine core; a H bond was present between the oxygen atom of 7-methoxy and the backbone of Asp630. The 4-aminopyrrolopyrimidine core interacted effectively with Glu551 and Ala553 through two H bonds at the adenine region. Pyrrolidine-linked electrophilic acrylamide was poised in a suitable position to engage Cys477 (FGFR4 residue numbering) in a covalent bond. The simulated results generated a reasonable binding mode of <b>9g</b>, further strengthening our concept of this rational design.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Proposed binding mode of <b>9g</b> with FGFR4 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R6V">4R6V</a>). (A) The docked protein structure of FGFR4 is shown on the surface. (B) The atoms of <b>9g</b> are colored as follows: carbon, green; oxygen, red; nitrogen, blue; sulfur, dark yellow. The protein is shown in the cartoon, and key residues are colored as follows: carbon, yellow; oxygen, red; nitrogen, blue, sulfur, dark yellow. H bonds are indicated by red dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chemistry</h3><div class="NLM_p">The pyrrolopyrimidine compounds were prepared according to <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Commercially available 4-chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>10</b>) or <b>14</b> were modified with <i>N</i>-Boc-substituted aliphatic amines via Mitsunobu or S<sub>N</sub>2 reactions, which were transformed to the 4-amino-5-iodopyrrolo[2,3-<i>d</i>]pyrimidines (<b>12</b> and <b>16</b>) by treatment with aqueous ammonia (<a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch2" aria-label="2">2</a><named-content content-type="anchor" rid="sch3" type="simple"></named-content>). Intermediates <b>13</b>, <b>17</b>, and <b>18</b> were prepared from iodopyrrolo[2,3-<i>d</i>]pyrimidines (<b>12</b> or <b>16</b>) and boronic acids (or boronate esters) using conventional Suzuki coupling conditions. Then, intermediates <b>13</b>, <b>17</b>, and <b>18</b> were deprotected using HCl/dioxane and subsequently coupled with various electrophiles to provide the desired products.</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Target Compounds <b>6a</b>–<b>l</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HO-linker-Boc, PPh<sub>3</sub>, DIAD, THF, 0 °C to rt or <i>tert</i>-butyl 2-bromoethylcarbamate, cesium carbonate, 80 °C; (b) ammonia (aq), 110 °C; (c) boronic acids or boronate esters, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 80 °C; (d) (i) HCl/dioxane, rt, (ii) acryloyl chloride, TEA, DCM, rt.</p></p></figure><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Target Compounds <b>7a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HO-linker-Boc, PPh<sub>3</sub>, DIAD, THF, 0 °C to rt; (b) ammonia or methylamine (aq), 110 °C; (c) (7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl) boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 80 °C; (d) (i) HCl/dioxane, rt, (ii) acryloyl chloride, TEA, DCM, rt.</p></p></figure><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Target Compounds <b>8a</b>–<b>e</b>, <b>9a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl) boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 80 °C; (b) (i) HCl/dioxane, rt, (ii) acyl chloride, TEA, DCM, rt or corresponding carboxylic acid, HATU, DMF, DIPEA, rt.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50451" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50451" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We described the design and SAR exploration of pyrrolopyrimidine-based irreversible pan-FGFR inhibitors. Structural optimizations that were rationalized by computer-aided simulations led to the identification of <b>9g</b>, which exhibited excellent potencies against FGFR1–4 and acceptable selectivity over VEGFR2. On the cellular level, <b>9g</b> displayed superior antiproliferative effects on various cell lines associated with FGFR dysregulation, which was supported by the Western blot study. Despite the moderate pharmacokinetic profile of <b>9g</b>, we proposed that only a sufficient concentration pulse was required for irreversible inhibitors to bind to the target kinases and to exert an antitumor effect in vivo. The pharmacodynamics evaluations of <b>9g</b> confirmed our assumption via dose-dependent TGIs in NCI-H1581 and SNU-16 xenograft models. Moreover, the irreversible assay demonstrated that <b>9g</b> covalently bonded to the FGFR kinase.</div><div class="NLM_p last">Although our newly designed irreversible pan-FGFR inhibitor exhibited good selectivity over VEGFR2, it seems difficult to avoid the on-target side effect (i.e., hyperphosphatemia), which is commonly seen in patients treated with pan-FGFR inhibitors. Luckily, the preliminary data from clinic suggests that the issue can be managed by diet modification and drug intervention,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and we believe that this new pharmacophore and binding mode-based inhibitor, such as <b>9g</b>, would be a potential FGFR inhibitor for further drug development.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28132" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28132" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Chemistry</h3><div class="NLM_p">All starting materials and reagents were obtained from commercial suppliers or prepared according to known procedures. All starting materials and solvents were used without further purification unless otherwise noted. Chemical reactions were monitored by thin-layer chromatography (TLC), using silica gel plates with fluorescence F254 and visualized under UV light. Flash chromatography was conducted using silica gel (300–400 mesh). <sup>1</sup>H NMR and <sup>13</sup>C NMR were generated in CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, or CD<sub>3</sub>OD on Varian Mercury 300, 400, or 500 NMR spectrometers. ESI (Low resolution mass spectra) were recorded on a Thermo Fisher LCQ-DECA spectrometer; ESI (high resolution mass spectra) were determined on an Agilent G6520 Q-TOF spectrometer. All tested compounds were purified to ≥95% purity as determined by the Agilent infinity 1260 HPLC system coupled with a diode array detector (DAD) and the ZORBAX Eclipse Plus column (C18, 4.6 mm × 150 mm, 5 μm).</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> General Procedure A: Synthesis of Compounds <b>11a</b>–<b>g</b>, <b>11i</b>,<b>j</b>, <b>15a</b>–<b>c</b></h4><div class="NLM_p last">To a stirred solution of 4-chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>10</b>) or <b>14a</b>–<b>c</b> (0.5 mmol, 1.0 equiv), requisite <i>N</i>-Boc-hydroxylsubstituted amine (0.75 mmol, 1.5 equiv) and triphenylphosphine (1.0 mmol, 2.0 equiv) in anhydrous tetrahydrofuran (5 mL) were slowly added diisopropyl azodicarboxylate (1.0 mmol, 2.0 equiv) at 0 °C under argon atmosphere. The resulting mixture was subsequently warmed up to room temperature and stirred for additional 2 h (24 h for <b>11d</b>). The reaction mixture was concentrated, and the resulting residue was purified by silica gel chromatography (petroleum ether/ethyl acetate = 4:1) to afford compounds <b>11a</b>–<b>g</b>, <b>11i</b>,<b>j</b>, and <b>15a</b>–<b>c</b>.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> General Procedure B: Synthesis of Compounds <b>12a</b>–<b>j</b>, <b>16a</b>–<b>d</b></h4><div class="NLM_p last">A mixture of <b>11</b> or <b>15</b> (2.5 mmol, 1.0 equiv) and aqueous ammonia (3 mL) (aqueous methylamine for <b>16d</b>) in dioxane (4 mL) was heated in a seal tube at 110 °C for 16 h (48 h for <b>16c</b>). After cooling, the mixture was distributed in water and ethyl acetate. The organic layer was separated and washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel chromatography (dichloromethane/methanol = 99:1 to 98:2) to afford compounds <b>12a</b>–<b>j</b> and <b>16a</b>–<b>d</b>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> General Procedure C: Synthesis of Compounds <b>13a</b>–<b>l</b>, <b>17a</b>–<b>d</b>, <b>18a</b>–<b>i</b></h4><div class="NLM_p last">A mixture of appropriate boronic acid or boronate ester (3.4 mmol, 1.3 equiv), corresponding <b>12</b> or <b>16</b> (2.3 mmol, 1.0 equiv), Na<sub>2</sub>CO<sub>3</sub> (4.7 mmol, 2.0 equiv), and tetrakis(triphenylphosphine)palladium (0.12 mmol, 0.05 equiv) in dioxane (20 mL)/water (5 mL) was heated to 90 °C under argon for 6 h. After cooling, the mixture was distributed in water and ethyl acetate. The organic layer was separated and washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel chromatography (dichloromethane/methanol = 98:2) to afford compounds <b>13a</b>–<b>l</b>, <b>17a</b>–<b>d</b>, and <b>18a</b>–<b>i</b>.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> General Procedure D: Synthesis of Target Compounds <b>6a</b>–<b>l</b>, <b>7a</b>–<b>d</b>, <b>8a</b>, <b>9a</b>–<b>i</b></h4><div class="NLM_p last">To a reaction flask containing <b>13</b>, <b>17</b>, or <b>18</b> (0.21 mmol, 1.0 equiv) was added 4 N HCl/dioxane (4 mL). The reaction mixture was stirred at room temperature for 3 h, then dioxane was removed to dryness. The deprotected amine was taken up in dry dichloromethane (5 mL) and cooled to 0 °C. The solution was treated with triethylamine (0.63 mmol, 3.0 equiv) and stirred for 15 min at 0 °C. Acryloyl chloride or propionyl chloride (0.23 mmol, 1.1 equiv) was then added slowly, and the mixture was stirred at 0 °C for 30 min. After completion, the mixture was distributed in water and dichloromethane. The organic layer was separated and washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel chromatography (dichloromethane/methanol = 98:2) to afford target compounds <b>6a</b>–<b>l</b>, <b>7a</b>–<b>d</b>, <b>8a</b>, and <b>9a</b>–<b>i</b>.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> General Procedure E: Synthesis of Target Compounds <b>8c</b>–<b>e</b></h4><div class="NLM_p last">To a reaction flask containing <b>13j</b> or <b>18i</b> (0.21 mmol, 1.0 equiv) was added 4 N HCl/dioxane (4 mL). The reaction mixture was stirred at room temperature for 3 h, then dioxane was removed to dryness. The deprotected amine was taken up in dimethylforamide (4 mL) and cooled to 0 °C. Then corresponding carboxylic acid (1.2 mmol, 1.2 equiv) and 2-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate (1.5 mmol, 1.5 equiv) were added, and the solution was stirred for 15 min at 0 °C. After that <i>N</i>,<i>N</i>-diisopropyl ethylamin (4.0 mmol, 4.0 equiv) was added dropwise to the mixture at 0 °C, and the resulting mixture was stirred at room temperature overnight. After completion, the mixture was distributed in water and ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel chromatography (dichloromethane/methanol = 98:2 + 1% of aqueous ammonia) to afford target compounds <b>8c</b>–<b>e</b>.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 1-(3-(4-Amino-5-(3,5-dimethoxyphenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one (<b>6a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13a</b> following general procedure D. Yield: 47%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.32 (s, 1H), 6.97 (d, <i>J</i> = 8.4 Hz, 1H), 6.58 (s, 2H), 6.52–6.39 (m, 3H), 5.78–5.70 (m, 1H), 5.57–5.45 (m, 1H), 5.36 (s, 2H), 4.25–4.00 (m, 2H), 3.83 (s, 6H), 3.84–3.75 (m, 2H), 2.60–2.35 (m, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.52, 163.44, 160.76, 157.20, 151.65, 151.62, 150.38, 136.45, 136.42, 129.47, 129.10, 127.02, 126.97, 120.87, 120.78, 115.99, 115.90, 106.39, 106.35, 100.06, 99.99, 98.83, 55.23, 52.89, 51.62, 50.36, 49.99, 44.58, 44.05, 31.06, 29.28. HRMS <i>m</i>/<i>z</i> C<sub>21</sub>H<sub>24</sub>N<sub>5</sub>O<sub>3</sub>: calcd 394.1874, found 394.1877 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 1-(3-(4-Amino-5-(5,7-dimethoxybenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one (<b>6b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13b</b> following general procedure D. Yield: 41%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.33 (s, 1H), 7.21 (s, 1H), 7.13 (s, 0.5H), 7.09 (s, 0.5H), 6.87 (s, 1H), 6.50–6.46 (m, 2H), 6.42 (d, <i>J</i> = 5.6 Hz, 1H), 5.80–5.70 (m, 1H), 5.60 (s, 2H), 5.55–5.45 (m, 1H), 4.20–4.00 (m, 2H), 3.97 (s, 3H), 3.88 (s, 3H), 3.88–3.75 (m, 2H), 2.60–2.40 (m, 2H). HRMS <i>m</i>/<i>z</i> C<sub>23</sub>H<sub>24</sub>N<sub>5</sub>O<sub>3</sub>S: calcd 450.1594, found 450.1600 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 1-(3-(4-Amino-5-(7-methoxybenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one (<b>6c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13c</b> following general procedure D. Yield: 62%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.34 (s, 1H), 7.45–7.31 (m, 2H), 7.29 (d, <i>J</i> = 1.7 Hz, 1H), 7.14 (s, 0.5H), 7.11 (s, 0.5H), 6.81 (d, <i>J</i> = 7.8 Hz, 1H), 6.51–6.45 (m, 1H), 6.45–6.39 (m, 1H), 5.81–5.68 (m, 1H), 5.58 (s, 2H), 5.55–5.45 (m, 1H), 4.25–4.04 (m, 1H), 4.02 (s, 3H), 3.95–3.75 (m, 3H), 2.62–2.38 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.93, 164.83, 157.27, 157.22, 154.35, 152.58, 152.52, 151.08, 151.01, 142.08, 136.73, 136.58, 128.80, 128.70, 128.57, 128.18, 127.91, 126.37, 126.33, 123.23, 123.19, 121.13, 121.06, 116.28, 109.99, 109.81, 104.57, 104.52, 101.64, 101.58, 55.87, 53.74, 52.24, 51.57, 50.44, 45.00, 44.47, 32.72, 30.06. HRMS <i>m</i>/<i>z</i> C<sub>22</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 420.1489, found 420.1495 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 1-(3-(4-Amino-5-(7-methoxybenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidin-1-yl)prop-2-en-1-one (<b>6d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13d</b> following general procedure D. Yield: 45%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.31 (s, 1H), 7.44–7.30 (m, 4H), 6.81 (d, <i>J</i> = 7.5 Hz, 1H), 6.42 (dd, <i>J</i> = 16.9, 1.6 Hz, 1H), 6.24 (dd, <i>J</i> = 17.0, 10.2 Hz, 1H), 5.80–5.57 (m, 4H), 4.84–4.45 (m, 4H), 4.02 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.04, 157.32, 154.37, 152.83, 151.45, 142.06, 136.43, 128.62, 128.45, 126.39, 125.75, 123.33, 120.88, 116.31, 110.69, 104.61, 101.62, 57.81, 55.88, 55.26, 43.34. HRMS <i>m</i>/<i>z</i> C<sub>21</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 406.1332, found 406.1342 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 1-(3-(4-Amino-5-(6-methoxybenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidin-1-yl)prop-2-en-1-one (<b>6e</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13e</b> following general procedure D. Yield: 48%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.32 (s, 1H), 7.68 (d, <i>J</i> = 8.7 Hz, 1H), 7.34 (s, 2H), 7.24 (s, 1H), 7.07–7.00 (m, 1H), 6.42 (d, <i>J</i> = 17.0 Hz, 1H), 6.25 (dd, <i>J</i> = 16.9, 10.3 Hz, 1H), 5.80–5.65 (m, 2H), 5.52 (s, 2H), 4.85–4.75 (m, 1H), 4.72–4.62 (m, 1H), 4.60–4.45 (m, 2H), 3.90 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.05, 157.81, 157.34, 152.88, 151.40, 141.47, 134.38, 133.16, 128.48, 125.75, 124.31, 122.63, 120.62, 115.05, 110.71, 104.92, 101.67, 57.86, 55.82, 55.29, 43.23. HRMS <i>m</i>/<i>z</i> C<sub>21</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 406.1332, found 406.1343 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 1-(3-(4-Amino-5-(5-methoxybenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidin-1-yl)prop-2-en-1-one (<b>6f</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13f</b> following general procedure D. Yield: 57%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.32 (s, 1H), 7.71 (d, <i>J</i> = 8.8 Hz, 1H), 7.37 (s, 1H), 7.26 (s, 2H), 7.02 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 6.43 (d, <i>J</i> = 15.2 Hz, 1H), 6.25 (dd, <i>J</i> = 17.0, 10.2 Hz, 1H), 5.80–5.60 (m, 4H), 4.85–4.45 (m, 4H), 3.89 (s, 3H). HRMS <i>m</i>/<i>z</i> C<sub>21</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 406.1332, found 406.1342 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 1-(3-(4-Amino-5-(7-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one (<b>6g</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13g</b> following general procedure D. Yield: 49%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.34 (s, 1H), 7.65 (d, <i>J</i> = 8.0 Hz, 1H), 7.37–7.29 (m, 2H), 7.20–7.08 (m, 2H), 6.51–6.39 (m, 2H), 5.80–5.68 (m, 1H), 5.60 (s, 2H), 5.54–5.46 (m, 1H), 4.25–4.05 (m, 1H), 3.80–3.75 (m, 3H), 2.58 (s, 3H), 2.54–2.35 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.95, 164.85, 157.27, 157.23, 152.63, 152.56, 151.10, 151.03, 140.30, 140.17, 135.80, 135.65, 131.98, 128.81, 128.73, 128.18, 127.93, 125.45, 125.42, 125.01, 124.95, 123.62, 123.60, 121.26, 121.12, 121.02, 110.13, 109.93, 101.67, 101.58, 53.72, 52.25, 51.65, 50.43, 45.01, 44.51, 32.78, 30.11, 20.53. HRMS <i>m</i>/<i>z</i> C<sub>22</sub>H<sub>22</sub>N<sub>5</sub>OS: calcd 404.1540, found 404.1541 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 1-(3-(4-Amino-5-(benzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidin-1-yl)prop-2-en-1-one (<b>6h</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13h</b> following general procedure D. Yield: 53%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.19 (s, 1H), 7.98 (d, <i>J</i> = 7.3 Hz, 1H), 7.92 (s, 1H), 7.87 (d, <i>J</i> = 7.0 Hz, 1H), 7.46 (s, 1H), 7.45–7.32 (m, 2H), 6.56 (s, 2H), 6.38 (dd, <i>J</i> = 17.0, 10.2 Hz, 1H), 6.17 (dd, <i>J</i> = 18.0, 3.2 Hz, 1H), 5.71 (dd, <i>J</i> = 9.8, 3.0 Hz, 1H), 5.67–5.57 (m, 1H), 4.79–4.66 (m, 2H), 4.50–4.35 (m, 2H). HRMS <i>m</i>/<i>z</i> C<sub>20</sub>H<sub>18</sub>N<sub>5</sub>OS: calcd 376.1227, found 376.1232 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 1-(3-(4-Amino-5-(4,7-dimethoxybenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidin-1-yl)prop-2-en-1-one (<b>6i</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13i</b> following general procedure D. Yield: 63%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.19 (s, 1H), 7.95 (s, 1H), 7.40 (s, 1H), 6.86 (s, 2H), 6.54 (s, 2H), 6.45–6.30 (m, 1H), 6.15 (d, <i>J</i> = 17.1 Hz, 1H), 5.71 (d, <i>J</i> = 10.2 Hz, 1H), 5.68–5.55 (m, 1H), 4.78–4.65 (m, 2H), 4.48–4.35 (m, 2H), 3.91 (s, 3H), 3.88 (s, 3H). HRMS <i>m</i>/<i>z</i> C<sub>22</sub>H<sub>22</sub>N<sub>5</sub>O<sub>3</sub>S: calcd 436.1438, found 436.1446 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 1-(3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one (<b>6j</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13j</b> following general procedure D. Yield: 49%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.33 (s, 1H), 7.21 (s, 2H), 7.11 (d, <i>J</i> = 10.6 Hz, 1H), 6.63 (s, 1H), 6.50–6.39 (m, 2H), 5.79–5.68 (m, 1H), 5.60–5.42 (m, 3H), 4.24–4.02 (m, 1H), 3.99 (s, 3H), 3.93–3.70 (m, 3H), 2.62–2.50 (s, 1H), 2.48 (s, 3H), 2.45–2.33 (m, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.92, 164.82, 157.25, 157.19, 153.99, 152.46, 152.37, 151.00, 150.92, 142.12, 136.61, 136.59, 136.54, 136.48, 128.77, 128.67, 128.18, 127.90, 125.82, 122.99, 122.96, 121.03, 120.95, 116.19, 110.14, 109.98, 106.47, 106.42, 101.62, 101.57, 55.79, 53.71, 52.21, 51.54, 50.42, 44.99, 44.46, 32.69, 30.03, 22.05. HRMS <i>m</i>/<i>z</i> C<sub>23</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 434.1645, found 434.1647 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 1-(3-(4-Amino-5-(benzofuran-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one (<b>6k</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13k</b> following general procedure D. Yield: 57%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.34 (s, 1H), 7.61–7.55 (m, 1H), 7.51 (d, <i>J</i> = 7.1 Hz, 1H), 7.35 (d, <i>J</i> = 9.1 Hz, 1H), 7.31–7.25 (m, 2H), 6.85 (d, <i>J</i> = 5.5 Hz, 1H), 6.53–6.46 (m, 1H), 6.46–6.41 (m, 1H), 6.22 (s, 2H), 5.81–5.71 (m, 1H), 5.60–5.46 (m, 1H), 4.25–3.76 (m, 4H), 2.64–2.37 (m, 2H). HRMS <i>m</i>/<i>z</i> C<sub>21</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub>: calcd 374.1612, found 374.1622 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 1-(3-(4-Amino-5-(7-methoxy-5-methylbenzofuran-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidin-1-yl)prop-2-en-1-one (<b>6l</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13l</b> following general procedure D. Yield: 50%. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 8.14 (s, 1H), 8.00 (s, 1H), 6.94 (s, 2H), 6.71 (s, 1H), 6.48–6.25 (m, 2H), 5.79 (d, <i>J</i> = 10.0 Hz, 1H), 5.68–5.58 (m, 1H), 4.90–4.78 (m, 2H), 4.66–4.48 (m, 2H), 3.98 (s, 3H), 2.42 (s, 3H). HRMS <i>m</i>/<i>z</i> C<sub>22</sub>H<sub>22</sub>N<sub>5</sub>O<sub>3</sub>: calcd 404.1717, found 404.1718 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 1-(3-(4-Amino-2-chloro-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidin-1-yl)prop-2-en-1-one (<b>7a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>17a</b> following general procedure D. Yield: 49%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.36 (s, 1H), 7.23 (s, 2H), 6.66 (s, 1H), 6.42 (d, <i>J</i> = 16.9 Hz, 1H), 6.30–6.19 (m, 1H), 5.80–5.65 (m, 4H), 4.85–4.60 (m, 2H), 4.50–4.35 (m, 2H), 4.00 (s, 3H), 2.49 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.07, 158.08, 154.38, 154.00, 152.22, 141.98, 136.77, 135.55, 128.65, 125.87, 125.62, 123.32, 120.55, 116.26, 111.43, 106.65, 99.97, 57.88, 55.81, 55.31, 43.05, 22.07. HRMS <i>m</i>/<i>z</i> C<sub>22</sub>H<sub>21</sub>ClN<sub>5</sub>O<sub>2</sub>S: calcd 454.1099, found 454.1094 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 1-(3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-2-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one (<b>7b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>17b</b> following general procedure D. Yield: 54%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.21 (s, 1H), 7.19 (s, 1H), 7.05 (d, <i>J</i> = 9.7 Hz, 1H), 6.63 (s, 1H), 6.50–6.40 (m, 2H), 5.78–5.68 (m, 1H), 5.61–5.41 (m, 3H), 4.21–4.07 (m, 1H), 3.98 (s, 3H), 3.96–3.70 (m, 3H), 2.55 (s, 3H), 2.48 (s, 3H), 2.47–2.31 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.90, 164.81, 161.69, 161.51, 156.91, 156.83, 153.98, 152.03, 151.95, 142.17, 136.96, 136.83, 136.53, 136.48, 128.70, 128.61, 128.23, 127.94, 125.72, 122.69, 122.67, 120.39, 120.25, 116.17, 110.16, 109.97, 106.40, 106.36, 99.27, 99.21, 55.79, 53.25, 51.84, 51.62, 50.58, 45.08, 44.53, 32.67, 30.17, 25.71, 25.66, 22.05. HRMS <i>m</i>/<i>z</i> C<sub>24</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 448.1802, found 448.1809 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 1-(3-(2,4-Diamino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one (<b>7c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>17c</b> following general procedure D. Yield: 47%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.19 (s, 1H), 7.18 (s, 1H), 6.82 (d, <i>J</i> = 9.5 Hz, 1H), 6.62 (s, 1H), 6.50–6.36 (m, 2H), 5.78–5.66 (m, 1H), 5.39 (s, 2H), 5.35–5.20 (m, 1H), 4.71 (s, 2H), 4.17–4.02 (m, 1H), 3.99 (s, 3H), 3.94–3.65 (m, 3H), 2.47 (s, 3H), 2.45–2.30 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.88, 164.82, 159.50, 159.45, 157.89, 157.84, 153.99, 153.57, 153.51, 142.23, 137.57, 137.43, 136.42, 136.37, 128.60, 128.50, 128.31, 128.00, 125.54, 122.17, 122.13, 118.24, 118.16, 116.10, 110.54, 110.35, 106.29, 106.24, 95.86, 95.81, 55.78, 53.23, 51.74, 51.38, 50.37, 45.05, 44.51, 32.48, 29.95, 22.05. HRMS <i>m</i>/<i>z</i> C<sub>23</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub>S: calcd 449.1754, found 449.1754 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 1-(3-(5-(7-Methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-4-(methylamino)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one (<b>7d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>17d</b> following general procedure D. Yield: 44%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (s, 1H), 7.58 (s, 0.5H), 7.52 (s, 0.5H), 7.29 (s, 1H), 7.27 (s, 1H), 6.79 (s, 1H), 6.71–6.53 (m, 1H), 6.22–6.08 (m, 2H), 5.78–5.62 (m, 1H), 5.45–5.25 (m, 1H), 4.21–3.99 (m, 1H), 3.94 (s, 3H), 3.80–3.65 (m, 2H), 3.57–3.45 (m, 1H), 2.95 (d, <i>J</i> = 3.7 Hz, 3H), 2.43 (s, 3H), 2.42–2.32 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.89, 164.80, 157.47, 157.44, 154.00, 152.76, 152.71, 150.06, 149.99, 142.12, 137.11, 136.96, 136.60, 136.55, 128.73, 128.63, 128.20, 127.93, 125.90, 122.95, 122.91, 120.28, 120.21, 116.18, 109.64, 109.47, 106.42, 106.37, 101.79, 101.75, 55.80, 53.61, 52.09, 51.61, 50.46, 44.99, 44.47, 32.77, 30.05, 28.01, 22.07. HRMS <i>m</i>/<i>z</i> C<sub>24</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 448.1802, found 448.1798 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 1-(3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidin-1-yl)propan-1-one (<b>8a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13j</b> following general procedure D. Yield: 45%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.32 (s, 1H), 7.23–7.19 (m, 2H), 7.12 (s, 0.5H), 7.07 (s, 0.5H), 6.63 (s, 1H), 5.68 (s, 2H), 5.52–5.39 (m, 1H), 4.10–4.02 (m, 1H), 4.00 (s, 3H), 3.93–3.80 (m, 1H), 3.74–3.62 (m, 2H), 2.48 (s, 3H), 2.44–2.22 (m, 4H), 1.25–1.13 (m, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 172.95, 172.78, 157.26, 157.20, 153.99, 152.47, 152.38, 150.99, 150.91, 142.14, 142.12, 136.69, 136.60, 136.55, 125.82, 122.97, 122.93, 121.08, 120.98, 116.19, 110.11, 109.90, 106.47, 106.42, 101.62, 101.55, 55.80, 53.72, 52.34, 51.59, 50.30, 44.88, 44.26, 32.74, 30.19, 28.10, 27.76, 22.06, 9.05. HRMS <i>m</i>/<i>z</i> C<sub>23</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 436.1802, found 436.1797 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Synthesis of 5-(7-Methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7-(1-(vinylsulfonyl)azetidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>8b</b>)</h4><div class="NLM_p last">To a reaction flask containing <b>18i</b> (100 mg, 0.21 mmol, 1.0 equiv) was added 4 N HCl/dioxane (4 mL). The reaction mixture was stirred at room temperature for 3 h, then dioxane was removed to dryness. The deprotected amine was taken up in dry dichloromethane (5 mL). The resulting solution was treated with triethylamine (0.63 mmol, 3.0 equiv) and stirred for 15 min at 0 °C. Then 2-chloroethanesulfochloride (0.23 mmol, 1.1 equiv) was added dropwise to the mixture at 0 °C and the mixture was stirred at room temperature overnight. After completion, the mixture was distributed in water and dichloromethane. The organic layer was separated and washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel chromatography (dichloromethane/methanol = 98:2) to afford target compound <b>8b</b>. Yield: 64%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.30 (s, 1H), 7.39 (s, 1H), 7.24 (s, 2H), 6.73 (dd, <i>J</i> = 16.6, 9.9 Hz, 1H), 6.65 (s, 1H), 6.43 (d, <i>J</i> = 16.6 Hz, 1H), 6.24 (d, <i>J</i> = 9.9 Hz, 1H), 5.65–5.50 (m, 3H), 4.46–4.33 (m, 4H), 4.01 (s, 3H), 2.49 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.34, 154.01, 152.60, 151.32, 142.08, 136.67, 136.20, 131.59, 130.80, 125.88, 123.19, 121.31, 116.24, 110.86, 106.54, 101.70, 57.38, 55.82, 42.84, 22.08. HRMS <i>m</i>/<i>z</i> C<sub>21</sub>H<sub>22</sub>N<sub>5</sub>O<sub>3</sub>S<sub>2</sub>: calcd 456.1159, found 456.1158 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 1-(3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-yn-1-one (<b>8c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13j</b> following general procedure E. Yield: 34%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.31 (d, <i>J</i> = 3.0 Hz, 1H), 7.22 (s, 2H), 7.10 (d, <i>J</i> = 9.7 Hz, 1H), 6.64 (s, 1H), 5.75 (s, 2H), 5.53–5.42 (m, 1H), 4.32–4.23 (m, 0.5H), 4.12–4.02 (m, 1H), 3.99 (s, 3H), 3.96–3.84 (m, 2H), 3.75–3.66 (m, 0.5H), 3.12 (s, 0.5H), 3.07 (s, 0.5H), 2.57–2.50 (m, 1H), 2.48 (s, 3H), 2.45–2.37 (m, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.22, 157.19, 154.01, 152.44, 152.38, 151.89, 151.69, 151.02, 150.94, 142.12, 136.64, 136.61, 136.48, 136.40, 125.85, 123.05, 120.93, 120.90, 116.23, 110.32, 110.23, 106.51, 106.48, 101.65, 101.62, 78.47, 78.31, 76.43, 76.34, 55.82, 52.96, 52.71, 52.66, 43.93, 46.48, 43.99, 31.87, 30.55, 22.08. HRMS <i>m</i>/<i>z</i> C<sub>23</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 432.1489, found 432.1496 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (<i>E</i>)-1-(3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidin-1-yl)-4-(dimethylamino)but-2-en-1-one (<b>8d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13j</b> following general procedure E. Yield: 39%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.32 (s, 1H), 7.22 (s, 2H), 7.11 (d, <i>J</i> = 11.4 Hz,1H), 7.03–6.86 (m, 1H), 6.78 (d, <i>J</i> = 15.9 Hz, 0.5H), 6.61 (d, <i>J</i> = 17.7 Hz, 1.5H), 5.57 (s, 2H), 5.53–5.39 (m, 1H), 4.33–3.81 (m, 4H), 3.99 (s, 3H), 3.52 (s, 2H), 2.63 (s, 3H), 2.57 (s, 2H), 2.53–2.44 (m, 6H). HRMS <i>m</i>/<i>z</i> C<sub>26</sub>H<sub>31</sub>N<sub>6</sub>O<sub>2</sub>S: calcd 491.2224, found 491.2212 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 1-(3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidin-1-yl)-2-((dimethylamino)methyl)prop-2-en-1-one (<b>8e</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13j</b> following general procedure E. Yield: 41%. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 8.18 (s, 1H), 7.45 (d, <i>J</i> = 2.6 Hz, 1H), 7.25 (s, 1H), 7.22 (s, 1H), 6.73 (s, 1H), 5.92 (d, <i>J</i> = 10.7 Hz, 1H), 5.84 (d, <i>J</i> = 11.0 Hz, 1H), 5.46–5.32 (m, 1H), 4.25–3.58 (m, 9H), 2.70 (s, 3H), 2.62 (s, 3H), 2.58–2.47 (m, 2H), 2.46 (s, 3H). HRMS <i>m</i>/<i>z</i> C<sub>26</sub>H<sub>31</sub>N<sub>6</sub>O<sub>2</sub>S: calcd 491.2224, found 491.2210 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 1-(4-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)piperidin-1-yl)prop-2-en-1-one (<b>9a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>18a</b> following general procedure D. Yield: 53%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.30 (s, 1H), 7.20 (s, 1H), 7.19 (s, 1H), 7.13 (s, 1H), 6.68–6.56 (m, 2H), 6.31 (dd, <i>J</i> = 16.7, 1.7 Hz, 1H), 5.80–5.68 (m, 3H), 5.04–4.84 (m, 2H), 4.18 (d, <i>J</i> = 11.4 Hz, 1H), 3.98 (s, 3H), 3.40–3.32 (m, 1H), 2.95–2.75 (m, 1H), 2.47 (s, 3H), 2.25–1.80 (m, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 165.67, 157.25, 153.95, 152.10, 150.32, 142.14, 136.93, 136.48, 128.35, 127.58, 125.72, 122.67, 121.01, 116.12, 109.57, 106.33, 101.38, 55.76, 51.66, 45.29, 41.66, 33.28, 31.95, 22.03. HRMS <i>m</i>/<i>z</i> C<sub>24</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 448.1802, found 448.1805 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 1-(3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)piperidin-1-yl)prop-2-en-1-one (<b>9b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>18b</b> following general procedure D. Yield: 43%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.30 (s, 1H), 7.21 (s, 1H), 7.20 (s, 1H), 7.16 (s, 1H), 6.66–6.57 (m, 2H), 6.31 (dd, <i>J</i> = 16.9, 1.8 Hz, 1H), 5.82–5.66 (m, 3H), 4.90–4.55 (m, 2H), 4.40–4.25 (m, 0.5H), 3.99 (s, 3H), 3.45–3.10 (m, 2H), 2.90–2.70 (m, 0.5H), 2.48 (s, 3H) 2.35–1.65 (m, 4H). HRMS <i>m</i>/<i>z</i> C<sub>24</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 448.1802, found 448.1804 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i>-(4-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)cyclohexyl)acrylamide (<b>9c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>18c</b> following general procedure D. Yield: 44%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.31 (s, 1H), 7.23–7.18 (m, 3H), 6.64 (s, 1H), 6.35 (d, <i>J</i> = 16.6 Hz, 1H), 6.27–6.13 (m, 2H), 5.69 (d, <i>J</i> = 10.1 Hz, 1H), 5.55 (s, 2H), 4.70–4.55 (m, 1H), 4.40–4.30 (m, 1H), 3.99 (s, 3H), 2.48 (s, 3H), 2.15–2.20 (m, 6H), 1.90–1.80 (m, 2H). HRMS <i>m</i>/<i>z</i> C<sub>25</sub>H<sub>28</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 462.1958, found 462.1964 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-(3-((4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)methyl)pyrrolidin-1-yl)prop-2-en-1-one (<b>9d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>18d</b> following general procedure D. Yield: 48%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.32 (s, 1H), 7.22 (s, 2H), 7.11 (d, <i>J</i> = 7.2 Hz, 1H), 6.64 (s, 1H), 6.45–6.30 (m, 2H), 5.72–5.62 (m, 1H), 5.55 (s, 2H), 4.38–4.15 (m, 2H), 4.00 (s, 3H), 3.83–3.35 (m, 4H), 3.00–2.80 (m, 1H), 2.49 (s, 3H), 2.17–1.96 (m, 1H), 1.88–1.81 (m, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.75, 157.23, 157.18, 154.01, 152.62, 152.51, 151.04, 151.00, 142.20, 136.83, 136.79, 136.60, 136.51, 128.54, 128.39, 127.99, 127.95, 125.82, 125.77, 124.33, 124.31, 122.81, 122.76, 116.18, 109.51, 109.45, 106.43, 106.39, 101.34, 101.32, 55.81, 50.00, 49.30, 46.91, 46.85, 45.84, 45.22, 40.46, 38.43, 29.75, 28.13, 22.07. HRMS <i>m</i>/<i>z</i> C<sub>24</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 448.1802, found 448.1803 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-(2-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)ethyl)acrylamide (<b>9e</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>18e</b> following general procedure D. Yield: 50%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.31 (s, 1H), 7.21 (s, 1H), 7.20 (s, 1H), 7.11 (s, 1H), 7.07 (s, 1H), 6.64 (s, 1H), 6.25 (d, <i>J</i> = 17.3 Hz, 1H), 6.14–6.01 (m, 1H), 5.67–5.56 (m, 3H), 4.47–4.36 (m, 2H), 4.00 (s, 3H), 3.80–3.70 (m, 2H), 2.48 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.15, 157.31, 154.01, 152.40, 151.01, 142.17, 136.70, 136.56, 130.95, 126.56, 125.82, 125.17, 122.81, 116.19, 109.22, 106.41, 101.60, 55.80, 44.89, 40.99, 22.06. HRMS <i>m</i>/<i>z</i> C<sub>21</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 408.1489, found 408.1491 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 1-(2-((4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)methyl)pyrrolidin-1-yl)prop-2-en-1-one (<b>9f</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>18f</b> following general procedure D. Yield: 55%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.37–8.30 (m, 1H), 7.23–7.16 (m, 3H), 6.63 (s, 1H), 6.52–6.42 (m, 2H), 5.78–5.72 (m, 1H), 5.62–5.45 (m, 3H), 4.53 (s, 3H), 3.99 (s, 3H), 3.55–3.43 (m, 2H), 2.48 (s, 3H), 2.00–1.55 (m, 3H). HRMS <i>m</i>/<i>z</i> C<sub>24</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 448.1802, found 448.1803 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (<i>S</i>)-1-(3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one (<b>9g</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>18g</b> following general procedure D. Yield: 46%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.31 (s, 1H), 7.20 (s, 2H), 7.11 (d, <i>J</i> = 10.8 Hz, 1H), 6.62 (s, 1H), 6.49–6.38 (m, 2H), 5.78–5.64 (m, 3H), 5.55–5.40 (m, 1H), 4.22–3.68 (m, 4H), 3.99 (s, 3H), 2.62–2.32 (m, 2H), 2.48 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.88, 164.78, 157.32, 157.28, 153.96, 152.59, 152.54, 151.02, 150.94, 142.11, 136.67, 136.55, 136.52, 136.50, 128.72, 128.61, 128.17, 127.90, 125.78, 122.95, 122.91, 120.97, 120.90, 116.17, 110.06, 109.89, 106.43, 106.38, 101.61, 101.56, 55.77, 53.67, 52.17, 51.50, 50.39, 44.97, 44.44, 32.65, 29.99, 22.03. HRMS <i>m</i>/<i>z</i> C<sub>23</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 434.1645, found 434.1647 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (<i>R</i>)-1-(3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one (<b>9h</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>18h</b> following general procedure D. Yield: 40%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.33 (s, 1H), 7.21 (s, 2H), 7.11 (d, <i>J</i> = 10.6 Hz, 1H), 6.63 (s, 1H), 6.50–6.39 (m, 2H), 5.79–5.68 (m, 1H), 5.60–5.42 (m, 3H), 4.24–4.02 (m, 1H), 3.99 (s, 3H), 3.93–3.70 (m, 3H), 2.62–2.50 (m, 1H), 2.48 (s, 3H), 2.45–2.33 (m, 1H). HRMS <i>m</i>/<i>z</i> C<sub>23</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 434.1645, found 434.1647 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 1-(3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidin-1-yl)prop-2-en-1-one (<b>9i</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>18i</b> following general procedure D. Yield: 53%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.30 (s, 1H), 7.35 (s, 1H), 7.25–7.21 (m, 2H), 6.64 (s, 1H), 6.47–6.37 (m, 1H), 6.24 (dd, <i>J</i> = 17.0, 10.1 Hz, 1H), 5.79–5.61 (m, 4H), 4.83–4.73 (m, 1H), 4.72–4.62 (m, 1H), 4.60–4.45 (m, 2H), 3.99 (s, 3H), 2.48 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.04, 157.33, 154.02, 152.83, 151.42, 142.10, 136.63, 136.36, 128.45, 125.89, 125.76, 123.11, 120.77, 116.23, 110.83, 106.52, 101.64, 57.82, 55.81, 55.26, 43.31, 22.07. HRMS <i>m</i>/<i>z</i> C<sub>22</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>S: calcd 420.1489, found 420.1493 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>tert</i>-Butyl 3-(4-Chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>11a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>10</b> following general procedure A. Yield: 78%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.62 (s, 1H), 7.39 (s, 1H), 5.47 (s, 1H), 3.95–3.85 (m, 1H), 3.78–3.52 (m, 3H), 2.52–2.38 (m, 1H), 2.30–2.18 (m, 1H), 1.49 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 449.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>tert</i>-Butyl 3-(4-Chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidine-1-carboxylate (<b>11b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>10</b> following general procedure A. Yield: 75%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.61 (s, 1H), 7.69 (s, 1H), 5.63–5.53 (m, 1H), 4.50 (t, <i>J</i> = 8.9 Hz, 2H), 4.25–4.18 (m, 2H), 1.48 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 435.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>tert</i>-Butyl 4-(4-Chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)piperidine-1-carboxylate (<b>11c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>10</b> following general procedure A. Yield: 51%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.60 (s, 1H), 7.43 (s, 1H), 4.95–4.82 (m, 1H), 4.40–4.20 (m, 2H), 3.00–2.85 (m, 2H), 2.10–2.00 (m, 2H), 1.97–1.80 (m, 2H), 1.49 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 463.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>tert</i>-Butyl 3-(4-Chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)piperidine-1-carboxylate (<b>11d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>10</b> following general procedure A. Yield: 19%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.62 (s, 1H), 7.47 (s, 1H), 4.82–4.72 (m, 1H), 4.25–4.12 (m, 1H), 4.00–3.85 (m, 1H), 3.38–3.24 (m, 1H), 3.09–2.97 (m, 1H), 2.20–2.01 (m, 2H), 1.86–1.65 (m, 2H), 1.46 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 463.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>tert</i>-Butyl (4-(4-Chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)cyclohexyl)carbamate (<b>11e</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>10</b> following general procedure A. Yield: 73%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.59 (s, 1H), 7.50 (s, 1H), 4.78 (s, 1H), 4.75–4.65 (m, 1H), 3.91 (s, 1H), 2.08–1.88 (m, 6H), 1.87–1.74 (m, 2H), 1.47 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 477.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>tert</i>-Butyl 2-((4-Chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)methyl)pyrrolidine-1-carboxylate (<b>11f</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>10</b> following general procedure A. Yield: 45%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.59 (s, 1H), 7.41 (s, 0.5H), 7.30 (s, 0.5H), 5.09–4.95 (m, 1H), 4.53–4.28 (m, 2H), 4.22–4.10 (m, 1H), 3.48–3.15 (m, 2H), 1.90–1.70 (m, 3H), 1.50–1.36 (m, 9H). MS (ESI) <i>m</i>/<i>z</i> 463.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>tert</i>-Butyl 3-((4-Chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)methyl)pyrrolidine-1-carboxylate (<b>11g</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>10</b> following general procedure A. Yield: 51%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.61 (s, 1H), 7.37 (s, 1H), 4.28–4.20 (m, 2H), 3.49–3.30 (m, 3H), 3.16–3.05 (m, 1H), 2.80–2.70 (m, 1H), 1.98–1.85 (m, 1H), 1.70–1.60 (m, 1H), 1.45 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 463.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Synthesis of <i>tert</i>-Butyl (2-(4-Chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)ethyl)carbamate (<b>11h</b>)</h4><div class="NLM_p last">In a reaction flask, 4-chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>10</b> (100 mg, 0.4 mmol, 1.0 equiv), <i>tert</i>-butyl 2-bromoethylcarbamate (108 mg, 0.5 mmol, 1.2 equiv), and cesium carbonate (200 mg, 0.6 mmol, 1.5 equiv) were suspended in dimethylforamide (2 mL), and the mixture was stirred at 80 °C under argon for 6 h. After cooling, the mixture was distributed in water and ethyl acetate. The organic layer was separated and washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel chromatography (petroleum ether/ethyl acetate = 4:1) to afford compound <b>11h</b>. Yield: 63%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.60 (s, 1H), 7.38 (s, 1H), 4.75 (s, 1H), 4.40 (t, <i>J</i> = 6.0 Hz, 2H), 3.55–3.45 (m, 2H), 1.40 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 423.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>tert</i>-Butyl (<i>S</i>)-3-(4-Chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>11i</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>10</b> following general procedure A. Yield: 75%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.62 (s, 1H), 7.39 (s, 1H), 5.47 (s, 1H), 3.95–3.85 (m, 1H), 3.78–3.52 (m, 3H), 2.52–2.38 (m, 1H), 2.30–2.18 (m, 1H), 1.49 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 449.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>tert</i>-Butyl (<i>R</i>)-3-(4-Chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>11j</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>10</b> following general procedure A. Yield: 76%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.62 (s, 1H), 7.39 (s, 1H), 5.47 (s, 1H), 3.95–3.85 (m, 1H), 3.78–3.52 (m, 3H), 2.52–2.38 (m, 1H), 2.30–2.18 (m, 1H), 1.49 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 449.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>tert</i>-Butyl 3-(4-Amino-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>12a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>11a</b> following general procedure B. Yield: 95%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.26 (s, 1H), 7.06 (s, 1H), 5.72 (s, 2H), 5.39 (s, 1H), 3.90–3.80 (m, 1H), 3.70–3.46 (m, 3H), 2.46–2.35 (m, 1H), 2.26–2.14 (m, 1H), 1.48 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 430.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> <i>tert</i>-Butyl 3-(4-Amino-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidine-1-carboxylate (<b>12b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>11b</b> following general procedure B. Yield: 93%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.22 (s, 1H), 7.35 (s, 1H), 5.99 (s, 2H), 5.56–5.46 (m, 1H), 4.45 (t, <i>J</i> = 8.6 Hz, 2H), 4.20–4.12 (m, 2H), 1.47 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 416.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> <i>tert</i>-Butyl 4-(4-Amino-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)piperidine-1-carboxylate (<b>12c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>11c</b> following general procedure B. Yield: 91%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.25 (s, 1H), 7.08 (s, 1H), 5.79 (s, 2H), 4.85–4.73 (m, 1H), 4.40–4.20 (m, 2H), 2.98–2.82 (m, 2H), 2.06–1.96 (m, 2H), 1.91–1.77 (m, 2H), 1.47 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 444.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> <i>tert</i>-Butyl 3-(4-Amino-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)piperidine-1-carboxylate (<b>12d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>11d</b> following general procedure B. Yield: 92%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.25 (s, 1H), 7.12 (s, 1H), 5.85 (s, 2H), 4.74–4.62 (m, 1H), 4.25–4.06 (m, 1H), 3.95 (d, <i>J</i> = 13.0 Hz, 1H), 3.30–3.15 (m, 1H), 3.05–2.90 (m, 1H), 2.18–2.08 (m, 1H), 2.05–1.90 (m, 1H), 1.88–1.73(m, 1H), 1.72–1.60 (m, 1H), 1.45 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 444.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> <i>tert</i>-Butyl (4-(4-Amino-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)cyclohexyl)carbamate (<b>12e</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>11e</b> following general procedure B. Yield: 89%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.07 (s, 1H), 7.69 (s, 1H), 7.07 (d, <i>J</i> = 8.1 Hz, 1H), 6.57 (s, 2H), 4.63–4.50 (m, 1H), 3.78 (s, 1H), 2.10–1.95 (m, 2H), 1.73–1.59 (m, 6H), 1.42 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 458.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> <i>tert</i>-Butyl 2-((4-Amino-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)methyl)pyrrolidine-1-carboxylate (<b>12f</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>11f</b> following general procedure B. Yield: 90%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.21 (s, 1H), 7.06 (s, 0.5H), 6.95 (s, 0.5H), 5.95 (s, 2H), 5.00–4.87 (m, 1H), 4.41–4.07 (m, 3H), 3.41–3.15 (m, 2H), 1.90–1.70 (m, 3H), 1.50–1.35 (m, 9H). MS (ESI) <i>m</i>/<i>z</i> 444.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> <i>tert</i>-Butyl 3-((4-Amino-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)methyl)pyrrolidine-1-carboxylate (<b>12g</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>11g</b> following general procedure B. Yield: 90%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.23 (s, 1H), 7.01 (s, 1H), 5.87 (s, 2H), 4.28–4.04 (m, 2H), 3.55–3.40 (m, 2H), 3.35–3.23 (m, 1H), 3.17–3.03 (m, 1H), 2.80–2.65 (m, 1H), 1.95–1.85 (m, 1H), 1.69–1.55 (m, 1H), 1.44 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 444.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> <i>tert</i>-Butyl (2-(4-Amino-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)ethyl)carbamate (<b>12h</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>11h</b> following general procedure B. Yield: 90%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.24 (s, 1H), 7.04 (s, 1H), 5.66 (s, 2H), 5.03–4.94 (m, 1H), 4.29 (t, <i>J</i> = 5.3 Hz, 2H), 3.49 (dd, <i>J</i> = 11.7, 5.9 Hz, 2H), 1.41 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 404.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> <i>tert</i>-Butyl (<i>S</i>)-3-(4-Amino-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>12i</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>11i</b> following general procedure B. Yield: 93%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.26 (s, 1H), 7.06 (s, 1H), 5.72 (s, 2H), 5.39 (s, 1H), 3.90–3.80 (m, 1H), 3.70–3.46 (m, 3H), 2.46–2.35 (m, 1H), 2.26–2.14 (m, 1H), 1.48 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 430.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> <i>tert</i>-Butyl (<i>R</i>)-3-(4-Amino-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>12j</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>11j</b> following general procedure B. Yield: 95%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.26 (s, 1H), 7.06 (s, 1H), 5.72 (s, 2H), 5.39 (s, 1H), 3.90–3.80 (m, 1H), 3.70–3.46 (m, 3H), 2.46–2.35 (m, 1H), 2.26–2.14 (m, 1H), 1.48 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 430.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> <i>tert</i>-Butyl 3-(4-Amino-5-(3,5-dimethoxyphenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>13a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12a</b> following general procedure C. Yield: 77%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.32 (s, 1H), 7.00 (s, 1H), 6.60 (s, 2H), 6.47 (s, 1H), 5.52–5.40 (m, 1H), 5.28 (s, 2H), 3.95–3.88 (m, 1H), 3.83 (s, 6H), 3.65–3.50 (m, 3H), 2.50–2.38 (m, 1H), 2.35–2.23 (m, 1H), 1.47 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 440.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> <i>tert</i>-Butyl 3-(4-Amino-5-(5,7-dimethoxybenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>13b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12a</b> and <b>23b</b> following general procedure C. Yield: 76%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.37 (s, 1H), 7.30–7.27 (m, 1H), 7.18 (s, 1H), 6.91 (s, 1H), 6.52 (s, 1H), 5.70 (s, 2H), 5.55–5.45 (m, 1H), 4.02 (s, 3H), 3.98–3.89 (m, 1H), 3.93 (s, 3H), 3.80–3.50 (m, 3H), 2.55–2.40 (m, 1H), 2.40–2.25 (m, 1H), 1.52 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 496.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> <i>tert</i>-Butyl 3-(4-Amino-5-(7-methoxybenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>13c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12a</b> and <b>23c</b> following general procedure C. Yield: 72%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.34 (s, 1H), 7.41 (t, <i>J</i> = 7.5 Hz, 1H), 7.34 (d, <i>J</i> = 7.8 Hz, 1H), 7.30 (s, 1H), 7.16 (s, 1H), 6.81 (d, <i>J</i> = 7.7 Hz, 1H), 5.59 (s, 2H), 5.50–5.42 (m, 1H), 4.02 (s, 3H), 3.98–3.88 (m, 1H), 3.76–3.52 (m, 3H), 2.51–2.37 (m, 1H), 2.36–2.24 (m, 1H), 1.48 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 466.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> <i>tert</i>-Butyl 3-(4-Amino-5-(7-methoxybenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidine-1-carboxylate (<b>13d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12b</b> and <b>23c</b> following general procedure C. Yield: 75%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.31 (s, 1H), 7.44 (s, 1H), 7.42–7.31 (m, 3H), 6.81 (d, <i>J</i> = 7.6 Hz, 1H), 5.59 (s, 3H), 4.51 (t, <i>J</i> = 8.9 Hz, 2H), 4.30–4.21 (m, 2H), 4.02 (s, 3H), 1.49 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 452.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> <i>tert</i>-Butyl 3-(4-Amino-5-(6-methoxybenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidine-1-carboxylate (<b>13e</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12b</b> and <b>23d</b> following general procedure C. Yield: 69%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.30 (s, 1H), 7.68 (d, <i>J</i> = 8.7 Hz, 1H), 7.41 (s, 1H), 7.33 (s, 1H), 7.25 (s, 1H), 7.04 (d, <i>J</i> = 8.7 Hz, 1H), 5.73 (s, 2H), 5.65–5.58 (m, 1H), 4.51 (t, <i>J</i> = 8.9 Hz, 2H), 4.32–4.20 (m, 2H), 3.90 (s, 3H), 1.49 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 452.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> <i>tert</i>-Butyl 3-(4-Amino-5-(5-methoxybenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidine-1-carboxylate (<b>13f</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12b</b> and <b>23e</b> following general procedure C. Yield: 72%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.31 (s, 1H), 7.70 (d, <i>J</i> = 8.9 Hz, 1H), 7.42 (s, 1H), 7.26 (s, 2H), 7.02 (d, <i>J</i> = 8.8 Hz, 1H), 5.65 (s, 2H), 5.61–5.54 (m, 1H), 4.51 (t, <i>J</i> = 8.8 Hz, 2H), 4.30–4.20 (m, 2H), 3.89 (s, 3H), 1.48 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 452.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> <i>tert</i>-Butyl 3-(4-Amino-5-(7-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>13g</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12a</b> and <b>23f</b> following general procedure C. Yield: 78%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.34 (s, 1H), 7.65 (d, <i>J</i> = 7.3 Hz, 1H), 7.40–7.29 (m, 2H), 7.20–7.14 (m, 2H), 5.67 (s, 2H), 5.48 (s, 1H), 4.00–3.87 (m, 1H), 3.80–3.53 (m, 3H), 2.58 (s, 3H), 2.50–2.40 (m, 1H), 2.35–2.25 (m, 1H), 1.49 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 450.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> <i>tert</i>-Butyl 3-(4-Amino-5-(benzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidine-1-carboxylate (<b>13h</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12b</b> and 2-benzothienylboronic acid following general procedure C. Yield: 73%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.32 (s, 1H), 7.88–7.78 (m, 2H), 7.45–7.32 (m, 4H), 5.66–5.58 (m, 1H), 5.56 (s, 2H), 4.51 (t, <i>J</i> = 8.8 Hz, 2H), 4.29–4.22 (m, 2H), 1.49 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 422.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> <i>tert</i>-Butyl 3-(4-Amino-5-(4,7-dimethoxybenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidine-1-carboxylate (<b>13i</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12b</b> and <b>23a</b> following general procedure C. Yield: 71%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.30 (s, 1H), 7.47 (s, 1H), 7.42 (s, 1H), 6.71 (s, 2H), 5.65 (s, 2H), 5.62–5.55 (m, 1H), 4.50 (t, <i>J</i> = 8.8 Hz, 2H), 4.29–4.15 (m, 2H), 3.97 (s, 3H), 3.93 (s, 3H), 1.49 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 482.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> <i>tert</i>-Butyl 3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>13j</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12a</b> and <b>23h</b> following general procedure C. Yield: 73%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.33 (s, 1H), 7.22 (s, 1H), 7.21 (s, 1H), 7.14 (s, 1H), 6.64 (s, 1H), 5.63 (s, 2H), 5.50–5.40 (m, 1H), 4.00 (s, 3H), 3.97–3.88 (m, 1H), 3.75–3.52 (m, 3H), 2.49 (s, 3H), 2.47–2.39 (m, 1H), 2.35–2.25 (m, 1H), 1.48 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 480.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> <i>tert</i>-Butyl 3-(4-Amino-5-(benzofuran-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>13k</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12a</b> and benzofuran-2-boronic acid following general procedure C. Yield: 70%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.33 (s, 1H), 7.60–7.55 (m, 1H), 7.54–7.47 (m, 1H), 7.37 (s, 1H), 7.30–7.25 (m, 2H), 6.84 (s, 1H), 6.25 (s, 2H), 5.47 (s, 1H), 3.99–3.87 (m, 1H), 3.80–3.50 (m, 3H), 2.53–2.40 (m, 1H), 2.36–2.20 (m, 1H), 1.49 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 420.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> <i>tert</i>-Butyl 3-(4-Amino-5-(7-methoxy-5-methylbenzofuran-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidine-1-carboxylate (<b>13l</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12b</b> and <b>23g</b> following general procedure C. Yield: 75%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.28 (s, 1H), 7.66 (s, 1H), 6.96 (s, 1H), 6.80 (s, 1H), 6.62 (s, 1H), 6.52 (s, 2H), 5.62 (s, 1H), 4.51 (t, <i>J</i> = 9.0 Hz, 2H), 4.24 (s, 2H), 3.99 (s, 3H), 2.45 (s, 3H), 1.50 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 450.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> <i>tert</i>-Butyl 3-(2,4-Dichloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidine-1-carboxylate (<b>15a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14a</b> following general procedure A. Yield: 39%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.37 (s, 1H), 5.53−5.43 (m, 1H), 4.35–4.20 (m, 4H), 1.42 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 468.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> <i>tert</i>-Butyl 3-(4-Chloro-5-iodo-2-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>15b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14b</b> following general procedure A. Yield: 56%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.27 (s, 1H), 5.52–5.36 (m, 1H), 3.95–3.83 (m, 1H), 3.72–3.48 (m, 3H), 2.73 (s, 3H), 2.47–2.36 (m, 1H), 2.28–2.14 (m, 1H), 1.49 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 463.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> <i>tert</i>-Butyl 3-(4-Chloro-5-iodo-2-pivalamido-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>15c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14c</b> following general procedure A. Yield: 55%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.15 (s, 1H), 5.52 (s, 1H), 3.88 (dd, <i>J</i> = 11.8, 6.8 Hz, 1H), 3.70–3.45 (m, 3H), 2.50–2.40 (m, 1H), 2.23–2.12 (m, 1H), 1.48 (s, 9H), 1.34 (s, 9H).</div></div><div id="sec4_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> <i>tert</i>-Butyl 3-(4-Amino-2-chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidine-1-carboxylate (<b>16a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>15a</b> following general procedure B. Yield: 93%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.37 (s, 1H), 5.91 (s, 2H), 5.55–5.45 (m, 1H), 4.45 (t, <i>J</i> = 8.9 Hz, 2H), 4.13–4.06 (m, 2H), 1.48 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 450.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> <i>tert</i>-Butyl 3-(4-Amino-5-iodo-2-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>16b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>15b</b> following general procedure B. Yield: 92%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.98 (s, 1H), 5.64 (s, 2H), 5.45–5.32 (m, 1H), 3.91–3.82 (m, 1H), 3.65–3.45 (m, 3H), 2.53 (s, 3H), 2.45–2.30 (m, 1H), 2.22–2.10 (m, 1H), 1.48 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 444.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> <i>tert</i>-Butyl 3-(2,4-Diamino-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>16c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>15c</b> following general procedure B. Yield: 58%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.76 (s, 1H), 5.51 (s, 2H), 5.18 (s, 1H), 4.67 (s, 2H), 3.85–3.70 (m, 1H), 3.68–3.40 (m, 3H), 2.40–2.24 (m, 1H), 2.20–2.08 (m, 1H), 1.45 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 445.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> <i>tert</i>-Butyl 3-(5-Iodo-4-(methylamino)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>16d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>11a</b> following general procedure B. Yield: 88%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.35 (s, 1H), 6.98 (s, 1H), 6.08 (s, 1H), 5.38 (s, 1H), 3.90–3.80 (m, 1H), 3.70–3.48 (m, 3H), 3.16 (d, <i>J</i> = 4.9 Hz, 3H), 2.45–2.30 (m, 1H), 2.26–2.10 (m, 1H), 1.47 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 444.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> <i>tert</i>-Butyl 3-(4-Amino-2-chloro-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidine-1-carboxylate (<b>17a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>16a</b> and <b>23h</b> following general procedure C. Yield: 70%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.42 (s, 1H), 7.23 (s, 2H), 6.65 (s, 1H), 5.69 (s, 2H), 5.63–5.53 (m, 1H), 4.55–4.43 (m, 2H), 4.22–4.15 (m, 2H), 4.00 (s, 3H), 2.49 (s, 3H), 1.48 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 500.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> <i>tert</i>-Butyl 3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-2-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>17b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>16b</b> and <b>23h</b> following general procedure C. Yield: 76%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.21 (s, 1H), 7.20 (s, 1H), 7.08 (s, 1H), 6.63 (s, 1H), 5.74 (s, 2H), 5.48 (s, 1H), 3.99 (s, 3H), 3.95–3.88 (m, 1H), 3.73–3.50 (m, 3H), 2.59 (s, 3H), 2.48 (s, 3H), 2.47–2.37 (m, 1H), 2.30–2.20 (m, 1H), 1.48 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 494.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> <i>tert</i>-Butyl 3-(2,4-Diamino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>17c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>16c</b> and <b>23h</b> following general procedure C. Yield: 72%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.19 (s, 1H), 7.18 (s, 1H), 6.86 (s, 1H), 6.61 (s, 1H), 5.38 (s, 2H), 5.30–5.20 (m, 1H), 4.71 (s, 2H), 3.99 (s, 3H), 3.93–3.80 (m, 1H), 3.73–3.60 (m, 1H), 3.60–3.47 (m, 2H), 2.47 (s, 3H), 2.43–2.32 (m, 1H), 2.28–2.18 (m, 1H), 1.47 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 495.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> <i>tert</i>-Butyl 3-(5-(7-Methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-4-(methylamino)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>17d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>16d</b> and <b>23h</b> following general procedure C. Yield: 75%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.42 (s, 1H), 7.24 (s, 1H), 7.17 (s, 1H), 7.07 (s, 1H), 6.65 (s, 1H), 5.58 (s, 1H), 5.51–5.37 (m, 1H), 4.01 (s, 3H), 3.96–3.87 (m, 1H), 3.70–3.52 (m, 3H), 3.07 (d, <i>J</i> = 4.6 Hz, 3H), 2.50 (s, 3H), 2.48–2.38 (m, 1H), 2.34–2.24 (m, 1H), 1.47 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 494.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> <i>tert</i>-Butyl 4-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)piperidine-1-carboxylate (<b>18a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12c</b> and <b>23h</b> following general procedure C. Yield: 77%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.33 (s, 1H), 7.22 (s, 1H), 7.21 (s, 1H), 7.17 (s, 1H), 6.63 (s, 1H), 5.59 (s, 2H), 4.93–4.81 (m, 1H), 4.40–4.20 (m, 2H), 4.00 (s, 3H), 3.02–2.88 (m, 2H), 2.49 (s, 3H), 2.14–2.05 (m, 2H), 1.96–1.84 (m, 2H), 1.49 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 494.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> <i>tert</i>-Butyl 3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)piperidine-1-carboxylate (<b>18b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12d</b> and <b>23h</b> following general procedure C. Yield: 80%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.31 (s, 1H), 7.23–7.18 (m, 3H), 6.63 (s, 1H), 5.73 (s, 2H), 4.80–4.70 (m, 1H), 4.35–4.20 (m, 1H), 4.10–4.00 (m, 1H), 3.99 (s, 3H), 3.29–3.16 (m, 1H), 3.00–2.85 (m, 1H), 2.48 (s, 3H), 2.25–2.15 (m, 1H), 2.10–1.95 (m, 1H), 1.90–1.80 (m, 1H), 1.75–1.65 (m, 1H), 1.45 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 494.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> <i>tert</i>-Butyl (4-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)cyclohexyl)carbamate (<b>18c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12e</b> and <b>23h</b> following general procedure C. Yield: 74%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.32 (s, 1H), 7.23 (s, 1H), 7.22–7.19 (m, 2H), 6.63 (s, 1H), 5.68 (s, 2H), 4.88 (s, 1H), 4.70 (s, 1H), 3.99 (s, 3H), 3.92 (s, 1H), 2.48 (s, 3H), 2.05–1.96 (m, 4H), 1.95–1.75 (m, 4H), 1.47 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 508.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> <i>tert</i>-Butyl 3-((4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)methyl)pyrrolidine-1-carboxylate (<b>18d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12g</b> and <b>23h</b> following general procedure C. Yield: 76%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.31 (s, 1H), 7.22 (s, 2H), 7.10 (s, 1H), 6.63 (s, 1H), 5.70 (s, 2H), 4.30–4.15 (m, 2H), 4.00 (s, 3H), 3.60–3.42 (m, 2H), 3.40–3.25 (m, 1H), 3.23–3.10 (m, 1H), 2.86–2.74 (m, 1H), 2.49 (s, 3H), 2.02–1.90 (m, 1H), 1.74–1.62 (m, 1H), 1.45 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 494.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> <i>tert</i>-Butyl (2-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)ethyl)carbamate (<b>18e</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12h</b> and <b>23h</b> following general procedure C. Yield: 78%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.29 (s, 1H), 7.19 (s, 2H), 7.12 (s, 1H), 6.63 (s, 1H), 5.70 (s, 2H), 5.14 (t, <i>J</i> = 5.3 Hz, 1H), 4.36 (t, <i>J</i> = 5.2 Hz, 2H), 3.99 (s, 3H), 3.61–3.52 (m, 2H), 2.48 (s, 3H), 1.41 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 454.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> <i>tert</i>-Butyl 2-((4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)methyl)pyrrolidine-1-carboxylate (<b>18f</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12f</b> and <b>23h</b> following general procedure C. Yield: 71%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.32 (s, 1H), 7.22 (s, 1H), 7.20 (s, 1H), 7.16 (s, 0.5H), 7.07 (s, 0.5H), 6.63 (s, 1H), 5.64 (s, 2H), 4.50–4.15 (m, 3H), 4.00 (s, 3H), 3.50–3.21 (m, 2H), 2.49 (s, 3H), 2.30–1.78 (m, 4H), 1.52–1.38 (m, 9H). MS (ESI) <i>m</i>/<i>z</i> 494.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> <i>tert</i>-Butyl (<i>S</i>)-3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>18g</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12i</b> and <b>23h</b> following general procedure C. Yield: 73%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.33 (s, 1H), 7.22 (s, 1H), 7.21 (s, 1H), 7.15 (s, 1H), 6.64 (s, 1H), 5.64 (s, 2H), 5.50–5.40 (m, 1H), 4.00 (s, 3H), 3.97–3.88 (m, 1H), 3.75–3.52 (m, 3H), 2.49 (s, 3H), 2.47–2.39 (m, 1H), 2.35–2.25 (m, 1H), 1.48 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 480.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> <i>tert</i>-Butyl (<i>R</i>)-3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)pyrrolidine-1-carboxylate (<b>18h</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12j</b> and <b>23h</b> following general procedure C. Yield: 70%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.33 (s, 1H), 7.22 (s, 1H), 7.21 (s, 1H), 7.15 (s, 1H), 6.64 (s, 1H), 5.64 (s, 2H), 5.50–5.40 (m, 1H), 4.00 (s, 3H), 3.97–3.88 (m, 1H), 3.75–3.52 (m, 3H), 2.49 (s, 3H), 2.47–2.39 (m, 1H), 2.35–2.25 (m, 1H), 1.48 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 480.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> <i>tert</i>-Butyl 3-(4-Amino-5-(7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)azetidine-1-carboxylate (<b>18i</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12b</b> and <b>23h</b> following general procedure C. Yield: 74%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.30 (s, 1H), 7.42 (s, 1H), 7.24 (s, 1H), 7.23 (s, 1H), 6.64 (s, 1H), 5.68–5.57 (m, 3H), 4.50 (t, <i>J</i> = 8.8 Hz, 2H), 4.29–4.22 (m, 2H), 4.00 (s, 3H), 2.49 (s, 3H), 1.48 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 466.3 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> ELISA Kinase Assay</h3><div class="NLM_p last">The effects of indicated compounds on the activities of various tyrosine kinases were determined using enzyme-linked immunosorbent assays (ELISAs) with purified recombinant proteins. Briefly, 20 μg/mL poly(Glu, Tyr) 4:1 (Sigma, St Louis, MO, USA) was precoated in 96-well plates as a substrate. A 50 μL aliquot of 10 μM ATP solution diluted in kinase reaction buffer (50 mM HEPES [pH 7.4], 50 mM MgCl<sub>2</sub>, 0.5 mM MnCl<sub>2</sub>, 0.2 mM Na<sub>3</sub>VO<sub>4</sub>, and 1 mM DTT) was added to each well; 1 μL of various concentrations of indicated compounds diluted in 1% DMSO (v/v) (Sigma, St Louis, MO, USA) were then added to each reaction well. 1% DMSO (v/v) was used as the negative control. The kinase reaction was initiated by the addition of purified tyrosine kinase proteins diluted in 49 μL of kinase reaction buffer. After incubation for 60 min at 37 °C, the plate was washed three times with phosphate-buffered saline (PBS) containing 0.1% Tween 20 (T-PBS). Antiphosphotyrosine (PY99) antibody (100 μL; 1:500, diluted in 5 mg/mL BSA T-PBS) was then added. After a 30 min incubation at 37 °C, the plate was washed three times, and 100 μL of horseradish peroxidase-conjugated goat antimouse IgG (1:1000, diluted in 5 mg/mL BSA T-PBS) was added. The plate was then incubated at 37 °C for 30 min and washed 3 times. A 100 μL aliquot of a solution containing 0.03% H<sub>2</sub>O<sub>2</sub> and 2 mg/mL <i>o</i>-phenylenediamine in 0.1 M citrate buffer (pH 5.5) was added. The reaction was terminated by the addition of 50 μL of 2 M H<sub>2</sub>SO<sub>4</sub> as the color changed, and the plate was analyzed using a multiwell spectrophotometer (SpectraMAX190, from Molecular Devices, Palo Alto, CA, USA) at 490 nm. The inhibition rate (%) was calculated using the following equation: [1 – (A490/A490 control)] × 100%. The IC<sub>50</sub> values were calculated from the inhibition curves in two separate experiments.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> Cell Proliferation Assay</h3><div class="NLM_p last">Cells were seeded in 96-well cell culture plates. On the day when seeding, the cells were exposed to various concentrations of compounds and further cultured for 72 h at 37 °C. Cell proliferation was then determined using Cell Counts Kit-8 (CCK8) or the thiazolyl blue tetrazolium bromide (MTT, from Sigma-Aldrich, St. Louis, MO, USA) assay. The IC<sub>50</sub> values were calculated by concentration–response curve fitting using the four-parameter method.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> Pharmacokinetic Parameters Obtained in Rats</h3><div class="NLM_p last">Compound <b>9g</b> or <b>9i</b> was administrated to male Sprague–Dawley (SD) rats (<i>n</i> = 3) orally by gavage as a solution in 5% DMSO/95% (0.5% CMC-Na) at a 10 mg/kg dose. Blood samples were collected at 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h following oral dosing. The blood samples were placed on wet ice, and serum was collected after centrifugation. Serum samples were frozen and stored at −20 °C. The serum samples were analyzed utilizing HPLC-coupled tandem mass spectrometry (LC-MS/MS). All animal experiments were performed according to the institutional ethical guidelines on animal care and approved by the Institute Animal Care and Use Committee at Shanghai Institute of Materia Medica (approval no. 2015-08-ZDF-39).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> Cell Culture</h3><div class="NLM_p last">Human lung cancer cell line NCI-H1581, human acute myelogenous leukemia cell line KG-1, and human gastric cancer cell line SNU-16 were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Human bladder cancer cell line RT-112, human multiple myeloma cell line OPM-2, and mouse Pre-B cell line BaF3 were purchased from DSMZ–German Collection of Microorganisms and Cell Cultures. Human bladder cancer cell line UMUC-14 was purchased from European Collection of Cell Cultures (ECACC). All the cell lines were routinely maintained in media according to the suppliers’ recommendations and authenticated via short tandem repeats analysis by Genesky Biopharma Technology (last tested in 2016).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> Western Blot Analysis</h3><div class="NLM_p last">KG-1, SNU-16, and UMUC-14 cells were treated with the indicated dose of <b>9g</b> for 2 h and then lysed in 1× sodium dodecyl sulfate (SDS) sample buffer. The cell lysates were subsequently resolved by 10% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with the appropriate primary antibodies [phospho-FGFR, FGFR1, FGFR2, FGFR3, phospho-ERK, ERK, PLCγ (all from Cell Signaling Technology, Beverly, MA, USA), phospho-PLCγ, GAPDH (KangChen Biotech, Shanghai, China)] and then with horseradish peroxidase-conjugated antirabbit or antimouse IgG. The immunoreactive proteins were detected using an enhanced chemilluminescense detection reagent (Thermo Fisher Scientific, Rockford, IL, USA).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> Irreversible Assay</h3><div class="NLM_p last">Rapid dilution experiment was used to demonstrate reversible binding of <b>9g</b> to FGFR1. FGFR1 kinase (2 nM) was preincubated with excessive <b>9g</b> at a final concentration of 100-fold IC<sub>50</sub> under room temperature for 30 min, then the mixed solution was diluted with reaction solution containing substrate peptide (5-FAM-KKSRGDYMTMQIG-CONH<sub>2</sub>) and ATP (262 μM) to a hundred times. Then the enzyme activity of this mixture was assayed by the EZ Reader (Caliper Life Sciences, MA). Wells were repeatedly read for 1 h.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> In Vivo Antitumor Activity Assay</h3><div class="NLM_p last">Female nude mice (4–6 weeks old) were housed and maintained under specific pathogen-free conditions. Animal procedures were approved by the Institutional Animal Care and Use Committee at Shanghai Institute of Materia Medica (approval nos. 2015-04-DJ-17 for NCI-H1581 model, and 2016-04-DJ-21 for SNU-16 model). The tumor cells at a density of 5 × 10<sup>6</sup> in 200 μL were injected subcutaneously (sc) into the right flank of nude mice and then allowed to grow to 700–800 mm<sup>3</sup>, which was defined as a well-developed tumor. Subsequently, the well-developed tumors were cut into 1 mm<sup>3</sup> fragments and transplanted sc into the right flank of nude mice using a trocar. When the tumor volume reached 100–150 mm<sup>3</sup>, the mice were randomly assigned into a vehicle control group (<i>n</i> = 12) and treatment groups (<i>n</i> = 6 per group). The control groups were given vehicle alone, and the treatment groups received <b>9g</b> at the indicated doses via oral administration once daily for 2–3 weeks. AZD4547 was a positive drug. The sizes of the tumors were measured twice per week using a microcaliper. Tumor volume (TV) = (length × width<sup>2</sup>)/2, and the individual relative tumor volume (RTV) was calculated as follows: RTV = <i>V</i><sub>t</sub>/<i>V</i><sub>0</sub>, where <i>V</i><sub>t</sub> is the volume on a particular day and <i>V</i><sub>0</sub> is the volume at the beginning of the treatment. The RTV was shown on indicated days as the median RTV ± SE indicated for groups of mice. Percent (%) inhibition (TGI) values were measured on the final day of study for the drug-treated mice compared with vehicle-treated mice and were calculated as 100 × {1 – [(<i>V</i><sub>Treated Final day</sub> – <i>V</i><sub>Treated Day 0</sub>)/(<i>V</i><sub>Control Final day</sub> – <i>V</i><sub>Control Day 0)</sub>]. Significant differences between the treated versus the control groups (<i>P</i> ≤ 0.05) were determined using Student’s <i>t</i> test.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> Modeling Method</h3><div class="NLM_p last">The docking studies were carried out on AutoDock 4.2 using the X-ray crystal structure of FGFR4 in complex with FIIN-3 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R6V">4R6V</a>). The enzyme preparation and the hydrogen atoms adding were performed in the prepared process. After moving the native ligand and the irrelevant water, the FGFR4 enzyme was defined as a receptor and the enclosing box centered in native ligand was set on the basis of the binding site of FIIN-3. In the docking protocol, the Lamarchian genetic algorithm (GA) and the default parameters of GA were applied. The designed compounds were docked into the protein, then the docked complexes were clustered and sorted according to the binding energy and the binding models with the lowest binding energy were used to further reveal the binding mechanism. <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a> were generated with PyMOL version 1.3.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i120"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01843" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35807" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35807" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01843" class="ext-link">10.1021/acs.jmedchem.7b01843</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthesis of requisite boronic acids <b>23a</b>–<b>h</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01843/suppl_file/jm7b01843_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01843/suppl_file/jm7b01843_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01843/suppl_file/jm7b01843_si_001.csv">jm7b01843_si_001.csv (3.24 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01843/suppl_file/jm7b01843_si_002.pdf">jm7b01843_si_002.pdf (646.87 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R6V">4R6V</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b01843" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70706" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70706" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Ai</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese
Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#402a21290033292d2d6e21236e232e"><span class="__cf_email__" data-cfemail="93f9f2fad3e0fafefebdf2f0bdf0fd">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenhu Duan</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Shanghai Institute
of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5084-6026" title="Orcid link">http://orcid.org/0000-0002-5084-6026</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#84f3ece0f1e5eac4f7ede9e9aae5e7aae7ea"><span class="__cf_email__" data-cfemail="a8dfc0ccddc9c6e8dbc1c5c586c9cb86cbc6">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuming Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Shanghai Institute
of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lijun Li</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese
Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun Fan</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Shanghai Institute
of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yang Dai</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese
Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan Jiang</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese
Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meiyu Geng</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese
Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, P. R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.W. and L.L. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i123">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31203" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31203" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the funds from the National Natural Science Foundation (nos. 81573271 and 81773762), Strategic Priority Research Program of the Chinese Academy of Sciences (no. XDA12020303), and the Shanghai Science and Technology Commission (no. 15431901300).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">FGF</td><td class="NLM_def"><p class="first last">fibroblast growth factor</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">KDR</td><td class="NLM_def"><p class="first last">kinase insert domain receptor, also known as VEGFR2</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term">PLCγ</td><td class="NLM_def"><p class="first last">phospholipase Cγ</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transduction and activation of transcription</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">ABL</td><td class="NLM_def"><p class="first last">Abelson tyrosine kinase</p></td></tr><tr><td class="NLM_term">ErK</td><td class="NLM_def"><p class="first last">extracellular regulated protein kinases</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">RTV</td><td class="NLM_def"><p class="first last">relative tumor volume</p></td></tr><tr><td class="NLM_term">IGF1R</td><td class="NLM_def"><p class="first last">insulin-like growth factor 1 receptor</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">3-tetramethyluronium hexafluorophosphate</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i125">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45122" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45122" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 44 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grose, R.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor signalling: from development to cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1038/nrc2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1038%2Fnrc2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=20094046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=116-129&author=N.+Turnerauthor=R.+Grose&title=Fibroblast+growth+factor+signalling%3A+from+development+to+cancer&doi=10.1038%2Fnrc2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signalling: from development to cancer</span></div><div class="casAuthors">Turner, Nicholas; Grose, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their receptors control a wide range of biol. functions, regulating cellular proliferation, survival, migration and differentiation.  Although targeting FGF signalling as a cancer therapeutic target has lagged behind that of other receptor tyrosine kinases, there is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumor types, and clin. reagents that specifically target the FGFs or FGF receptors are being developed.  Although FGF signalling can drive tumorigenesis, in different contexts FGF signalling can mediate tumor protective functions; the identification of the mechanisms that underlie these differential effects will be important to understand how FGF signalling can be most appropriately therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUBfz6uAu97bVg90H21EOLACvtfcHk0linblgsZV6OaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D&md5=7963bc75c149981560dffc8d91b4aaf1</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2780%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DGrose%26aufirst%3DR.%26atitle%3DFibroblast%2520growth%2520factor%2520signalling%253A%2520from%2520development%2520to%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fnrc2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fearon, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grose, R. P.</span></span> <span> </span><span class="NLM_article-title">Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2014.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2Fj.tcb.2014.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=25467007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2jtL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=221-233&author=E.+P.+Carterauthor=A.+E.+Fearonauthor=R.+P.+Grose&title=Careless+talk+costs+lives%3A+fibroblast+growth+factor+receptor+signalling+and+the+consequences+of+pathway+malfunction&doi=10.1016%2Fj.tcb.2014.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction</span></div><div class="casAuthors">Carter, Edward P.; Fearon, Abbie E.; Grose, Richard P.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">221-233</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Since its discovery 40 years ago, fibroblast growth factor (FGF) receptor (FGFR) signalling has been found to regulate fundamental cellular behaviors in a wide range of cell types.  FGFRs regulate development, homeostasis, and repair and are implicated in many disorders and diseases; and indeed, there is extensive potential for severe consequences, be they developmental, homeostatic, or oncogenic, should FGF-FGFR signalling go awry, so careful control of the pathway is critically important.  In this review, we discuss the recent developments in the FGF field, highlighting how FGFR signalling works in normal cells, how it can go wrong, how frequently it is compromised, and how it is being targeted therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJuJ0uV7rBFbVg90H21EOLACvtfcHk0liKlChl7x6JyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2jtL%252FL&md5=d184f8f455ae220c2265070479309dee</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2014.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2014.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DE.%2BP.%26aulast%3DFearon%26aufirst%3DA.%2BE.%26aulast%3DGrose%26aufirst%3DR.%2BP.%26atitle%3DCareless%2520talk%2520costs%2520lives%253A%2520fibroblast%2520growth%2520factor%2520receptor%2520signalling%2520and%2520the%2520consequences%2520of%2520pathway%2520malfunction%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2015%26volume%3D25%26spage%3D221%26epage%3D233%26doi%3D10.1016%2Fj.tcb.2014.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Touat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ileana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postel-Vinay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">Targeting FGFR signaling in cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2684</span>– <span class="NLM_lpage">2694</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F1078-0432.CCR-14-2329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=26078430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2684-2694&author=M.+Touatauthor=E.+Ileanaauthor=S.+Postel-Vinayauthor=F.+Andreauthor=J.+C.+Soria&title=Targeting+FGFR+signaling+in+cancer&doi=10.1158%2F1078-0432.CCR-14-2329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FGFR Signaling in Cancer</span></div><div class="casAuthors">Touat, Mehdi; Ileana, Ecaterina; Postel-Vinay, Sophie; Andre, Fabrice; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2684-2694</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor signaling pathway (FGFR signaling) is an evolutionary conserved signaling cascade that regulates several basic biol. processes, including tissue development, angiogenesis, and tissue regeneration.  Substantial evidence indicates that aberrant FGFR signaling is involved in the pathogenesis of cancer.  Recent developments of deep sequencing technologies have allowed the discovery of frequent mol. alterations in components of FGFR signaling among several solid tumor types.  Moreover, compelling preclin. models have demonstrated the oncogenic potential of these aberrations in driving tumor growth, promoting angiogenesis, and conferring resistance mechanisms to anticancer therapies.  Recently, the field of FGFR targeting has exponentially progressed thanks to the development of novel agents inhibiting FGFs or FGFRs, which had manageable safety profiles in early-phase trials.  Promising treatment efficacy has been obsd. in different types of malignancies, particularly in tumors harboring aberrant FGFR signaling, thus offering novel therapeutic opportunities in the era of precision medicine.  The most exciting challenges now focus on selecting patients who are most likely to benefit from these agents, increasing the efficacy of therapies with the development of novel potent compds. and combination strategies, and overcoming toxicities assocd. with FGFR inhibitors.  After examn. of the basic and translational research studies that validated the oncogenic potential of aberrant FGFR signaling, this review focuses on recent data from clin. trials evaluating FGFR targeting therapies and discusses the challenges and perspectives for the development of these agents.  Clin Cancer Res; 21(12); 2684-94. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSZpKbvUn0hrVg90H21EOLACvtfcHk0liKlChl7x6JyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfP&md5=3dbb11de3f3a7d25d3b4ccb56400fd4d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2329%26sid%3Dliteratum%253Aachs%26aulast%3DTouat%26aufirst%3DM.%26aulast%3DIleana%26aufirst%3DE.%26aulast%3DPostel-Vinay%26aufirst%3DS.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DTargeting%2520FGFR%2520signaling%2520in%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2684%26epage%3D2694%26doi%3D10.1158%2F1078-0432.CCR-14-2329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dieci, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnedos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">264</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F2159-8290.CD-12-0362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=23418312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=264-279&author=M.+V.+Dieciauthor=M.+Arnedosauthor=F.+Andreauthor=J.+C.+Soria&title=Fibroblast+growth+factor+receptor+inhibitors+as+a+cancer+treatment%3A+from+a+biologic+rationale+to+medical+perspectives&doi=10.1158%2F2159-8290.CD-12-0362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives</span></div><div class="casAuthors">Dieci, Maria Vittoria; Arnedos, Monica; Andre, Fabrice; Soria, Jean Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">264-279</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway plays a fundamental role in many physiol. processes, including embryogenesis, adult tissue homeostasis, and wound healing, by orchestrating angiogenesis.  Ligand-independent and ligand-dependent activation have been implicated in a broad range of human malignancies and promote cancer progression in tumors driven by FGF/FGFR oncogenic mutations or amplifications, tumor neoangiogenesis, and targeted treatment resistance, thereby supporting a strong rationale for anti-FGF/FGFR agent development.  Efforts are being pursued to develop selective approaches for use against this pathway by optimizing the management of emerging, class-specific toxicity profiles and correctly designing clin. trials to address these different issues.  Significance: FGF/FGFR pathway deregulations are increasingly recognized across different human cancers.  Understanding the mechanisms at the basis of these alterations and their multiple roles in cancer promotion and drug resistance is a fundamental step for further implementation of targeted therapies and research strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6bibZKwamTLVg90H21EOLACvtfcHk0lh83S2bN9qAMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D&md5=0e694a7641aa83c1540f745576f04bfa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0362%26sid%3Dliteratum%253Aachs%26aulast%3DDieci%26aufirst%3DM.%2BV.%26aulast%3DArnedos%26aufirst%3DM.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DFibroblast%2520growth%2520factor%2520receptor%2520inhibitors%2520as%2520a%2520cancer%2520treatment%253A%2520from%2520a%2520biologic%2520rationale%2520to%2520medical%2520perspectives%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D264%26epage%3D279%26doi%3D10.1158%2F2159-8290.CD-12-0362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Helsten, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomson, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span> <span> </span><span class="NLM_article-title">The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F1078-0432.CCR-14-3212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=26373574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVGqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=259-267&author=T.+Helstenauthor=S.+Elkinauthor=E.+Arthurauthor=B.+N.+Tomsonauthor=J.+Carterauthor=R.+Kurzrock&title=The+FGFR+landscape+in+cancer%3A+analysis+of+4%2C853+tumors+by+next-generation+sequencing&doi=10.1158%2F1078-0432.CCR-14-3212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing</span></div><div class="casAuthors">Helsten, Teresa; Elkin, Sheryl; Arthur, Elisa; Tomson, Brett N.; Carter, Jennifer; Kurzrock, Razelle</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">259-267</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Mol. profiling may have prognostic and predictive value, and is increasingly used in the clin. setting.  There are more than a dozen fibroblast growth factor receptor (FGFR) inhibitors in development.  Optimal therapeutic application of FGFR inhibitors requires knowledge of the rates and types of FGFR aberrations in a variety of cancer types.  Exptl. Design: We analyzed frequencies of FGFR aberrations in 4,853 solid tumors that were, on physician request, tested in a Clin. Lab.  Improvement Amendments (CLIA) lab. (Foundation Medicine) using next-generation sequencing (182 or 236 genes), and analyzed by N-of-One.  Results: FGFR aberrations were found in 7.1% of cancers, with the majority being gene amplification (66% of the aberrations), followed by mutations (26%) and rearrangements (8%).  FGFR1 (mostly amplification) was affected in 3.5% of 4,853 patients; FGFR2 in 1.5%; FGFR3 in 2.0%; and FGFR4 in 0.5%.  Almost every type of malignancy examd. showed some patients with FGFR aberrations, but the cancers most commonly affected were urothelial (32% FGFR-aberrant); breast (18%); endometrial (∼13%), squamous lung cancers (∼13%), and ovarian cancer (∼9%).  Among 35 unique FGFR mutations seen in this dataset, all but two are found in COSMIC.  Seventeen of the 35 are known to be activating, and 11 are transforming.  Conclusions: FGFR aberrations are common in a wide variety of cancers, with the majority being gene amplifications or activating mutations.  These data suggest that FGFR inhibition could be an important therapeutic option across multiple tumor types.  Clin Cancer Res; 22(1); 259-67. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_eQBJarU4mLVg90H21EOLACvtfcHk0lh83S2bN9qAMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVGqs7Y%253D&md5=7172cbee01331fe0d3fac5dada295fc2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3212%26sid%3Dliteratum%253Aachs%26aulast%3DHelsten%26aufirst%3DT.%26aulast%3DElkin%26aufirst%3DS.%26aulast%3DArthur%26aufirst%3DE.%26aulast%3DTomson%26aufirst%3DB.%2BN.%26aulast%3DCarter%26aufirst%3DJ.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DThe%2520FGFR%2520landscape%2520in%2520cancer%253A%2520analysis%2520of%25204%252C853%2520tumors%2520by%2520next-generation%2520sequencing%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D259%26epage%3D267%26doi%3D10.1158%2F1078-0432.CCR-14-3212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Garcia, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natrajan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iorns, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">2085</span>– <span class="NLM_lpage">2094</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F0008-5472.CAN-09-3746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=20179196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2085-2094&author=N.+Turnerauthor=A.+Pearsonauthor=R.+Sharpeauthor=M.+Lambrosauthor=F.+Geyerauthor=M.+A.+Lopez-Garciaauthor=R.+Natrajanauthor=C.+Marchioauthor=E.+Iornsauthor=A.+Mackayauthor=C.+Gillettauthor=A.+Grigoriadisauthor=A.+Tuttauthor=J.+S.+Reis-Filhoauthor=A.+Ashworth&title=FGFR1+amplification+drives+endocrine+therapy+resistance+and+is+a+therapeutic+target+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-09-3746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer</span></div><div class="casAuthors">Turner, Nicholas; Pearson, Alex; Sharpe, Rachel; Lambros, Maryou; Geyer, Felipe; Lopez-Garcia, Maria A.; Natrajan, Rachael; Marchio, Caterina; Iorns, Elizabeth; Mackay, Alan; Gillett, Cheryl; Grigoriadis, Anita; Tutt, Andrew; Reis-Filho, Jorge S.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2085-2094</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Amplification of fibroblast growth factor receptor 1 (FGFR1) occurs in ∼10% of breast cancers and is assocd. with poor prognosis.  However, it is uncertain whether overexpression of FGFR1 is causally linked to the poor prognosis of amplified cancers.  Here, we show that FGFR1 overexpression is robustly assocd. with FGFR1 amplification in two independent series of breast cancers.  Breast cancer cell lines with FGFR1 overexpression and amplification show enhanced ligand-dependent signaling, with increased activation of the mitogen-activated protein kinase and phosphoinositide 3-kinase-AKT signaling pathways in response to FGF2, but also show basal ligand-independent signaling, and are dependent on FGFR signaling for anchorage-independent growth.  FGFR1-amplified cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1, suggesting that FGFR1 overexpression also promotes endocrine therapy resistance.  FGFR1 signaling suppresses progesterone receptor (PR) expression in vitro, and likewise, amplified cancers are frequently PR neg., identifying a potential biomarker for FGFR1 activity.  Furthermore, we show that amplified cancers have a high proliferative rate assessed by Ki67 staining and that FGFR1 amplification is found in 16% to 27% of luminal B-type breast cancers.  Our data suggest that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbsQ_wPmoftLVg90H21EOLACvtfcHk0lh83S2bN9qAMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWis7s%253D&md5=d14ce3b47614b090c4f7bfa7e4ce8a38</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3746%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DPearson%26aufirst%3DA.%26aulast%3DSharpe%26aufirst%3DR.%26aulast%3DLambros%26aufirst%3DM.%26aulast%3DGeyer%26aufirst%3DF.%26aulast%3DLopez-Garcia%26aufirst%3DM.%2BA.%26aulast%3DNatrajan%26aufirst%3DR.%26aulast%3DMarchio%26aufirst%3DC.%26aulast%3DIorns%26aufirst%3DE.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DGillett%26aufirst%3DC.%26aulast%3DGrigoriadis%26aufirst%3DA.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DFGFR1%2520amplification%2520drives%2520endocrine%2520therapy%2520resistance%2520and%2520is%2520a%2520therapeutic%2520target%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D2085%26epage%3D2094%26doi%3D10.1158%2F0008-5472.CAN-09-3746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, P. M.</span></span> <span> </span><span class="NLM_article-title">Targeting mutant fibroblast growth factor receptors in cancer</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2011.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2Fj.molmed.2011.01.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=283-292&author=H.+Greulichauthor=P.+M.+Pollock&title=Targeting+mutant+fibroblast+growth+factor+receptors+in+cancer&doi=10.1016%2Fj.molmed.2011.01.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2011.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2011.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DPollock%26aufirst%3DP.%2BM.%26atitle%3DTargeting%2520mutant%2520fibroblast%2520growth%2520factor%2520receptors%2520in%2520cancer%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D283%26epage%3D292%26doi%3D10.1016%2Fj.molmed.2011.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, A. H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, B. T.</span></span> <span> </span><span class="NLM_article-title">Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.07.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2Fj.drudis.2013.07.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=23932951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyrsLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=51-62&author=H.+K.+Hoauthor=A.+H.+L.+Yeoauthor=T.+S.+Kangauthor=B.+T.+Chua&title=Current+strategies+for+inhibiting+FGFR+activities+in+clinical+applications%3A+opportunities%2C+challenges+and+toxicological+considerations&doi=10.1016%2Fj.drudis.2013.07.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations</span></div><div class="casAuthors">Ho, Han Kiat; Yeo, Angie Hui Ling; Kang, Tse Siang; Chua, Boon Tin</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-62</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Aberrations in fibroblast growth factor receptor (FGFR) signaling are instrumental to the pathophysiol. of several malignancies and disorders.  Hence, FGFR inhibitors are explored in therapeutics with early candidates developed as competitors for the ATP-binding pocket in the kinase domain.  More recent programs yielded compds. of diverse scaffolds with alternative binding modes.  Concurrently, monoclonal antibodies and peptide-based agents provide independent options for clin. development.  Notwithstanding this rapid progress, we contemplate the toxicol. impact of FGFR inhibition based on the defined role of FGFR family members in physiol. and homeostasis.  The high homol. among FGFR1-4 and also with other kinase subfamilies creates an addnl. challenge in developing selective inhibitors.  It orchestrates an ongoing conundrum of moderating a balance between synergism through multitargeting kinase inhibition and minimizing off-target toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonzqQ29AMdrbVg90H21EOLACvtfcHk0lgAAPsNsxVOXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyrsLrL&md5=2ff38789d72dbe11bfe053001e477ef7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.07.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.07.021%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DH.%2BK.%26aulast%3DYeo%26aufirst%3DA.%2BH.%2BL.%26aulast%3DKang%26aufirst%3DT.%2BS.%26aulast%3DChua%26aufirst%3DB.%2BT.%26atitle%3DCurrent%2520strategies%2520for%2520inhibiting%2520FGFR%2520activities%2520in%2520clinical%2520applications%253A%2520opportunities%252C%2520challenges%2520and%2520toxicological%2520considerations%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D51%26epage%3D62%26doi%3D10.1016%2Fj.drudis.2013.07.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiner, L. M.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1083</span>– <span class="NLM_lpage">1093</span>, <span class="refDoi"> DOI: 10.1038/onc.2014.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1038%2Fonc.2014.51" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=1083-1093&author=B.+Kimauthor=S.+Wangauthor=J.+M.+Leeauthor=Y.+Jeongauthor=T.+Ahnauthor=D.+S.+Sonauthor=H.+W.+Parkauthor=H.+S.+Yooauthor=Y.+J.+Songauthor=E.+Leeauthor=Y.+M.+Ohauthor=S.+B.+Leeauthor=J.+Choiauthor=J.+C.+Murrayauthor=Y.+Zhouauthor=P.+H.+Songauthor=K.+A.+Kimauthor=L.+M.+Weiner&title=Synthetic+lethal+screening+reveals+FGFR+as+one+of+the+combinatorial+targets+to+overcome+resistance+to+Met-targeted+therapy&doi=10.1038%2Fonc.2014.51"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fonc.2014.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2014.51%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DAhn%26aufirst%3DT.%26aulast%3DSon%26aufirst%3DD.%2BS.%26aulast%3DPark%26aufirst%3DH.%2BW.%26aulast%3DYoo%26aufirst%3DH.%2BS.%26aulast%3DSong%26aufirst%3DY.%2BJ.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DOh%26aufirst%3DY.%2BM.%26aulast%3DLee%26aufirst%3DS.%2BB.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DMurray%26aufirst%3DJ.%2BC.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DP.%2BH.%26aulast%3DKim%26aufirst%3DK.%2BA.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26atitle%3DSynthetic%2520lethal%2520screening%2520reveals%2520FGFR%2520as%2520one%2520of%2520the%2520combinatorial%2520targets%2520to%2520overcome%2520resistance%2520to%2520Met-targeted%2520therapy%26jtitle%3DOncogene%26date%3D2015%26volume%3D34%26spage%3D1083%26epage%3D1093%26doi%3D10.1038%2Fonc.2014.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morishima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukayama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefor, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niki, T.</span></span> <span> </span><span class="NLM_article-title">The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">82</span>, <span class="refDoi"> DOI: 10.1186/s12885-015-1065-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1186%2Fs12885-015-1065-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=82&author=S.+Saitoauthor=K.+Morishimaauthor=T.+Uiauthor=H.+Hoshinoauthor=D.+Matsubaraauthor=S.+Ishikawaauthor=H.+Aburataniauthor=M.+Fukayamaauthor=Y.+Hosoyaauthor=N.+Sataauthor=A.+K.+Leforauthor=Y.+Yasudaauthor=T.+Niki&title=The+role+of+HGF%2FMET+and+FGF%2FFGFR+in+fibroblast-derived+growth+stimulation+and+lapatinib-resistance+of+esophageal+squamous+cell+carcinoma&doi=10.1186%2Fs12885-015-1065-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-1065-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-1065-8%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DS.%26aulast%3DMorishima%26aufirst%3DK.%26aulast%3DUi%26aufirst%3DT.%26aulast%3DHoshino%26aufirst%3DH.%26aulast%3DMatsubara%26aufirst%3DD.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DFukayama%26aufirst%3DM.%26aulast%3DHosoya%26aufirst%3DY.%26aulast%3DSata%26aufirst%3DN.%26aulast%3DLefor%26aufirst%3DA.%2BK.%26aulast%3DYasuda%26aufirst%3DY.%26aulast%3DNiki%26aufirst%3DT.%26atitle%3DThe%2520role%2520of%2520HGF%252FMET%2520and%2520FGF%252FFGFR%2520in%2520fibroblast-derived%2520growth%2520stimulation%2520and%2520lapatinib-resistance%2520of%2520esophageal%2520squamous%2520cell%2520carcinoma%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D82%26doi%3D10.1186%2Fs12885-015-1065-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renhowe, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machajewski, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jazan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonios-McCrea, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapointe, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feucht, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warne, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heise, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aardalen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernette-Hammond, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. L.</span></span> <span> </span><span class="NLM_article-title">Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1021/jm800790t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800790t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Sl" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=278-292&author=P.+A.+Renhoweauthor=S.+Pecchiauthor=C.+M.+Shaferauthor=T.+D.+Machajewskiauthor=E.+M.+Jazanauthor=C.+Taylorauthor=W.+Antonios-McCreaauthor=C.+M.+McBrideauthor=K.+Frazierauthor=M.+Wiesmannauthor=G.+R.+Lapointeauthor=P.+H.+Feuchtauthor=R.+L.+Warneauthor=C.+C.+Heiseauthor=D.+Menezesauthor=K.+Aardalenauthor=H.+Yeauthor=M.+Heauthor=V.+Leauthor=J.+Voraauthor=J.+M.+Jansenauthor=M.+E.+Wernette-Hammondauthor=A.+L.+Harris&title=Design%2C+structure-activity+relationships+and+in+vivo+characterization+of+4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%3A+a+novel+class+of+receptor+tyrosine+kinase+inhibitors&doi=10.1021%2Fjm800790t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Structure-Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Renhowe, Paul A.; Pecchi, Sabina; Shafer, Cynthia M.; Machajewski, Timothy D.; Jazan, Elisa M.; Taylor, Clarke; Antonios-McCrea, William; McBride, Christopher M.; Frazier, Kelly; Wiesmann, Marion; Lapointe, Gena R.; Feucht, Paul H.; Warne, Robert L.; Heise, Carla C.; Menezes, Daniel; Aardalen, Kimberly; Ye, Helen; He, Molly; Le, Vincent; Vora, Jayesh; Jansen, Johanna M.; Wernette-Hammond, Mary Ellen; Harris, Alex L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-292</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The inhibition of key receptor tyrosine kinases (RTKs) that are implicated in tumor vasculature formation and maintenance, as well as tumor progression and metastasis, has been a major focus in oncol. research over the last several years.  Many potent small mol. inhibitors of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) kinases have been evaluated.  More recently, compds. that act through the complex inhibition of multiple kinase targets have been reported and may exhibit improved clin. efficacy.  We report herein a series of potent, orally efficacious 4-amino-3-benzimidazol-2-ylhydroquinolin-2-one analogs as inhibitors of VEGF, PDGF, and fibroblast growth factor (FGF) receptor tyrosine kinases.  Compds. in this class, such as TKI258 (I), are reversible ATP-competitive inhibitors of VEGFR-2, FGFR-1, and PDGFRβ with IC50 values <0.1 μM.  On the basis of its favorable in vitro and in vivo properties, compd. I was selected for clin. evaluation and is currently in phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUf3qVBfCr87Vg90H21EOLACvtfcHk0lgYdYj6iISGaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Sl&md5=f20f564bb7dacb5a450a29dae9e04b50</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm800790t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800790t%26sid%3Dliteratum%253Aachs%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DMachajewski%26aufirst%3DT.%2BD.%26aulast%3DJazan%26aufirst%3DE.%2BM.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DAntonios-McCrea%26aufirst%3DW.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DLapointe%26aufirst%3DG.%2BR.%26aulast%3DFeucht%26aufirst%3DP.%2BH.%26aulast%3DWarne%26aufirst%3DR.%2BL.%26aulast%3DHeise%26aufirst%3DC.%2BC.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DVora%26aufirst%3DJ.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DWernette-Hammond%26aufirst%3DM.%2BE.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26atitle%3DDesign%252C%2520structure-activity%2520relationships%2520and%2520in%2520vivo%2520characterization%2520of%25204-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%253A%2520a%2520novel%2520class%2520of%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D278%26epage%3D292%26doi%3D10.1021%2Fjm800790t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarlato, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valbusa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Incalci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalletti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giavazzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camboni, G.</span></span> <span> </span><span class="NLM_article-title">E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1396</span>– <span class="NLM_lpage">1405</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F0008-5472.CAN-10-2700" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1396-1405&author=E.+Belloauthor=G.+Colellaauthor=V.+Scarlatoauthor=P.+Olivaauthor=A.+Berndtauthor=G.+Valbusaauthor=S.+C.+Serraauthor=M.+D%E2%80%99Incalciauthor=E.+Cavallettiauthor=R.+Giavazziauthor=G.+Damiaauthor=G.+Camboni&title=E-3810+is+a+potent+dual+inhibitor+of+VEGFR+and+FGFR+that+exerts+antitumor+activity+in+multiple+preclinical+models&doi=10.1158%2F0008-5472.CAN-10-2700"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2700%26sid%3Dliteratum%253Aachs%26aulast%3DBello%26aufirst%3DE.%26aulast%3DColella%26aufirst%3DG.%26aulast%3DScarlato%26aufirst%3DV.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DValbusa%26aufirst%3DG.%26aulast%3DSerra%26aufirst%3DS.%2BC.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DCavalletti%26aufirst%3DE.%26aulast%3DGiavazzi%26aufirst%3DR.%26aulast%3DDamia%26aufirst%3DG.%26aulast%3DCamboni%26aufirst%3DG.%26atitle%3DE-3810%2520is%2520a%2520potent%2520dual%2520inhibitor%2520of%2520VEGFR%2520and%2520FGFR%2520that%2520exerts%2520antitumor%2520activity%2520in%2520multiple%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D1396%26epage%3D1405%26doi%3D10.1158%2F0008-5472.CAN-10-2700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbatzky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handschuh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann-Lintz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontsch-Grunt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilberg, F.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4466</span>– <span class="NLM_lpage">4480</span>, <span class="refDoi"> DOI: 10.1021/jm900431g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900431g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntFygsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4466-4480&author=G.+J.+Rothauthor=A.+Heckelauthor=F.+Colbatzkyauthor=S.+Handschuhauthor=J.+Kleyauthor=T.+Lehmann-Lintzauthor=R.+Lotzauthor=U.+Tontsch-Gruntauthor=R.+Walterauthor=F.+Hilberg&title=Design%2C+synthesis%2C+and+evaluation+of+indolinones+as+triple+angiokinase+inhibitors+and+the+discovery+of+a+highly+specific+6-methoxycarbonyl-substituted+indolinone+%28BIBF+1120%29&doi=10.1021%2Fjm900431g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)</span></div><div class="casAuthors">Roth, Gerald J.; Heckel, Armin; Colbatzky, Florian; Handschuh, Sandra; Kley, Jorg; Lehmann-Lintz, Thorsten; Lotz, Ralf; Tontsch-Grunt, Ulrike; Walter, Rainer; Hilberg, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4466-4480</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a new treatment modality in oncol.  Preclin. findings suggest that blockade of addnl. pro-angiogenic kinases, such as fibroblast and platelet-derived growth factor receptors (FGFR and PDGFR), may improve the efficacy of pharmacol. cancer treatment.  Indolinones substituted in position 6 were identified as selective inhibitors of VEGF-, PDGF-, and FGF-receptor kinases.  In particular, 6-methoxycarbonyl-substituted indolinones showed a highly favorable selectivity profile.  Optimization identified potent inhibitors of VEGF-related endothelial cell proliferation with addnl. efficacy on pericyctes and smooth muscle cells.  In contrast, no direct inhibition of tumor cell proliferation was obsd.  Compds. 2 (BIBF 1000) and 3 (BIBF 1120) are orally available and display encouraging efficacy in in vivo tumor models while being well tolerated.  The triple angiokinase inhibitor 3 (I) is currently in phase III clin. trials for the treatment of nonsmall cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvvcX-_HYCS7Vg90H21EOLACvtfcHk0li4cxCF9Ji3xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntFygsL4%253D&md5=1b8af461631ae3117520fc4811130bb3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm900431g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900431g%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DHandschuh%26aufirst%3DS.%26aulast%3DKley%26aufirst%3DJ.%26aulast%3DLehmann-Lintz%26aufirst%3DT.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DWalter%26aufirst%3DR.%26aulast%3DHilberg%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520indolinones%2520as%2520triple%2520angiokinase%2520inhibitors%2520and%2520the%2520discovery%2520of%2520a%2520highly%2520specific%25206-methoxycarbonyl-substituted%2520indolinone%2520%2528BIBF%25201120%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4466%26epage%3D4480%26doi%3D10.1021%2Fjm900431g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gozgit, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F1535-7163.MCT-11-0450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=22238366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=690-699&author=J.+M.+Gozgitauthor=M.+J.+Wongauthor=L.+Moranauthor=S.+Wardwellauthor=Q.+K.+Mohemmadauthor=N.+I.+Narasimhanauthor=W.+C.+Shakespeareauthor=F.+Wangauthor=T.+Clacksonauthor=V.+M.+Rivera&title=Ponatinib+%28AP24534%29%2C+a+multitargeted+pan-FGFR+inhibitor+with+activity+in+multiple+FGFR-amplified+or+mutated+cancer+models&doi=10.1158%2F1535-7163.MCT-11-0450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models</span></div><div class="casAuthors">Gozgit, Joseph M.; Wong, Matthew J.; Moran, Lauren; Wardwell, Scott; Mohemmad, Qurish K.; Narasimhan, Narayana I.; Shakespeare, William C.; Wang, Frank; Clackson, Tim; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">690-699</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Members of the fibroblast growth factor receptor family of kinases (FGFR1-4) are dysregulated in multiple cancers.  Ponatinib (AP24534) is an oral multitargeted tyrosine kinase inhibitor being explored in a pivotal phase II trial in patients with chronic myelogenous leukemia due to its potent activity against BCR-ABL.  Ponatinib has also been shown to inhibit the in vitro kinase activity of all four FGFRs, prompting us to examine its potential as an FGFR inhibitor.  In Ba/F3 cells engineered to express activated FGFR1-4, ponatinib potently inhibited FGFR-mediated signaling and viability with IC50 values <40 nmol/L, with substantial selectivity over parental Ba/F3 cells.  In a panel of 14 cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon) and contg. FGFRs dysregulated by a variety of mechanisms, ponatinib inhibited FGFR-mediated signaling with IC50 values <40 nmol/L and inhibited cell growth with GI50 (concn. needed to reduce the growth of treated cells to half that of untreated cells) values of 7 to 181 nmol/L.  Daily oral dosing of ponatinib (10-30 mg/kg) to mice reduced tumor growth and inhibited signaling in all three tumor models examd.  Importantly, the potency of ponatinib in these models is similar to that previously obsd. in BCR-ABL-driven models and plasma levels of ponatinib that exceed the IC50 values for FGFR1-4 inhibition can be sustained in patients.  These results show that ponatinib is a potent pan-FGFR inhibitor and provide strong rationale for its evaluation in patients with FGFR-driven cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4-w5b7EPxLLVg90H21EOLACvtfcHk0li4cxCF9Ji3xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKis70%253D&md5=771979af1fba727510e073d19335ef5a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0450%26sid%3Dliteratum%253Aachs%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DWong%26aufirst%3DM.%2BJ.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPonatinib%2520%2528AP24534%2529%252C%2520a%2520multitargeted%2520pan-FGFR%2520inhibitor%2520with%2520activity%2520in%2520multiple%2520FGFR-amplified%2520or%2520mutated%2520cancer%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D690%26epage%3D699%26doi%3D10.1158%2F1535-7163.MCT-11-0450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavine, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilgour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span> <span> </span><span class="NLM_article-title">AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2045</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F0008-5472.CAN-11-3034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=22369928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2045-2056&author=P.+R.+Gavineauthor=L.+Mooneyauthor=E.+Kilgourauthor=A.+P.+Thomasauthor=K.+Al-Kadhimiauthor=S.+Beckauthor=C.+Rooneyauthor=T.+Colemanauthor=D.+Bakerauthor=M.+J.+Mellorauthor=A.+N.+Brooksauthor=T.+Klinowska&title=AZD4547%3A+an+orally+bioavailable%2C+potent%2C+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+tyrosine+kinase+family&doi=10.1158%2F0008-5472.CAN-11-3034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family</span></div><div class="casAuthors">Gavine, Paul R.; Mooney, Lorraine; Kilgour, Elaine; Thomas, Andrew P.; Al-Kadhimi, Katherine; Beck, Sarah; Rooney, Claire; Coleman, Tanya; Baker, Dawn; Mellor, Martine J.; Brooks, A. Nigel; Klinowska, Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2045-2056</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis and chemoresistance.  Several small-mol. FGF receptor (FGFR) kinase inhibitors are currently in clin. development; however, the predominant activity of the most advanced of these agents is against the kinase insert domain receptor (KDR), which compromises the FGFR selectivity.  Here, we report the pharmacol. profile of AZD4547, a novel and selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases.  AZD4547 inhibited recombinant FGFR kinase activity in vitro and suppressed FGFR signaling and growth in tumor cell lines with deregulated FGFR expression.  In a representative FGFR-driven human tumor xenograft model, oral administration of AZD4547 was well tolerated and resulted in potent dose-dependent antitumor activity, consistent with plasma exposure and pharmacodynamic modulation of tumor FGFR.  Importantly, at efficacious doses, no evidence of anti-KDR-related effects were obsd., confirming the in vivo FGFR selectivity of AZD4547.  Taken together, our findings show that AZD4547 is a novel selective small-mol. inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclin. models.  AZD4547 is under clin. investigation for the treatment of FGFR-dependent tumors.  Cancer Res; 72(8); 2045-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnpExryJc9xbVg90H21EOLACvtfcHk0lgXyluLYUjizw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D&md5=cba90ad8f9b9e51cd10288868bbcc85e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3034%26sid%3Dliteratum%253Aachs%26aulast%3DGavine%26aufirst%3DP.%2BR.%26aulast%3DMooney%26aufirst%3DL.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DRooney%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DKlinowska%26aufirst%3DT.%26atitle%3DAZD4547%253A%2520an%2520orally%2520bioavailable%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2045%26epage%3D2056%26doi%3D10.1158%2F0008-5472.CAN-11-3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spanka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Douget, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brueggen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghausen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drueckes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graus Porta, D.</span></span> <span> </span><span class="NLM_article-title">Graus Porta, D. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7066</span>– <span class="NLM_lpage">7083</span>, <span class="refDoi"> DOI: 10.1021/jm2006222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2006222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7066-7083&author=V.+Guagnanoauthor=P.+Furetauthor=C.+Spankaauthor=V.+Bordasauthor=M.+Le+Dougetauthor=C.+Stammauthor=J.+Brueggenauthor=M.+R.+Jensenauthor=C.+Schnellauthor=H.+Schmidauthor=M.+Wartmannauthor=J.+Berghausenauthor=P.+Drueckesauthor=A.+Zimmerlinauthor=D.+Bussiereauthor=J.+Murrayauthor=D.+Graus+Porta&title=Graus+Porta%2C+D.+Discovery+of+3-%282%2C6-dichloro-3%2C5-dimethoxy-phenyl%29-1-%7B6-%5B4-%284-ethyl-piperazin-1-yl%29-phenylamino%5D-pyrimidin-4-yl%7D-1-methyl-urea+%28NVP-BGJ398%29%2C+a+potent+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+family+of+receptor+tyrosine+kinase&doi=10.1021%2Fjm2006222"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm2006222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2006222%26sid%3Dliteratum%253Aachs%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSpanka%26aufirst%3DC.%26aulast%3DBordas%26aufirst%3DV.%26aulast%3DLe%2BDouget%26aufirst%3DM.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DH.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DBerghausen%26aufirst%3DJ.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DGraus%2BPorta%26aufirst%3DD.%26atitle%3DGraus%2520Porta%252C%2520D.%2520Discovery%2520of%25203-%25282%252C6-dichloro-3%252C5-dimethoxy-phenyl%2529-1-%257B6-%255B4-%25284-ethyl-piperazin-1-yl%2529-phenylamino%255D-pyrimidin-4-yl%257D-1-methyl-urea%2520%2528NVP-BGJ398%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520family%2520of%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7066%26epage%3D7083%26doi%3D10.1021%2Fjm2006222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perera, T. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovcheva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mevellec, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vialard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lange, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhulst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulussen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van De Ven, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilissen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platero, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkera, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angibaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span> <span> </span><span class="NLM_article-title">Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1010</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F1535-7163.MCT-16-0589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=28341788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1010-1020&author=T.+P.+S.+Pereraauthor=E.+Jovchevaauthor=L.+Mevellecauthor=J.+Vialardauthor=D.+De+Langeauthor=T.+Verhulstauthor=C.+Paulussenauthor=K.+Van+De+Venauthor=P.+Kingauthor=E.+Freyneauthor=D.+C.+Reesauthor=M.+Squiresauthor=G.+Saxtyauthor=M.+Pageauthor=C.+W.+Murrayauthor=R.+Gilissenauthor=G.+Wardauthor=N.+T.+Thompsonauthor=D.+R.+Newellauthor=N.+Chengauthor=L.+Xieauthor=J.+Yangauthor=S.+J.+Plateroauthor=J.+D.+Karkeraauthor=C.+Moyauthor=P.+Angibaudauthor=S.+Laquerreauthor=M.+V.+Lorenzi&title=Discovery+and+pharmacological+characterization+of+JNJ-42756493+%28erdafitinib%29%2C+a+functionally+selective+small-molecule+FGFR+family+inhibitor&doi=10.1158%2F1535-7163.MCT-16-0589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor</span></div><div class="casAuthors">Perera, Timothy P. S.; Jovcheva, Eleonora; Mevellec, Laurence; Vialard, Jorge; De Lange, Desiree; Verhulst, Tinne; Paulussen, Caroline; Van De Ven, Kelly; King, Peter; Freyne, Eddy; Rees, David C.; Squires, Matthew; Saxty, Gordon; Page, Martin; Murray, Christopher W.; Gilissen, Ron; Ward, George; Thompson, Neil T.; Newell, David R.; Cheng, Na; Xie, Liang; Yang, Jennifer; Platero, Suso J.; Karkera, Jayaprakash D.; Moy, Christopher; Angibaud, Patrick; Laquerre, Sylvie; Lorenzi, Matthew V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1010-1020</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fibroblast growth factor (FGF) signaling plays crit. roles in key biol. processes ranging from embryogenesis to wound healing and has strong links to several hallmarks of cancer.  Genetic alterations in FGF receptor (FGFR) family members are assocd. with increased tumor growth, metastasis, angiogenesis, and decreased survival.  JNJ-42756493, erdafitinib, is an orally active small mol. with potent tyrosine kinase inhibitory activity against all four FGFR family members and selectivity vs. other highly related kinases.  JNJ-42756493 shows rapid uptake into the lysosomal compartment of cells in culture, which is assocd. with prolonged inhibition of FGFR signaling, possibly due to sustained release of the inhibitor.  In xenografts from human tumor cell lines or patient-derived tumor tissue with activating FGFR alterations, JNJ-42756493 administration results in potent and dose-dependent antitumor activity accompanied by pharmacodynamic modulation of phospho-FGFR and phospho-ERK in tumors.  The results of the current study provide a strong rationale for the clin. investigation of JNJ-42756493 in patients with tumors harboring FGFR pathway alterations.  Mol Cancer Ther; 16(6); 1010-20. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhJZ2AgFcI6LVg90H21EOLACvtfcHk0ljTQwTI0bPaiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D&md5=2cae21f09ad519925ab2a3c760284b02</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0589%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DT.%2BP.%2BS.%26aulast%3DJovcheva%26aufirst%3DE.%26aulast%3DMevellec%26aufirst%3DL.%26aulast%3DVialard%26aufirst%3DJ.%26aulast%3DDe%2BLange%26aufirst%3DD.%26aulast%3DVerhulst%26aufirst%3DT.%26aulast%3DPaulussen%26aufirst%3DC.%26aulast%3DVan%2BDe%2BVen%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DFreyne%26aufirst%3DE.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DSquires%26aufirst%3DM.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DPage%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DPlatero%26aufirst%3DS.%2BJ.%26aulast%3DKarkera%26aufirst%3DJ.%2BD.%26aulast%3DMoy%26aufirst%3DC.%26aulast%3DAngibaud%26aufirst%3DP.%26aulast%3DLaquerre%26aufirst%3DS.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26atitle%3DDiscovery%2520and%2520pharmacological%2520characterization%2520of%2520JNJ-42756493%2520%2528erdafitinib%2529%252C%2520a%2520functionally%2520selective%2520small-molecule%2520FGFR%2520family%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D1010%26epage%3D1020%26doi%3D10.1158%2F1535-7163.MCT-16-0589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span> <span> </span><span class="NLM_article-title">The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2547</span>– <span class="NLM_lpage">2558</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F1535-7163.MCT-14-0248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=25169980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2547-2558&author=Y.+Nakanishiauthor=N.+Akiyamaauthor=T.+Tsukaguchiauthor=T.+Fujiiauthor=K.+Sakataauthor=H.+Saseauthor=T.+Isobeauthor=K.+Morikamiauthor=H.+Shindohauthor=T.+Mioauthor=H.+Ebiikeauthor=N.+Takaauthor=Y.+Aokiauthor=N.+Ishii&title=The+fibroblast+growth+factor+receptor+genetic+status+as+a+potential+predictor+of+the+sensitivity+to+CH5183284%2FDebio+1347%2C+a+novel+selective+FGFR+inhibitor&doi=10.1158%2F1535-7163.MCT-14-0248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor</span></div><div class="casAuthors">Nakanishi, Yoshito; Akiyama, Nukinori; Tsukaguchi, Toshiyuki; Fujii, Toshihiko; Sakata, Kiyoaki; Sase, Hitoshi; Isobe, Takehito; Morikami, Kenji; Shindoh, Hidetoshi; Mio, Toshiyuki; Ebiike, Hirosato; Taka, Naoki; Aoki, Yuko; Ishii, Nobuya</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2547-2558</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The FGF receptors (FGFR) are tyrosine kinases that are constitutively activated in a subset of tumors by genetic alterations such as gene amplifications, point mutations, or chromosomal translocations/rearrangements.  Recently, small-mol. inhibitors that can inhibit the FGFR family as well as the VEGF receptor (VEGFR) or platelet-derived growth factor receptor (PDGFR) family displayed clin. benefits in cohorts of patients with FGFR genetic alterations.  However, to achieve more potent and prolonged activity in such populations, a selective FGFR inhibitor is still needed.  Here, we report the identification of CH5183284/Debio 1347, a selective and orally available FGFR1, FGFR2, and FGFR3 inhibitor that has a unique chem. scaffold.  By interacting with unique residues in the ATP-binding site of FGFR1, FGFR2, or FGFR3, CH5183284/Debio 1347 selectively inhibits FGFR1, FGFR2, and FGFR3 but does not inhibit kinase insert domain receptor (KDR) or other kinases.  Consistent with its high selectivity for FGFR enzymes, CH5183284/Debio 1347 displayed preferential antitumor activity against cancer cells with various FGFR genetic alterations in a panel of 327 cancer cell lines and in xenograft models.  Because of its unique binding mode, CH5183284/Debio 1347 can inhibit FGFR2 harboring one type of the gatekeeper mutation that causes resistance to other FGFR inhibitors and block FGFR2 V564F-driven tumor growth.  CH5183284/Debio 1347 is under clin. investigation for the treatment of patients harboring FGFR genetic alterations.  Mol Cancer Ther; 13(11); 2547-58. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGIBEnK21337Vg90H21EOLACvtfcHk0ljTQwTI0bPaiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73F&md5=35629d891a421582022b0f6ae0496479</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0248%26sid%3Dliteratum%253Aachs%26aulast%3DNakanishi%26aufirst%3DY.%26aulast%3DAkiyama%26aufirst%3DN.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DT.%26aulast%3DSakata%26aufirst%3DK.%26aulast%3DSase%26aufirst%3DH.%26aulast%3DIsobe%26aufirst%3DT.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DShindoh%26aufirst%3DH.%26aulast%3DMio%26aufirst%3DT.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DTaka%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DN.%26atitle%3DThe%2520fibroblast%2520growth%2520factor%2520receptor%2520genetic%2520status%2520as%2520a%2520potential%2520predictor%2520of%2520the%2520sensitivity%2520to%2520CH5183284%252FDebio%25201347%252C%2520a%2520novel%2520selective%2520FGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2547%26epage%3D2558%26doi%3D10.1158%2F1535-7163.MCT-14-0248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zia-Ebrahimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloem, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D. J.</span></span> <span> </span><span class="NLM_article-title">A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2200</span>– <span class="NLM_lpage">2210</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F1535-7163.MCT-11-0306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=21900693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2200-2210&author=G.+Zhaoauthor=W.+Y.+Liauthor=D.+Chenauthor=J.+R.+Henryauthor=H.+Y.+Liauthor=Z.+Chenauthor=M.+Zia-Ebrahimiauthor=L.+Bloemauthor=Y.+Zhaiauthor=K.+Hussauthor=S.+B.+Pengauthor=D.+J.+McCann&title=A+novel%2C+selective+inhibitor+of+fibroblast+growth+factor+receptors+that+shows+a+potent+broad+spectrum+of+antitumor+activity+in+several+tumor+xenograft+models&doi=10.1158%2F1535-7163.MCT-11-0306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models</span></div><div class="casAuthors">Zhao, Genshi; Li, Wei-ying; Chen, Daohong; Henry, James R.; Li, Hong-Yu; Chen, Zhaogen; Zia-Ebrahimi, Mohammad; Bloem, Laura; Zhai, Yan; Huss, Karen; Peng, Sheng-bin; McCann, Denis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2200-2210</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptors (FGFR) are tyrosine kinases that are present in many types of endothelial and tumor cells and play an important role in tumor cell growth, survival, and migration as well as in maintaining tumor angiogenesis.  Overexpression of FGFRs or aberrant regulation of their activities has been implicated in many forms of human malignancies.  Therefore, targeting FGFRs represents an attractive strategy for development of cancer treatment options by simultaneously inhibiting tumor cell growth, survival, and migration as well as tumor angiogenesis.  Here, we describe a potent, selective, small-mol. FGFR inhibitor, (R)-(E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)ethoxy)-1H-indazol-3yl)vinyl)-1H-pyrazol-1-yl)ethanol, designated as LY2874455.  This mol. is active against all 4 FGFRs, with a similar potency in biochem. assays.  It exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activity in several tumor xenograft models representing the major FGF/FGFR relevant tumor histologies including lung, gastric, and bladder cancers and multiple myeloma, and with a well-defined pharmacokinetic/pharmacodynamic relationship.  LY2874455 also exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.  Furthermore, LY2874455 did not show VEGF receptor 2-mediated toxicities such as hypertension at efficacious doses.  Currently, this mol. is being evaluated for its potential use in the clinic.  Mol Cancer Ther; 10(11); 2200-10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLrzAyZQK_grVg90H21EOLACvtfcHk0lhkj7-9FKUWZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N&md5=eaf08fd213a836f48da2055e01bd9c29</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0306%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DW.%2BY.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZia-Ebrahimi%26aufirst%3DM.%26aulast%3DBloem%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DPeng%26aufirst%3DS.%2BB.%26aulast%3DMcCann%26aufirst%3DD.%2BJ.%26atitle%3DA%2520novel%252C%2520selective%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptors%2520that%2520shows%2520a%2520potent%2520broad%2520spectrum%2520of%2520antitumor%2520activity%2520in%2520several%2520tumor%2520xenograft%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2200%26epage%3D2210%26doi%3D10.1158%2F1535-7163.MCT-11-0306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">476</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.11.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2Fj.ejmech.2016.11.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=27914362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFymu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=476-490&author=W.+Chengauthor=M.+Wangauthor=X.+Tianauthor=X.+Zhang&title=An+overview+of+the+binding+models+of+FGFR+tyrosine+kinases+in+complex+with+small+molecule+inhibitors&doi=10.1016%2Fj.ejmech.2016.11.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors</span></div><div class="casAuthors">Cheng, Weiyan; Wang, Mixiang; Tian, Xin; Zhang, Xiaojian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">476-490</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptor (FGFR) family receptor tyrosine kinase (RTK) includes four structurally related members, termed as FGFR1, FGFR2, FGFR3, and FGFR4.  Given its intimate role in the progression of several solid tumors, excessive FGFR signaling provides an opportunity for anticancer therapy.  Along with extensive pharmacol. studies validating the therapeutic potential of targeting the FGFRs for cancer treatment, co-crystal structures of FGFRs/inhibitors are continuously coming up to study the mechanism of actions and explore new inhibitors.  Herein, we review the reported co-crystals of FGFRs in complex with the corresponding inhibitors, main focusing our attention on the binding models and the pharmacol. activities of the inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP6Sw0C-AnwrVg90H21EOLACvtfcHk0lhkj7-9FKUWZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFymu7rF&md5=8f207cd73cd860fcb6ddedfad01dfdda</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.11.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.11.052%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DAn%2520overview%2520of%2520the%2520binding%2520models%2520of%2520FGFR%2520tyrosine%2520kinases%2520in%2520complex%2520with%2520small%2520molecule%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D476%26epage%3D490%26doi%3D10.1016%2Fj.ejmech.2016.11.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traxler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span> <span> </span><span class="NLM_article-title">Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(98)00044-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2FS0163-7258%2898%2900044-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10454197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1999&pages=195-206&author=P.+Traxlerauthor=P.+Furet&title=Strategies+toward+the+design+of+novel+and+selective+protein+tyrosine+kinase+inhibitors&doi=10.1016%2FS0163-7258%2898%2900044-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</span></div><div class="casAuthors">Traxler, Peter; Furet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 37 refs.  Protein tyrosine kinases play a fundamental role in signal transduction pathways.  Deregulated tyrosine kinase activity has been obsd. in many proliferative diseases (e.g., cancer, psoriasis, restenosis, etc.).  Tyrosine kinases are, therefore, attractive targets for the design of new therapeutic agents against cancer.  We have built up a pharmacophore model of the ATP-binding site of the epidermal growth factor receptor (EGFR) kinase and used it for the rational design of kinase inhibitors.  Several examples of the successful use of this model are presented in this review.  Amongst these, 4-substituted-pyrrolo[2,3-d]pyrimidines, a new class of highly potent and selective inhibitors of the EGFR kinase, have been identified and further optimized.  The most active derivs. inhibited the EGFR tyrosine kinase with IC50 values between 1 and 5 nM.  In EGF-dependent cellular systems, tyrosine phosphorylation, as well as c-fos mRNA expression, was inhibited with similar IC50 values.  Further successful application of this pharmacophore model led to the identification and optimization of phenylamino-pyrazolo[4,3-d]pyrimidines and substituted isoflavones and quinolones, other classes of potent, selective, and ATP competitive EGFR kinase inhibitors with IC50 values in the low nanomolar range.  Structure-activity relationships of both classes are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzTOVAYLwK77Vg90H21EOLACvtfcHk0ljSjngoYqUb4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D&md5=26e5ed297e37b0cb188a0676e5b27f5b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2898%2900044-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252898%252900044-8%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DStrategies%2520toward%2520the%2520design%2520of%2520novel%2520and%2520selective%2520protein%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D1999%26volume%3D82%26spage%3D195%26epage%3D206%26doi%3D10.1016%2FS0163-7258%2898%2900044-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yosaatmadja, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squire, C. J.</span></span> <span> </span><span class="NLM_article-title">The 1.65 A° resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1107/S1399004714027539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1107%2FS1399004714027539" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=525-533&author=Y.+Yosaatmadjaauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=C.+J.+Squire&title=The+1.65+A%C2%B0+resolution+structure+of+the+complex+of+AZD4547+with+the+kinase+domain+of+FGFR1+displays+exquisite+molecular+recognition&doi=10.1107%2FS1399004714027539"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1107%2FS1399004714027539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS1399004714027539%26sid%3Dliteratum%253Aachs%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26atitle%3DThe%25201.65%2520A%25C2%25B0%2520resolution%2520structure%2520of%2520the%2520complex%2520of%2520AZD4547%2520with%2520the%2520kinase%2520domain%2520of%2520FGFR1%2520displays%2520exquisite%2520molecular%2520recognition%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2015%26volume%3D71%26spage%3D525%26epage%3D533%26doi%3D10.1107%2FS1399004714027539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunney, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiyagarajan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashford, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, C. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breeze, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orengo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katan, M.</span></span> <span> </span><span class="NLM_article-title">Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">24252</span>– <span class="NLM_lpage">24268</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.18632%2Foncotarget.8132" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=24252-24268&author=H.+Pataniauthor=T.+D.+Bunneyauthor=N.+Thiyagarajanauthor=R.+A.+Normanauthor=D.+Oggauthor=J.+Breedauthor=P.+Ashfordauthor=A.+Pottertonauthor=M.+Edwardsauthor=S.+V.+Williamsauthor=G.+S.+Thomsonauthor=C.+S.+M.+Pangauthor=M.+A.+Knowlesauthor=A.+L.+Breezeauthor=C.+Orengoauthor=C.+Phillipsauthor=M.+Katan&title=Landscape+of+activating+cancer+mutations+in+FGFR+kinases+and+their+differential+responses+to+inhibitors+in+clinical+use&doi=10.18632%2Foncotarget.8132"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8132%26sid%3Dliteratum%253Aachs%26aulast%3DPatani%26aufirst%3DH.%26aulast%3DBunney%26aufirst%3DT.%2BD.%26aulast%3DThiyagarajan%26aufirst%3DN.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DOgg%26aufirst%3DD.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DAshford%26aufirst%3DP.%26aulast%3DPotterton%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%2BV.%26aulast%3DThomson%26aufirst%3DG.%2BS.%26aulast%3DPang%26aufirst%3DC.%2BS.%2BM.%26aulast%3DKnowles%26aufirst%3DM.%2BA.%26aulast%3DBreeze%26aufirst%3DA.%2BL.%26aulast%3DOrengo%26aufirst%3DC.%26aulast%3DPhillips%26aufirst%3DC.%26aulast%3DKatan%26aufirst%3DM.%26atitle%3DLandscape%2520of%2520activating%2520cancer%2520mutations%2520in%2520FGFR%2520kinases%2520and%2520their%2520differential%2520responses%2520to%2520inhibitors%2520in%2520clinical%2520use%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D24252%26epage%3D24268%26doi%3D10.18632%2Foncotarget.8132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyohdoh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayase, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of [5-amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-(1<i>H</i>-indol-2-yl)methanone (CH5183284/Debio 1347), an orally available and selective fibroblast growth factor receptor (FGFR) inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10586</span>– <span class="NLM_lpage">10600</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01156</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01156" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10586-10600&author=H.+Ebiikeauthor=N.+Takaauthor=M.+Matsushitaauthor=M.+Ohmoriauthor=K.+Takamiauthor=I.+Hyohdohauthor=M.+Kohchiauthor=T.+Hayaseauthor=H.+Nishiiauthor=K.+Morikamiauthor=Y.+Nakanishiauthor=N.+Akiyamaauthor=H.+Shindohauthor=N.+Ishiiauthor=T.+Isobeauthor=H.+Matsuoka&title=Discovery+of+%5B5-amino-1-%282-methyl-3H-benzimidazol-5-yl%29pyrazol-4-yl%5D-%281H-indol-2-yl%29methanone+%28CH5183284%2FDebio+1347%29%2C+an+orally+available+and+selective+fibroblast+growth+factor+receptor+%28FGFR%29+inhibitor&doi=10.1021%2Facs.jmedchem.6b01156"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01156%26sid%3Dliteratum%253Aachs%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DTaka%26aufirst%3DN.%26aulast%3DMatsushita%26aufirst%3DM.%26aulast%3DOhmori%26aufirst%3DM.%26aulast%3DTakami%26aufirst%3DK.%26aulast%3DHyohdoh%26aufirst%3DI.%26aulast%3DKohchi%26aufirst%3DM.%26aulast%3DHayase%26aufirst%3DT.%26aulast%3DNishii%26aufirst%3DH.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DNakanishi%26aufirst%3DY.%26aulast%3DAkiyama%26aufirst%3DN.%26aulast%3DShindoh%26aufirst%3DH.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DIsobe%26aufirst%3DT.%26aulast%3DMatsuoka%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520%255B5-amino-1-%25282-methyl-3H-benzimidazol-5-yl%2529pyrazol-4-yl%255D-%25281H-indol-2-yl%2529methanone%2520%2528CH5183284%252FDebio%25201347%2529%252C%2520an%2520orally%2520available%2520and%2520selective%2520fibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10586%26epage%3D10600%26doi%3D10.1021%2Facs.jmedchem.6b01156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibition of fibroblast growth factor receptors in cancer</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">475</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2013.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2Fj.cytogfr.2013.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=23830577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKntrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=467-475&author=G.+Liangauthor=G.+Chenauthor=X.+Weiauthor=Y.+Zhaoauthor=X.+Li&title=Small+molecule+inhibition+of+fibroblast+growth+factor+receptors+in+cancer&doi=10.1016%2Fj.cytogfr.2013.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibition of fibroblast growth factor receptors in cancer</span></div><div class="casAuthors">Liang, Guang; Chen, Gaozhi; Wei, Xiaoyan; Zhao, Yunjie; Li, Xiaokun</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">467-475</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) signal through FGF receptors (FGFRs), which are a sub-family of the superfamily of receptor tyrosine kinases, to regulate human development and metab.  Uncontrolled FGF signaling is responsible for diverse array of developmental disorders, most notably skeletal syndromes due to FGFR gain-of-function mutations.  Studies in the last few years have provided significant evidence for the importance of FGF signaling in the pathogenesis of diverse cancers, including endometrial and bladder cancers.  FGFs are both potent mitogenic and angiogenic factors and can contribute to carcinogenesis by stimulating cell proliferation and tumor angiogenesis.  Gene knockout and pharmacol. inhibition of FGFRs in in vivo and in vitro models validate FGFRs as a target for cancer treatment.  Considerable efforts are being expended to develop specific, small-mol. inhibitors for treating FGFR-driven cancers.  Recent reviews on the FGF/FGFR system have focused primarily on signaling, pathophysiol., and functions in cancer.  In this article, we review the key roles of FGFR in cancer, provide an update on the status of clin. trials with small-mol. FGFR inhibitors, and discuss how the current structural data on FGFR kinases guide the design and characterization of new FGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbj2wCb5EOc7Vg90H21EOLACvtfcHk0lheIPFJHxFGSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKntrnO&md5=d372fecac21b7eb341c6944b433daa95</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2013.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2013.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DSmall%2520molecule%2520inhibition%2520of%2520fibroblast%2520growth%2520factor%2520receptors%2520in%2520cancer%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2013%26volume%3D24%26spage%3D467%26epage%3D475%26doi%3D10.1016%2Fj.cytogfr.2013.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the FGFR4/LY2874455 complex reveals insights into the pan-FGFR selectivity of LY2874455</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0162491</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0162491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1371%2Fjournal.pone.0162491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=27618313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFKjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0162491&author=D.+Wuauthor=M.+Guoauthor=M.+A.+Philipsauthor=L.+Quauthor=L.+Jiangauthor=J.+Liauthor=X.+Chenauthor=Z.+Chenauthor=L.+Chenauthor=Y.+Chen&title=Crystal+structure+of+the+FGFR4%2FLY2874455+complex+reveals+insights+into+the+pan-FGFR+selectivity+of+LY2874455&doi=10.1371%2Fjournal.pone.0162491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the FGFR4/LY2874455 complex reveals insights into the pan-FGFR selectivity of LY2874455</span></div><div class="casAuthors">Wu, Daichao; Guo, Ming; Philips, Michael A.; Qu, Lingzhi; Jiang, Longying; Li, Jun; Chen, Xiaojuan; Chen, Zhuchu; Chen, Lin; Chen, Yongheng</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0162491/1-e0162491/11</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Aberrant FGFR4 signaling has been documented abundantly in various human cancers.  The majority of FGFR inhibitors display significantly reduced potency toward FGFR4 compared to FGFR1-3.  However, LY2874455 has similar inhibition potency for FGFR1-4 with IC50 less than 6.4 nM.  To date, there is no published crystal structure of LY2874455 in complex with any kinase.  To better understand the pan-FGFR selectivity of LY2874455, we have detd. the crystal structure of the FGFR4 kinase domain bound to LY2874455 at a resoln. of 2.35 Å.  LY2874455, a type I inhibitor for FGFR4, binds to the ATP-binding pocket of FGFR4 in a DFG-in active conformation with three hydrogen bonds and a no. of van derWaals contacts.  After alignment of the kinase domain sequence of 4 FGFRs, and superposition of the ATP binding pocket of 4 FGFRs, our structural analyses reveal that the interactions of LY2874455 to FGFR4 are largely conserved in 4 FGFRs, explaining at least partly, the broad inhibitory activity of LY2874455 toward 4 FGFRs.  Consequently, our studies reveal new insights into the pan-FGFR selectivity of LY2874455 and provide a structural basis for developing novel FGFR inhibitors that target FGFR1-4 broadly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquH9zGVO6xArVg90H21EOLACvtfcHk0lheIPFJHxFGSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFKjt74%253D&md5=444e0d350dac9196672923565b10f2ba</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0162491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0162491%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DPhilips%26aufirst%3DM.%2BA.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DCrystal%2520structure%2520of%2520the%2520FGFR4%252FLY2874455%2520complex%2520reveals%2520insights%2520into%2520the%2520pan-FGFR%2520selectivity%2520of%2520LY2874455%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0162491%26doi%3D10.1371%2Fjournal.pone.0162491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miduturu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stransky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodous, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shutes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T.</span></span> <span> </span><span class="NLM_article-title">First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-1029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F2159-8290.CD-14-1029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=25776529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVSrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=424-437&author=M.+Hagelauthor=C.+Miduturuauthor=M.+Sheetsauthor=N.+Rubinauthor=W.+Wengauthor=N.+Stranskyauthor=N.+Bifulcoauthor=J.+L.+Kimauthor=B.+Hodousauthor=N.+Brooijmansauthor=A.+Shutesauthor=C.+Winterauthor=C.+Lengauerauthor=N.+E.+Kohlauthor=T.+Guzi&title=First+selective+small+molecule+inhibitor+of+FGFR4+for+the+treatment+of+hepatocellular+carcinomas+with+an+activated+FGFR4+signaling+pathway&doi=10.1158%2F2159-8290.CD-14-1029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway</span></div><div class="casAuthors">Hagel, Margit; Miduturu, Chandra; Sheets, Michael; Rubin, Nooreen; Weng, Weifan; Stransky, Nicolas; Bifulco, Neil; Kim, Joseph L.; Hodous, Brian; Brooijmans, Natasja; Shutes, Adam; Winter, Christopher; Lengauer, Christoph; Kohl, Nancy E.; Guzi, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">424-437</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HCC cells with FGF19 gene amplification or overexpression and an intact FGFR4 signaling pathway are sensitive to potent and selective FGFR4 inhibition by the small mol. BLU9931 in vitro and in xenograft models.  Aberrant signaling through the fibroblast growth factor 19 (FGF19)/fibroblast growth factor receptor 4 (FGFR 4) signaling complex has been shown to cause hepatocellular carcinoma (HCC) in mice and has been implicated to play a similar role in humans.  We have developed BLU9931, a potent and irreversible small-mol. inhibitor of FGFR4, as a targeted therapy to treat patients with HCC whose tumors have an activated FGFR4 signaling pathway.  BLU9931 is exquisitely selective for FGFR4 vs. other FGFR family members and all other kinases.  BLU9931 shows remarkable antitumor activity in mice bearing an HCC tumor xenograft that overexpresses FGF19 due to amplification as well as a liver tumor xenograft that overexpresses FGF19 mRNA but lacks FGF19 amplification.  Approx. one third of patients with HCC whose tumors express FGF19 together with FGFR4 and its coreceptor klotho β (KLB) could potentially respond to treatment with an FGFR4 inhibitor.  These findings are the first demonstration of a therapeutic strategy that targets a subset of patients with HCC.  Significance: This article documents the discovery of BLU9931, a novel irreversible kinase inhibitor that specifically targets FGFR4 while sparing all other FGFR paralogs and demonstrates exquisite kinome selectivity.  BLU9931 is efficacious in tumors with an intact FGFR4 signaling pathway that includes FGF19, FGFR4, and KLB.  BLU9931 is the first FGFR4-selective mol. for the treatment of patients with HCC with aberrant FGFR4 signaling.  Cancer Discov; 5(4); 424-37. cpr2015 AACR.  See related commentary by Packer and Pollock, p. 355 This article is highlighted in the In This Issue feature, p.  333.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcHNr-1ZnG7Vg90H21EOLACvtfcHk0lheIPFJHxFGSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVSrtL8%253D&md5=4a69439aee01a3c090c14851a785362e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-1029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-1029%26sid%3Dliteratum%253Aachs%26aulast%3DHagel%26aufirst%3DM.%26aulast%3DMiduturu%26aufirst%3DC.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DRubin%26aufirst%3DN.%26aulast%3DWeng%26aufirst%3DW.%26aulast%3DStransky%26aufirst%3DN.%26aulast%3DBifulco%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DHodous%26aufirst%3DB.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DShutes%26aufirst%3DA.%26aulast%3DWinter%26aufirst%3DC.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DGuzi%26aufirst%3DT.%26atitle%3DFirst%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520FGFR4%2520for%2520the%2520treatment%2520of%2520hepatocellular%2520carcinomas%2520with%2520an%2520activated%2520FGFR4%2520signaling%2520pathway%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D424%26epage%3D437%26doi%3D10.1158%2F2159-8290.CD-14-1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A structure-guided approach to creating covalent FGFR inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+S.+Gray&title=A+structure-guided+approach+to+creating+covalent+FGFR+inhibitors&doi=10.1016%2Fj.chembiol.2010.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0lh10FOPxPiF6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520structure-guided%2520approach%2520to%2520creating%2520covalent%2520FGFR%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D285%26epage%3D295%26doi%3D10.1016%2Fj.chembiol.2010.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">E4869</span>– <span class="NLM_lpage">E4877</span>, <span class="refDoi"> DOI: 10.1073/pnas.1403438111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1073%2Fpnas.1403438111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=25349422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=E4869-E4877&author=L.+Tanauthor=J.+Wangauthor=J.+Tanizakiauthor=Z.+Huangauthor=A.+R.+Arefauthor=M.+Rusanauthor=S.+J.+Zhuauthor=Y.+Zhangauthor=D.+Ercanauthor=R.+G.+Liaoauthor=M.+Capellettiauthor=W.+Zhouauthor=W.+Hurauthor=N.+Kimauthor=T.+Simauthor=S.+Gaudetauthor=D.+A.+Barbieauthor=J.+R.+J.+Yehauthor=C.+H.+Yunauthor=P.+S.+Hammermanauthor=M.+Mohammadiauthor=P.+A.+Janneauthor=N.+S.+Gray&title=Development+of+covalent+inhibitors+that+can+overcome+resistance+to+first-generation+FGFR+kinase+inhibitors&doi=10.1073%2Fpnas.1403438111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</span></div><div class="casAuthors">Tan, Li; Wang, Jun; Tanizaki, Junko; Huang, Zhifeng; Aref, Amir R.; Rusan, Maria; Zhu, Su-Jie; Zhang, Yiyun; Ercan, Dalia; Liao, Rachel G.; Capelletti, Marzia; Zhou, Wenjun; Hur, Wooyoung; Kim, NamDoo; Sim, Taebo; Gaudet, Suzanne; Barbie, David A.; Yeh, Jing-Ruey Joanna; Yun, Cai-Hong; Hammerman, Peter S.; Mohammadi, Moosa; Janne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">E4869-E4877</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The human FGF receptors (FGFRs) play crit. roles in various human cancers, and several FGFR inhibitors are currently under clin. investigation.  Resistance usually results from selection for mutant kinases that are impervious to the action of the drug or from up-regulation of compensatory signaling pathways.  Preclin. studies have demonstrated that resistance to FGFR inhibitors can be acquired through mutations in the FGFR gatekeeper residue, as clin. obsd. for FGFR4 in embryonal rhabdomyosarcoma and neuroendocrine breast carcinomas.  Here the authors report on the use of a structure-based drug design to develop two selective, next-generation covalent FGFR inhibitors, the FGFR irreversible inhibitors I and II.  To our knowledge, I and II are the first inhibitors that can potently inhibit the proliferation of cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2, which confer resistance to first-generation clin. FGFR inhibitors such as NVP-BGJ398 and AZD4547.  Because of the conformational flexibility of the reactive acrylamide substituent, II has the unprecedented ability to inhibit both the EGF receptor (EGFR) and FGFR covalently by targeting two distinct cysteine residues.  The authors report the cocrystal structure of FGFR4 with I, which unexpectedly exhibits a "DFG-out" covalent binding mode.  The structural basis for dual FGFR and EGFR targeting by FIIN3 also is illustrated by crystal structures of II bound with FGFR4 V550L and EGFR L858R.  These results have important implications for the design of covalent FGFR inhibitors that can overcome clin. resistance and provide the first example, to the knowledge, of a kinase inhibitor that covalently targets cysteines located in different positions within the ATP-binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmCbTDKPA32LVg90H21EOLACvtfcHk0lh10FOPxPiF6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsL%252FP&md5=fd4a7eac1e0c17e7c9f2651dd2d76ac7</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1403438111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1403438111%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DRusan%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DR.%2BG.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGaudet%26aufirst%3DS.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DYeh%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520covalent%2520inhibitors%2520that%2520can%2520overcome%2520resistance%2520to%2520first-generation%2520FGFR%2520kinase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3DE4869%26epage%3DE4877%26doi%3D10.1073%2Fpnas.1403438111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. K.</span></span> <span> </span><span class="NLM_article-title">Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2096</span>– <span class="NLM_lpage">2106</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F1535-7163.MCT-16-0136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=27371729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCnsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2096-2106&author=W.+S.+Brownauthor=L.+Tanauthor=A.+Smithauthor=N.+S.+Grayauthor=M.+K.+Wendt&title=Covalent+targeting+of+fibroblast+growth+factor+receptor+inhibits+metastatic+breast+cancer&doi=10.1158%2F1535-7163.MCT-16-0136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer</span></div><div class="casAuthors">Brown, Wells S.; Tan, Li; Smith, Andrew; Gray, Nathanael S.; Wendt, Michael K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2096-2106</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Therapeutic targeting of late-stage breast cancer is limited by an inadequate understanding of how tumor cell signaling evolves during metastatic progression and by the currently available small mol. inhibitors capable of targeting these processes.  Herein, we demonstrate that both β3 integrin and fibroblast growth factor receptor-1 (FGFR1) are part of an epithelial-mesenchymal transition (EMT) program that is required to facilitate metastatic outgrowth in response to fibroblast growth factor-2 (FGF2).  Mechanistically, β3 integrin phys. disrupts an interaction between FGFR1 and E-cadherin, leading to a dramatic redistribution of FGFR1 subcellular localization, enhanced FGF2 signaling and increased three-dimensional (3D) outgrowth of metastatic breast cancer cells.  This ability of β3 integrin to drive FGFR signaling requires the enzymic activity of focal adhesion kinase (FAK).  Consistent with these mechanistic data, we demonstrate that FGFR, β3 integrin, and FAK constitute a mol. signature capable of predicting decreased survival of patients with the basal-like subtype of breast cancer.  Importantly, covalent targeting of a conserved cysteine in the P-loop of FGFR1-4 with our newly developed small mol., FIIN-4, more effectively blocks 3D metastatic outgrowth as compared with currently available FGFR inhibitors.  In vivo application of FIIN-4 potently inhibited the growth of metastatic, patient-derived breast cancer xenografts and murine-derived metastases growing within the pulmonary microenvironment.  Overall, the current studies demonstrate that FGFR1 works in concert with other EMT effector mols. to drive aberrant downstream signaling, and that these events can be effectively targeted using our novel therapeutics for the treatment of the most aggressive forms of breast cancer.  Mol Cancer Ther; 15(9); 2096-106. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQFBxSpCHYZ7Vg90H21EOLACvtfcHk0ljsGtw2f9IF6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCnsLvI&md5=f58566c7181197b10a9dcc3c203ef13e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0136%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DW.%2BS.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWendt%26aufirst%3DM.%2BK.%26atitle%3DCovalent%2520targeting%2520of%2520fibroblast%2520growth%2520factor%2520receptor%2520inhibits%2520metastatic%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2096%26epage%3D2106%26doi%3D10.1158%2F1535-7163.MCT-16-0136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venetsanakos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughhead, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span> <span> </span><span class="NLM_article-title">Discovery of the irreversible covalent FGFR inhibitor 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (PRN1371) for the treatment of solid tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6516</span>– <span class="NLM_lpage">6527</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00360</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00360" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6516-6527&author=K.+A.+Brameldauthor=T.+D.+Owensauthor=E.+Vernerauthor=E.+Venetsanakosauthor=J.+M.+Bradshawauthor=V.+T.+Phanauthor=D.+Tamauthor=K.+Leungauthor=J.+Shuauthor=J.+LaStantauthor=D.+G.+Loughheadauthor=T.+Tonauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=D.+M.+Goldsteinauthor=J.+O.+Funk&title=Discovery+of+the+irreversible+covalent+FGFR+inhibitor+8-%283-%284-acryloylpiperazin-1-yl%29propyl%29-6-%282%2C6-dichloro-3%2C5-dimethoxyphenyl%29-2-%28methylamino%29pyrido%5B2%2C3-d%5Dpyrimidin-7%288H%29-one+%28PRN1371%29+for+the+treatment+of+solid+tumors&doi=10.1021%2Facs.jmedchem.7b00360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors</span></div><div class="casAuthors">Brameld, Ken A.; Owens, Timothy D.; Verner, Erik; Venetsanakos, Eleni; Bradshaw, J. Michael; Phan, Vernon T.; Tam, Danny; Leung, Kwan; Shu, Jin; LaStant, Jacob; Loughhead, David G.; Ton, Tony; Karr, Dane E.; Gerritsen, Mary E.; Goldstein, David M.; Funk, Jens Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6516-6527</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors.  Clin. validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers.  Our goal was to develop an irreversible covalent inhibitor of FGFR1-4 for use in oncol. indications.  An irreversible covalent binding mechanism imparts many desirable pharmacol. benefits including high potency, selectivity, and prolonged target inhibition.  Herein we report the structure-based design, medicinal chem. optimization, and unique ADME assays of our irreversible covalent drug discovery program which culminated in the discovery of compd. 34 (PRN1371), a highly selective and potent FGFR1-4 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpklTuvm1niy7Vg90H21EOLACvtfcHk0ljsGtw2f9IF6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK&md5=987069b645d5e0e36ccda5e5c81520b9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00360%26sid%3Dliteratum%253Aachs%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DLaStant%26aufirst%3DJ.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26atitle%3DDiscovery%2520of%2520the%2520irreversible%2520covalent%2520FGFR%2520inhibitor%25208-%25283-%25284-acryloylpiperazin-1-yl%2529propyl%2529-6-%25282%252C6-dichloro-3%252C5-dimethoxyphenyl%2529-2-%2528methylamino%2529pyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-one%2520%2528PRN1371%2529%2520for%2520the%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6516%26epage%3D6527%26doi%3D10.1021%2Facs.jmedchem.7b00360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib: a first in class covalent inhibitor of bruton’s tyrosine kinase</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.2217/fon.14.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.2217%2Ffon.14.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=24941982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=957-967&author=M.+S.+Davidsauthor=J.+R.+Brown&title=Ibrutinib%3A+a+first+in+class+covalent+inhibitor+of+bruton%E2%80%99s+tyrosine+kinase&doi=10.2217%2Ffon.14.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase</span></div><div class="casAuthors">Davids, Matthew S.; Brown, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">957-967</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Ibrutinib (formerly PCI-32765) is a potent, covalent inhibitor of Bruton's tyrosine kinase, a kinase downstream of the B-cell receptor that is crit. for B-cell survival and proliferation.  In preclin. studies, ibrutinib bound to Bruton's tyrosine kinase with high affinity, leading to inhibition of B-cell receptor signaling, decreased B-cell activation and induction of apoptosis.  In clin. studies, ibrutinib has been well-tolerated and has demonstrated profound anti-tumor activity in a variety of hematol. malignancies, most notably chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), leading to US FDA approval for relapsed CLL and MCL.  Ongoing studies are evaluating ibrutinib in other types of non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and Waldenstroem's macrogobulinemia, in larger Phase III studies in CLL and MCL, and in combination studies with monoclonal antibodies and chemotherapy.  Future studies will combine ibrutinib with other promising novel agents currently in development in hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3o_pMnFVskLVg90H21EOLACvtfcHk0lgvDccteHkUjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D&md5=345b4e839a830be822d474f62755a022</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.51%26sid%3Dliteratum%253Aachs%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DIbrutinib%253A%2520a%2520first%2520in%2520class%2520covalent%2520inhibitor%2520of%2520bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DFuture%2520Oncol.%26date%3D2014%26volume%3D10%26spage%3D957%26epage%3D967%26doi%3D10.2217%2Ffon.14.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, G. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8249</span>– <span class="NLM_lpage">8267</span>, <span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+V.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+potent+and+selective+EGFR+inhibitor+%28AZD9291%29+of+both+sensitizing+and+T790M+resistance+mutations+that+spares+the+wild+type+form+of+the+receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0lgvDccteHkUjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520EGFR%2520inhibitor%2520%2528AZD9291%2529%2520of%2520both%2520sensitizing%2520and%2520T790M%2520resistance%2520mutations%2520that%2520spares%2520the%2520wild%2520type%2520form%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Developing irreversible inhibitors of the protein kinase cysteinome</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&author=Q.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+irreversible+inhibitors+of+the+protein+kinase+cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0lj_aipyoTRMAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520irreversible%2520inhibitors%2520of%2520the%2520protein%2520kinase%2520cysteinome%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almaden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behenna, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho-Schultz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemkens, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson-Fisher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalaie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kephart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafontaine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ornelas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planken, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinrich, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-{(3<i>R</i>,4<i>R</i>)-3-[({5-chloro-2-[(1-methyl-1<i>H</i>-pyrazol-4-yl)amino]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a potent, wt sparing, irreversible inhibitor of T790M-containing EGFR mutants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2024</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01633</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01633" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2005-2024&author=H.+Chengauthor=S.+K.+Nairauthor=B.+W.+Murrayauthor=C.+Almadenauthor=S.+Baileyauthor=S.+Baxiauthor=D.+Behennaauthor=S.+Cho-Schultzauthor=D.+Dalvieauthor=D.+M.+Dinhauthor=M.+P.+Edwardsauthor=J.+L.+Fengauthor=R.+A.+Ferreauthor=K.+S.+Gajiwalaauthor=M.+D.+Hemkensauthor=A.+Jackson-Fisherauthor=M.+Jalaieauthor=T.+O.+Johnsonauthor=R.+S.+Kaniaauthor=S.+Kephartauthor=J.+Lafontaineauthor=B.+Lunneyauthor=K.+K.+C.+Liuauthor=Z.+Liuauthor=J.+Matthewsauthor=A.+Nagataauthor=S.+Niessenauthor=M.+A.+Ornelasauthor=S.+T.+M.+Orrauthor=M.+Pairishauthor=S.+Plankenauthor=S.+Renauthor=D.+Richterauthor=K.+Ryanauthor=N.+Sachauthor=H.+Shenauthor=T.+Smealauthor=J.+Solowiejauthor=S.+Suttonauthor=K.+Tranauthor=E.+Tsengauthor=W.+Vernierauthor=M.+Wallsauthor=S.+Wangauthor=S.+L.+Weinrichauthor=S.+Xinauthor=H.+Xuauthor=M.+J.+Yinauthor=M.+Zientekauthor=R.+Zhouauthor=J.+C.+Kath&title=Discovery+of+1-%7B%283R%2C4R%29-3-%5B%28%7B5-chloro-2-%5B%281-methyl-1H-pyrazol-4-yl%29amino%5D-7H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%7Doxy%29methyl%5D-4-methoxypyrrolidin-1-yl%7Dprop-2-en-1-one+%28PF-06459988%29%2C+a+potent%2C+wt+sparing%2C+irreversible+inhibitor+of+T790M-containing+EGFR+mutants&doi=10.1021%2Facs.jmedchem.5b01633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants</span></div><div class="casAuthors">Cheng, Hengmiao; Nair, Sajiv K.; Murray, Brion W.; Almaden, Chau; Bailey, Simon; Baxi, Sangita; Behenna, Doug; Cho-Schultz, Sujin; Dalvie, Deepak; Dinh, Dac M.; Edwards, Martin P.; Feng, Jun Li; Ferre, Rose Ann; Gajiwala, Ketan S.; Hemkens, Michelle D.; Jackson-Fisher, Amy; Jalaie, Mehran; Johnson, Ted O.; Kania, Robert S.; Kephart, Susan; Lafontaine, Jennifer; Lunney, Beth; Liu, Kevin K.-C.; Liu, Zhengyu; Matthews, Jean; Nagata, Asako; Niessen, Sherry; Ornelas, Martha A.; Orr, Suvi T. M.; Pairish, Mason; Planken, Simon; Ren, Shijian; Richter, Daniel; Ryan, Kevin; Sach, Neal; Shen, Hong; Smeal, Tod; Solowiej, Jim; Sutton, Scott; Tran, Khanh; Tseng, Elaine; Vernier, William; Walls, Marlena; Wang, Shuiwang; Weinrich, Scott L.; Xin, Shuibo; Xu, Haiwei; Yin, Min-Jean; Zientek, Michael; Zhou, Ru; Kath, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2005-2024</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">First generation EGFR TKIs (gefitinib, erlotinib) provide significant clin. benefit for NSCLC cancer patients with oncogenic EGFR mutations.  Ultimately, these patients' disease progresses, often driven by a second-site mutation in the EGFR kinase domain (T790M).  Another liability of the first generation drugs is severe adverse events driven by inhibition of WT EGFR.  As such, our goal was to develop a highly potent irreversible inhibitor with the largest selectivity ratio between the drug-resistant double mutants (L858R/T790M, Del/T790M) and WT EGFR.  A unique approach to develop covalent inhibitors, optimization of reversible binding affinity, served as a cornerstone of this effort.  PF-06459988 was discovered as a novel, third generation irreversible inhibitor, which demonstrates (i) high potency and specificity to the T790M-contg. double mutant EGFRs, (ii) minimal intrinsic chem. reactivity of the electrophilic warhead, (iii) greatly reduced proteome reactivity relative to earlier irreversible EGFR inhibitors, and (iv) minimal activity against WT EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfRspJvDDNKrVg90H21EOLACvtfcHk0lj_aipyoTRMAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslChtQ%253D%253D&md5=b8c07b22033543305964c9e8771f3db5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DNair%26aufirst%3DS.%2BK.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBaxi%26aufirst%3DS.%26aulast%3DBehenna%26aufirst%3DD.%26aulast%3DCho-Schultz%26aufirst%3DS.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DFeng%26aufirst%3DJ.%2BL.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DHemkens%26aufirst%3DM.%2BD.%26aulast%3DJackson-Fisher%26aufirst%3DA.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKephart%26aufirst%3DS.%26aulast%3DLafontaine%26aufirst%3DJ.%26aulast%3DLunney%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMatthews%26aufirst%3DJ.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DOrnelas%26aufirst%3DM.%2BA.%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DPlanken%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DK.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DVernier%26aufirst%3DW.%26aulast%3DWalls%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWeinrich%26aufirst%3DS.%2BL.%26aulast%3DXin%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DM.%2BJ.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%25201-%257B%25283R%252C4R%2529-3-%255B%2528%257B5-chloro-2-%255B%25281-methyl-1H-pyrazol-4-yl%2529amino%255D-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%257Doxy%2529methyl%255D-4-methoxypyrrolidin-1-yl%257Dprop-2-en-1-one%2520%2528PF-06459988%2529%252C%2520a%2520potent%252C%2520wt%2520sparing%252C%2520irreversible%2520inhibitor%2520of%2520T790M-containing%2520EGFR%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2005%26epage%3D2024%26doi%3D10.1021%2Facs.jmedchem.5b01633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, C. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panek, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klohs, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, A. M.</span></span> <span> </span><span class="NLM_article-title">Discovery and structure-activity studies of a novel series of pyrido[2,3-<i>d</i>]pyrimidine tyrosine kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2415</span>– <span class="NLM_lpage">2420</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(97)00445-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2FS0960-894X%2897%2900445-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=2415-2420&author=C.+J.+C.+Connollyauthor=J.+M.+Hambyauthor=M.+C.+Schroederauthor=M.+Barvianauthor=G.+H.+Luauthor=R.+L.+Panekauthor=A.+Amarauthor=C.+Shenauthor=A.+J.+Krakerauthor=D.+W.+Fryauthor=W.+D.+Klohsauthor=A.+M.+Doherty&title=Discovery+and+structure-activity+studies+of+a+novel+series+of+pyrido%5B2%2C3-d%5Dpyrimidine+tyrosine+kinase+inhibitors&doi=10.1016%2FS0960-894X%2897%2900445-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2897%2900445-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252897%252900445-9%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DC.%2BJ.%2BC.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DBarvian%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DAmar%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DC.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DKlohs%26aufirst%3DW.%2BD.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26atitle%3DDiscovery%2520and%2520structure-activity%2520studies%2520of%2520a%2520novel%2520series%2520of%2520pyrido%255B2%252C3-d%255Dpyrimidine%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1997%26volume%3D7%26spage%3D2415%26epage%3D2420%26doi%3D10.1016%2FS0960-894X%2897%2900445-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, C. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boushelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartl, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amar, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinkampf, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patmore, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klohs, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Showalter, H. D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span> <span> </span><span class="NLM_article-title">3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4200</span>– <span class="NLM_lpage">4211</span>, <span class="refDoi"> DOI: 10.1021/jm000161d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000161d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4200-4211&author=A.+M.+Thompsonauthor=C.+J.+C.+Connollyauthor=J.+M.+Hambyauthor=S.+Boushelleauthor=B.+G.+Hartlauthor=A.+M.+Amarauthor=A.+J.+Krakerauthor=D.+L.+Driscollauthor=R.+W.+Steinkampfauthor=S.+J.+Patmoreauthor=P.+W.+Vincentauthor=B.+J.+Robertsauthor=W.+L.+Elliottauthor=W.+Klohsauthor=W.+R.+Leopoldauthor=H.+D.+H.+Showalterauthor=W.+A.+Denny&title=3-%283%2C5-Dimethoxyphenyl%29-1%2C6-naphthyridine-2%2C7-diamines+and+related+2-urea+derivatives+are+potent+and+selective+inhibitors+of+the+FGF+receptor-1+tyrosine+kinase&doi=10.1021%2Fjm000161d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm000161d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000161d%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DConnolly%26aufirst%3DC.%2BJ.%2BC.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DBoushelle%26aufirst%3DS.%26aulast%3DHartl%26aufirst%3DB.%2BG.%26aulast%3DAmar%26aufirst%3DA.%2BM.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DDriscoll%26aufirst%3DD.%2BL.%26aulast%3DSteinkampf%26aufirst%3DR.%2BW.%26aulast%3DPatmore%26aufirst%3DS.%2BJ.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DKlohs%26aufirst%3DW.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3D3-%25283%252C5-Dimethoxyphenyl%2529-1%252C6-naphthyridine-2%252C7-diamines%2520and%2520related%25202-urea%2520derivatives%2520are%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520FGF%2520receptor-1%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4200%26epage%3D4211%26doi%3D10.1021%2Fjm000161d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoon, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crean, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Showalter, H. D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4628</span>– <span class="NLM_lpage">4653</span>, <span class="refDoi"> DOI: 10.1021/jm0500931</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0500931" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4628-4653&author=A.%0AM.+Thompsonauthor=A.+M.+Delaneyauthor=J.+M.+Hambyauthor=M.+C.+Schroederauthor=T.+A.+Spoonauthor=S.+M.+Creanauthor=H.+D.+H.+Showalterauthor=W.+A.+Denny&title=Synthesis+and+structure-activity+relationships+of+soluble+7-substituted+3-%283%2C5-dimethoxyphenyl%29-1%2C6-naphthyridin-2-amines+and+related+ureas+as+dual+inhibitors+of+the+fibroblast+growth+factor+receptor-1+and+vascular+endothelial+growth+factor+receptor-2+tyrosine+kinases&doi=10.1021%2Fjm0500931"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm0500931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0500931%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DSpoon%26aufirst%3DT.%2BA.%26aulast%3DCrean%26aufirst%3DS.%2BM.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520soluble%25207-substituted%25203-%25283%252C5-dimethoxyphenyl%2529-1%252C6-naphthyridin-2-amines%2520and%2520related%2520ureas%2520as%2520dual%2520inhibitors%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor-1%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4628%26epage%3D4653%26doi%3D10.1021%2Fjm0500931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of substituted 1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine derivatives as potent and selective FGFR kinase inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">634</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsVamsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=629-634&author=B.+Zhaoauthor=Y.+Liauthor=P.+Xuauthor=Y.+Daiauthor=C.+Luoauthor=Y.+Sunauthor=J.+Aiauthor=M.+Gengauthor=W.+Duan&title=Discovery+of+substituted+1H-pyrazolo%5B3%2C4-b%5Dpyridine+derivatives+as+potent+and+selective+FGFR+kinase+inhibitors&doi=10.1021%2Facsmedchemlett.6b00066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives as Potent and Selective FGFR Kinase Inhibitors</span></div><div class="casAuthors">Zhao, Bin; Li, Yixuan; Xu, Pan; Dai, Yang; Luo, Cheng; Sun, Yiming; Ai, Jing; Geng, Meiyu; Duan, Wenhu</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">629-634</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fibroblast growth factor receptors (FGFRs) are important targets for cancer therapy.  Herein, we describe the design, synthesis, and biol. evaluation of a novel series of 1H-pyrazolo[3,4-b]pyridine derivs. as potent and selective FGFR kinase inhibitors.  On the basis of its excellent in vitro potency and favorable pharmacokinetic properties, compd. I was selected for in vivo evaluation and showed significant antitumor activity in a FGFR1-driven H1581 xenograft model.  These results indicated that I would be a promising candidate for further drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt1RCtnNDMAbVg90H21EOLACvtfcHk0lgAMv71fDBRkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsVamsb0%253D&md5=08cf7f710e2dfa738c7904965fae0630</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00066%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDuan%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520substituted%25201H-pyrazolo%255B3%252C4-b%255Dpyridine%2520derivatives%2520as%2520potent%2520and%2520selective%2520FGFR%2520kinase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D629%26epage%3D634%26doi%3D10.1021%2Facsmedchemlett.6b00066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schott, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudge, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. G.</span></span> <span> </span><span class="NLM_article-title">Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5003</span>– <span class="NLM_lpage">5012</span>, <span class="refDoi"> DOI: 10.1021/jm3004043</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3004043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5003-5012&author=R.+A.+Normanauthor=A.+K.+Schottauthor=D.+M.+Andrewsauthor=J.+Breedauthor=K.+M.+Footeauthor=A.+P.+Garnerauthor=D.+Oggauthor=J.+P.+Ormeauthor=J.+H.+Pinkauthor=K.+Robertsauthor=D.+A.+Rudgeauthor=A.+P.+Thomasauthor=A.+G.+Leach&title=Protein-ligand+crystal+structures+can+guide+the+design+of+selective+inhibitors+of+the+FGFR+tyrosine+kinase&doi=10.1021%2Fjm3004043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm3004043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3004043%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DSchott%26aufirst%3DA.%2BK.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DGarner%26aufirst%3DA.%2BP.%26aulast%3DOgg%26aufirst%3DD.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DRudge%26aufirst%3DD.%2BA.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26atitle%3DProtein-ligand%2520crystal%2520structures%2520can%2520guide%2520the%2520design%2520of%2520selective%2520inhibitors%2520of%2520the%2520FGFR%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5003%26epage%3D5012%26doi%3D10.1021%2Fjm3004043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richters, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getlik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomassi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Termathe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Wrangowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruetter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlenbrock, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaumann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eppmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kibies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffgaard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menninger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Cuaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinnefeld, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kast, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Targeting drug resistance in EGFR with covalent inhibitors: a structure-based design approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6844</span>– <span class="NLM_lpage">6863</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01082</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6844-6863&author=J.+Engelauthor=A.+Richtersauthor=M.+Getlikauthor=S.+Tomassiauthor=M.+Keulauthor=M.+Termatheauthor=J.+Lategahnauthor=C.+Beckerauthor=S.+Mayer-Wrangowskiauthor=C.+Gruetterauthor=N.+Uhlenbrockauthor=J.+Kruellauthor=N.+Schaumannauthor=S.+Eppmannauthor=P.+Kibiesauthor=F.+Hoffgaardauthor=J.+Heilauthor=S.+Menningerauthor=S.+Ortiz-Cuaranauthor=J.+M.+Heuckmannauthor=V.+Tinnefeldauthor=R.+P.+Zahediauthor=M.+L.+Sosauthor=C.+Schultz-Fademrechtauthor=R.+K.+Thomasauthor=S.+M.+Kastauthor=D.+Rauh&title=Targeting+drug+resistance+in+EGFR+with+covalent+inhibitors%3A+a+structure-based+design+approach&doi=10.1021%2Facs.jmedchem.5b01082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach</span></div><div class="casAuthors">Engel, Julian; Richters, Andre; Getlik, Matthaeus; Tomassi, Stefano; Keul, Marina; Termathe, Martin; Lategahn, Jonas; Becker, Christian; Mayer-Wrangowski, Svenja; Gruetter, Christian; Uhlenbrock, Niklas; Kruell, Jasmin; Schaumann, Niklas; Eppmann, Simone; Kibies, Patrick; Hoffgaard, Franziska; Heil, Jochen; Menninger, Sascha; Ortiz-Cuaran, Sandra; Heuckmann, Johannes M.; Tinnefeld, Verena; Zahedi, Rene P.; Sos, Martin L.; Schultz-Fademrecht, Carsten; Thomas, Roman K.; Kast, Stefan M.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6844-6863</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases represent one of the prime targets in cancer therapy, as the dysregulation of these elementary transducers of extracellular signals, like the epidermal growth factor receptor (EGFR), contributes to the onset of cancer, such as non-small cell lung cancer (NSCLC).  Strong efforts were directed to the development of irreversible inhibitors and led to compd. CO-1686, which takes advantage of increased residence time at EGFR by alkylating Cys797 and thereby preventing toxic effects.  Here, the authors present a structure-based approach, rationalized by subsequent computational anal. of conformational ligand ensembles in soln., to design novel and irreversible EGFR inhibitors based on a screening hit that was identified in a phenotype screen of 80 NSCLC cell lines against approx. 1500 compds.  Using protein x-ray crystallog., the authors deciphered the binding mode in engineered cSrc (T338M/S345C), a validated model system for EGFR-T790M, which constituted the basis for further rational design approaches.  Chem. synthesis led to further compd. collections that revealed increased biochem. potency and, in part, selectivity toward mutated (L858R and L858R/T790M) vs. nonmutated EGFR.  Further cell-based and kinetic studies were performed to substantiate the authors initial findings.  Utilizing proteolytic digestion and nano-LC-MS/MS anal., the authors confirmed the alkylation of Cys797.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNGJPIuqoVObVg90H21EOLACvtfcHk0lgAMv71fDBRkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsrvM&md5=d5264a2a99d7752af0e587f23aeb7723</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01082%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DTermathe%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DGruetter%26aufirst%3DC.%26aulast%3DUhlenbrock%26aufirst%3DN.%26aulast%3DKruell%26aufirst%3DJ.%26aulast%3DSchaumann%26aufirst%3DN.%26aulast%3DEppmann%26aufirst%3DS.%26aulast%3DKibies%26aufirst%3DP.%26aulast%3DHoffgaard%26aufirst%3DF.%26aulast%3DHeil%26aufirst%3DJ.%26aulast%3DMenninger%26aufirst%3DS.%26aulast%3DOrtiz-Cuaran%26aufirst%3DS.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DTinnefeld%26aufirst%3DV.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DKast%26aufirst%3DS.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DTargeting%2520drug%2520resistance%2520in%2520EGFR%2520with%2520covalent%2520inhibitors%253A%2520a%2520structure-based%2520design%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6844%26epage%3D6863%26doi%3D10.1021%2Facs.jmedchem.5b01082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingipalli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sha, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span> <span> </span><span class="NLM_article-title">Utilization of structure-based design to identify novel, irreversible inhibitors of EGFR harboring the T790M mutation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=514-519&author=E.+J.+Hennessyauthor=C.+Chuaquiauthor=S.+Ashtonauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=J.+E.+Debreczeniauthor=C.+Eberleinauthor=L.+Gingipalliauthor=T.+C.+M.+Klinowskaauthor=J.+P.+Ormeauthor=L.+Shaauthor=X.+Wu&title=Utilization+of+structure-based+design+to+identify+novel%2C+irreversible+inhibitors+of+EGFR+harboring+the+T790M+mutation&doi=10.1021%2Facsmedchemlett.6b00058"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00058%26sid%3Dliteratum%253Aachs%26aulast%3DHennessy%26aufirst%3DE.%2BJ.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DGingipalli%26aufirst%3DL.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%2BM.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSha%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DX.%26atitle%3DUtilization%2520of%2520structure-based%2520design%2520to%2520identify%2520novel%252C%2520irreversible%2520inhibitors%2520of%2520EGFR%2520harboring%2520the%2520T790M%2520mutation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D514%26epage%3D519%26doi%3D10.1021%2Facsmedchemlett.6b00058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truesdale, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennisi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alligood, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L.</span></span> <span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">6652</span>– <span class="NLM_lpage">6659</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells&doi=10.1158%2F0008-5472.CAN-04-1168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0li7pAzVzhuCKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659%26doi%3D10.1158%2F0008-5472.CAN-04-1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahleda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dienstmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Italiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platero, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuyckens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee-Kishore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peddareddigari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">3401</span>– <span class="NLM_lpage">3408</span>, <span class="refDoi"> DOI: 10.1200/JCO.2014.60.7341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1200%2FJCO.2014.60.7341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=26324363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFGrtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=3401-3408&author=J.+Taberneroauthor=R.+Bahledaauthor=R.+Dienstmannauthor=J.+R.+Infanteauthor=A.+Mitaauthor=A.+Italianoauthor=E.+Calvoauthor=V.+Morenoauthor=B.+Adamoauthor=A.+Gazzahauthor=B.+Zhongauthor=S.+J.+Plateroauthor=J.+W.+Smitauthor=K.+Stuyckensauthor=M.+Chatterjee-Kishoreauthor=J.+Rodonauthor=V.+Peddareddigariauthor=F.+R.+Luoauthor=J.+C.+Soria&title=Phase+I+dose-escalation+study+of+JNJ-42756493%2C+an+oral+pan-fibroblast+growth+factor+receptor+inhibitor%2C+in+patients+with+advanced+solid+tumors&doi=10.1200%2FJCO.2014.60.7341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation study of JNJ-42756493, an oral Pan-Fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors</span></div><div class="casAuthors">Tabernero, Josep; Bahleda, Rastislav; Dienstmann, Rodrigo; Infante, Jeffrey R.; Mita, Alain; Italiano, Antoine; Calvo, Emiliano; Moreno, Victor; Adamo, Barbara; Gazzah, Anas; Zhong, Bob; Platero, Suso J.; Smit, Johan W.; Stuyckens, Kim; Chatterjee-Kishore, Moitreyee; Radon, Jordi; Peddareddigari, Vijay; Luo, Feng R.; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3401-3408</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: JNJ-42756493 is an orally administered pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.  This first-in-human study evaluates the safety, pharmacokinetics, and pharmaco-dynamics and defines the recommended phase II dose (RP2D) of JNJ-42756493.  Patients and Methods: Eligible patients with advanced solid tumors received escalating doses of JNJ-42756493 from 0.5 to 12 mg administered continuously daily or JNJ-42756493 10 or 12 mg administered intermittently (7 days on/7 days off).  Results: Sixty-five patients were enrolled.  The most common treatment-emergent adverse events included hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), constipation (34%), decreased appetite (32%), and dysgeusia (31%).  Twenty-seven patients (42%) experi- enced grade ≥ 3 treatment-emergent adverse events, and one dose-limiting toxicity of grade 3 ALT elevation was obsd. at 12 mg daily.  Maximum-tolerated dose was not defined.  Nine milligrams daily was considered as the initial RP2D; however, tolerability was improved with intermittent schedules, and 10 mg administered on a 7-days-on/7-days-off schedule was considered the final RP2D.  Pharmacokinetics were linear, dose proportional, and predictable, with a half-life of 50 to 60 h.  Dose-dependent elevations in serum phosphate, a manifestation of pharmacodynamic effect, occurred in all patients starting at 4 mg daily.  Among 23 response- evaluable patients with tumor FGFR pathway alterations, four confirmed responses and one unconfirmed partial response were obsd. in patients with glioblastoma and urothelial and endometrial cancer (all with FGFR2 or FGFR3 translocations); 16 patients had stable disease.  Conclusion: JNJ-42756493 administered at 10 mg on a 7-days-on/7-days-off schedule achieved exposures at which clin. responses were obsd., demonstrated pharmacodynamic biomarker activity, and had a manageable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo08TfKyvsabVg90H21EOLACvtfcHk0lg34kty5y_3Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFGrtb4%253D&md5=6d4a6b3c2f06f3d5d1a490cf9ffe44c5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.60.7341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.60.7341%26sid%3Dliteratum%253Aachs%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DBahleda%26aufirst%3DR.%26aulast%3DDienstmann%26aufirst%3DR.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMita%26aufirst%3DA.%26aulast%3DItaliano%26aufirst%3DA.%26aulast%3DCalvo%26aufirst%3DE.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DAdamo%26aufirst%3DB.%26aulast%3DGazzah%26aufirst%3DA.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DPlatero%26aufirst%3DS.%2BJ.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DStuyckens%26aufirst%3DK.%26aulast%3DChatterjee-Kishore%26aufirst%3DM.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DPeddareddigari%26aufirst%3DV.%26aulast%3DLuo%26aufirst%3DF.%2BR.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DPhase%2520I%2520dose-escalation%2520study%2520of%2520JNJ-42756493%252C%2520an%2520oral%2520pan-fibroblast%2520growth%2520factor%2520receptor%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D3401%26epage%3D3408%26doi%3D10.1200%2FJCO.2014.60.7341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yujiao Wei, Yanting Tang, Yunyun Zhou, Yuyu Yang, Yetong Cui, Xuan Wang, Yubo Wang, Yulin Liu, Ning Liu, Qianqian Wang, Chong Li, Hao Ruan, Honggang Zhou, Mingming Wei, Guang Yang, <span class="NLM_string-name hlFld-ContribAuthor">Cheng Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Optimization of a Novel 2H-Pyrazolo[3,4-d]pyrimidine Derivative as a Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 9078-9099. <a href="https://doi.org/10.1021/acs.jmedchem.1c00174" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00174</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00174%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BOptimization%252Bof%252Ba%252BNovel%252B2H-Pyrazolo%25255B3%25252C4-d%25255Dpyrimidine%252BDerivative%252Bas%252Ba%252BPotent%252BIrreversible%252BPan-Fibroblast%252BGrowth%252BFactor%252BReceptor%252BInhibitor%26aulast%3DWei%26aufirst%3DYujiao%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D31012021%26date%3D15062021%26volume%3D64%26issue%3D13%26spage%3D9078%26epage%3D9099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias R.  Bauer</span>, <span class="hlFld-ContribAuthor ">Paolo  Di Fruscia</span>, <span class="hlFld-ContribAuthor ">Simon C. C.  Lucas</span>, <span class="hlFld-ContribAuthor ">Iacovos N.  Michaelides</span>, <span class="hlFld-ContribAuthor ">Jennifer E.  Nelson</span>, <span class="hlFld-ContribAuthor ">R. Ian  Storer</span>, <span class="hlFld-ContribAuthor ">Benjamin C.  Whitehurst</span>. </span><span class="cited-content_cbyCitation_article-title">Put a ring on it: application of small aliphatic rings in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 448-471. <a href="https://doi.org/10.1039/D0MD00370K" title="DOI URL">https://doi.org/10.1039/D0MD00370K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00370K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00370K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DPut%252Ba%252Bring%252Bon%252Bit%25253A%252Bapplication%252Bof%252Bsmall%252Baliphatic%252Brings%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DBauer%26aufirst%3DMatthias%2BR.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D448%26epage%3D471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaowei  Wu</span>, <span class="hlFld-ContribAuthor ">Mengdi  Dai</span>, <span class="hlFld-ContribAuthor ">Rongrong  Cui</span>, <span class="hlFld-ContribAuthor ">Yulan  Wang</span>, <span class="hlFld-ContribAuthor ">Chunpu  Li</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Jihui  Zhao</span>, <span class="hlFld-ContribAuthor ">Bao  Wang</span>, <span class="hlFld-ContribAuthor ">Yang  Dai</span>, <span class="hlFld-ContribAuthor ">Dan  Feng</span>, <span class="hlFld-ContribAuthor ">Tianbiao  Yang</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Mingyue  Zheng</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>11 </em>
                                    (3)
                                     , 781-794. <a href="https://doi.org/10.1016/j.apsb.2020.09.002" title="DOI URL">https://doi.org/10.1016/j.apsb.2020.09.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2020.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2020.09.002%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bpyrazolo%25255B3%25252C4-d%25255Dpyridazinone%252Bderivatives%252Bas%252Bcovalent%252BFGFR%252Binhibitors%26aulast%3DWu%26aufirst%3DXiaowei%26date%3D2021%26volume%3D11%26issue%3D3%26spage%3D781%26epage%3D794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaolu  Chen</span>, <span class="hlFld-ContribAuthor ">Yanan  Liu</span>, <span class="hlFld-ContribAuthor ">Liting  Zhang</span>, <span class="hlFld-ContribAuthor ">Daoxing  Chen</span>, <span class="hlFld-ContribAuthor ">Zhaojun  Dong</span>, <span class="hlFld-ContribAuthor ">Chengguang  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhiguo  Liu</span>, <span class="hlFld-ContribAuthor ">Qinqin  Xia</span>, <span class="hlFld-ContribAuthor ">Jianzhang  Wu</span>, <span class="hlFld-ContribAuthor ">Yongheng  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Zheng</span>, <span class="hlFld-ContribAuthor ">Yuepiao  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113219. <a href="https://doi.org/10.1016/j.ejmech.2021.113219" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113219</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113219%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bindazole%252Bderivatives%252Bas%252Bselective%252Band%252Bpotent%252BFGFR4%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252BFGF19-driven%252Bhepatocellular%252Bcancer%26aulast%3DChen%26aufirst%3DXiaolu%26date%3D2021%26volume%3D214%26spage%3D113219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng-di  Dai</span>, <span class="hlFld-ContribAuthor ">Yue-liang  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Fan</span>, <span class="hlFld-ContribAuthor ">Yang  Dai</span>, <span class="hlFld-ContribAuthor ">Yin-chun  Ji</span>, <span class="hlFld-ContribAuthor ">Yi-ming  Sun</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Lan-lan  Li</span>, <span class="hlFld-ContribAuthor ">Yu-ming  Wang</span>, <span class="hlFld-ContribAuthor ">Wen-hu  Duan</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>. </span><span class="cited-content_cbyCitation_article-title">DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.1038/s41401-020-00567-3" title="DOI URL">https://doi.org/10.1038/s41401-020-00567-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41401-020-00567-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41401-020-00567-3%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DDW14383%252Bis%252Ban%252Birreversible%252Bpan-FGFR%252Binhibitor%252Bthat%252Bsuppresses%252BFGFR-dependent%252Btumor%252Bgrowth%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DDai%26aufirst%3DMeng-di%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akira  Yoshida</span>, <span class="hlFld-ContribAuthor ">Koichi  Okamoto</span>, <span class="hlFld-ContribAuthor ">Tomoyuki  Yanagi</span>, <span class="hlFld-ContribAuthor ">Keisuke  Nogi</span>, <span class="hlFld-ContribAuthor ">Hideki  Yorimitsu</span>. </span><span class="cited-content_cbyCitation_article-title">Metal-free synthesis of biaryls from aryl sulfoxides and sulfonanilides via sigmatropic rearrangement. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2020,</strong> <em>76 </em>
                                    (51)
                                     , 131232. <a href="https://doi.org/10.1016/j.tet.2020.131232" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131232%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DMetal-free%252Bsynthesis%252Bof%252Bbiaryls%252Bfrom%252Baryl%252Bsulfoxides%252Band%252Bsulfonanilides%252Bvia%252Bsigmatropic%252Brearrangement%26aulast%3DYoshida%26aufirst%3DAkira%26date%3D2020%26volume%3D76%26issue%3D51%26spage%3D131232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Niefang  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation: 5-amino-1H-pyrazole-1- carbonyl derivatives as FGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Letters in Drug Design & Discovery</span><span> <strong>2020,</strong> <em>17 </em>
                                    (11)
                                     , 1330-1341. <a href="https://doi.org/10.2174/1570180817999200608140628" title="DOI URL">https://doi.org/10.2174/1570180817999200608140628</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570180817999200608140628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570180817999200608140628%26sid%3Dliteratum%253Aachs%26jtitle%3DLetters%2520in%2520Drug%2520Design%2520%2526%2520Discovery%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%25253A%252B5-amino-1H-pyrazole-1-%252Bcarbonyl%252Bderivatives%252Bas%252BFGFR%252BInhibitors%26aulast%3DZhang%26aufirst%3DYan%26date%3D2020%26volume%3D17%26issue%3D11%26spage%3D1330%26epage%3D1341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bryan  Li</span>, <span class="hlFld-ContribAuthor ">Scott  Bader</span>, <span class="hlFld-ContribAuthor ">Steve M.  Guinness</span>, <span class="hlFld-ContribAuthor ">Sally Gut  Ruggeri</span>, <span class="hlFld-ContribAuthor ">Cheryl M.  Hayward</span>, <span class="hlFld-ContribAuthor ">Steve  Hoagland</span>, <span class="hlFld-ContribAuthor ">John  Lucas</span>, <span class="hlFld-ContribAuthor ">Ruizhi  Li</span>, <span class="hlFld-ContribAuthor ">David  Limburg</span>, <span class="hlFld-ContribAuthor ">J. Christopher  McWilliams</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Raggon</span>, <span class="hlFld-ContribAuthor ">John  Van Alsten</span>. </span><span class="cited-content_cbyCitation_article-title">Continuous flow aminolysis under high temperature and pressure. </span><span class="cited-content_cbyCitation_journal-name">Journal of Flow Chemistry</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     , 145-156. <a href="https://doi.org/10.1007/s41981-019-00049-6" title="DOI URL">https://doi.org/10.1007/s41981-019-00049-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s41981-019-00049-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs41981-019-00049-6%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Flow%2520Chemistry%26atitle%3DContinuous%252Bflow%252Baminolysis%252Bunder%252Bhigh%252Btemperature%252Band%252Bpressure%26aulast%3DLi%26aufirst%3DBryan%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1%26spage%3D145%26epage%3D156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bailing  Jiang</span>, <span class="hlFld-ContribAuthor ">Junhe  Li</span>, <span class="hlFld-ContribAuthor ">Jun  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Xiang</span>, <span class="hlFld-ContribAuthor ">Jianping  Xiong</span>, <span class="hlFld-ContribAuthor ">Jun  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Thoracic Cancer</span><span> <strong>2020,</strong> <em>11 </em>
                                    (2)
                                     , 461-464. <a href="https://doi.org/10.1111/1759-7714.13288" title="DOI URL">https://doi.org/10.1111/1759-7714.13288</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/1759-7714.13288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2F1759-7714.13288%26sid%3Dliteratum%253Aachs%26jtitle%3DThoracic%2520Cancer%26atitle%3DAortic%252Bdissection%252Bin%252Ba%252Bpatient%252Btreated%252Bwith%252Banlotinib%252Bfor%252Bmetastatic%252Blung%252Bsquamous%252Bcell%252Bcarcinoma%26aulast%3DJiang%26aufirst%3DBailing%26date%3D2020%26date%3D2019%26volume%3D11%26issue%3D2%26spage%3D461%26epage%3D464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Marseglia</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>. </span><span class="cited-content_cbyCitation_article-title">Fibroblast growth factor receptor inhibitors: patent review (2015–2019). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 965-977. <a href="https://doi.org/10.1080/13543776.2019.1688300" title="DOI URL">https://doi.org/10.1080/13543776.2019.1688300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1688300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1688300%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DFibroblast%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%25253A%252Bpatent%252Breview%252B%2525282015%2525E2%252580%2525932019%252529%26aulast%3DMarseglia%26aufirst%3DGiuseppe%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D965%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Güneş  Çoban</span>, <span class="hlFld-ContribAuthor ">Fadime  Aydın Köse</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, biological evaluations and molecular modelling studies of novel indolin-2-ones designing as FGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Saudi Pharmaceutical Journal</span><span> <strong>2019,</strong> <em>27 </em>
                                    (7)
                                     , 952-967. <a href="https://doi.org/10.1016/j.jsps.2019.07.004" title="DOI URL">https://doi.org/10.1016/j.jsps.2019.07.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jsps.2019.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jsps.2019.07.004%26sid%3Dliteratum%253Aachs%26jtitle%3DSaudi%2520Pharmaceutical%2520Journal%26atitle%3DSynthesis%25252C%252Bbiological%252Bevaluations%252Band%252Bmolecular%252Bmodelling%252Bstudies%252Bof%252Bnovel%252Bindolin-2-ones%252Bdesigning%252Bas%252BFGFR%252Binhibitors%26aulast%3D%25C3%2587oban%26aufirst%3DG%25C3%25BCne%25C5%259F%26date%3D2019%26volume%3D27%26issue%3D7%26spage%3D952%26epage%3D967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Lin-jiang  Tong</span>, <span class="hlFld-ContribAuthor ">Bai-you  Tang</span>, <span class="hlFld-ContribAuthor ">Hong-yan  Liu</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Xian-wen  Cao</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Hong-lin  Li</span>, <span class="hlFld-ContribAuthor ">Xu-hong  Qian</span>, <span class="hlFld-ContribAuthor ">Yu-fang  Xu</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2019,</strong> <em>40 </em>
                                    (6)
                                     , 823-832. <a href="https://doi.org/10.1038/s41401-018-0191-7" title="DOI URL">https://doi.org/10.1038/s41401-018-0191-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41401-018-0191-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41401-018-0191-7%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DC11%25252C%252Ba%252Bnovel%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%252B1%252B%252528FGFR1%252529%252Binhibitor%25252C%252Bsuppresses%252Bbreast%252Bcancer%252Bmetastasis%252Band%252Bangiogenesis%26aulast%3DChen%26aufirst%3DZhuo%26date%3D2019%26date%3D2018%26volume%3D40%26issue%3D6%26spage%3D823%26epage%3D832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michele  Montaruli</span>, <span class="hlFld-ContribAuthor ">Domenico  Alberga</span>, <span class="hlFld-ContribAuthor ">Fulvio  Ciriaco</span>, <span class="hlFld-ContribAuthor ">Daniela  Trisciuzzi</span>, <span class="hlFld-ContribAuthor ">Anna Rita  Tondo</span>, <span class="hlFld-ContribAuthor ">Giuseppe Felice  Mangiatordi</span>, <span class="hlFld-ContribAuthor ">Orazio  Nicolotti</span>. </span><span class="cited-content_cbyCitation_article-title">Accelerating Drug Discovery by Early Protein Drug Target Prediction Based on a Multi-Fingerprint Similarity Search †. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (12)
                                     , 2233. <a href="https://doi.org/10.3390/molecules24122233" title="DOI URL">https://doi.org/10.3390/molecules24122233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24122233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24122233%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DAccelerating%252BDrug%252BDiscovery%252Bby%252BEarly%252BProtein%252BDrug%252BTarget%252BPrediction%252BBased%252Bon%252Ba%252BMulti-Fingerprint%252BSimilarity%252BSearch%252B%2525E2%252580%2525A0%26aulast%3DMontaruli%26aufirst%3DMichele%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D12%26spage%3D2233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria  Kalyukina</span>, <span class="hlFld-ContribAuthor ">Yuliana  Yosaatmadja</span>, <span class="hlFld-ContribAuthor ">Martin J.  Middleditch</span>, <span class="hlFld-ContribAuthor ">Adam V.  Patterson</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Squire</span>. </span><span class="cited-content_cbyCitation_article-title">TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2019,</strong> <em>14 </em>
                                    (4)
                                     , 494-500. <a href="https://doi.org/10.1002/cmdc.201800719" title="DOI URL">https://doi.org/10.1002/cmdc.201800719</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800719%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DTAS%2525E2%252580%252590120%252BCancer%252BTarget%252BBinding%25253A%252BDefining%252BReactivity%252Band%252BRevealing%252Bthe%252BFirst%252BFibroblast%252BGrowth%252BFactor%252BReceptor%2525E2%252580%2525851%252B%252528FGFR1%252529%252BIrreversible%252BStructure%26aulast%3DKalyukina%26aufirst%3DMaria%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D4%26spage%3D494%26epage%3D500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Farideh  Badichi Akher</span>, <span class="hlFld-ContribAuthor ">Abdolkarim  Farrokhzadeh</span>, <span class="hlFld-ContribAuthor ">Fisayo A.  Olotu</span>, <span class="hlFld-ContribAuthor ">Clement  Agoni</span>, <span class="hlFld-ContribAuthor ">Mahmoud E. S.  Soliman</span>. </span><span class="cited-content_cbyCitation_article-title">The irony of chirality – unveiling the distinct mechanistic binding and activities of 1-(3-(4-amino-5-(7-methoxy-5-methylbenzo[
              b
              ]thiophen-2-yl)-7
              H
              -pyrrolo[2,3-
              d
              ]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one enantiomers as irreversible covalent FGFR4 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (5)
                                     , 1176-1190. <a href="https://doi.org/10.1039/C8OB02811G" title="DOI URL">https://doi.org/10.1039/C8OB02811G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB02811G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB02811G%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DThe%252Birony%252Bof%252Bchirality%252B%2525E2%252580%252593%252Bunveiling%252Bthe%252Bdistinct%252Bmechanistic%252Bbinding%252Band%252Bactivities%252Bof%252B1-%2525283-%2525284-amino-5-%2525287-methoxy-5-methylbenzo%25255B%252Bb%252B%25255Dthiophen-2-yl%252529-7%252BH%252B-pyrrolo%25255B2%25252C3-%252Bd%252B%25255Dpyrimidin-7-yl%252529pyrrolidin-1-yl%252529prop-2-en-1-one%252Benantiomers%252Bas%252Birreversible%252Bcovalent%252BFGFR4%252Binhibitors%26aulast%3DBadichi%2BAkher%26aufirst%3DFarideh%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D5%26spage%3D1176%26epage%3D1190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structural analysis of the FGFR and FGFR inhibitors. (A) Representative FGFR inhibitors. (B) X-ray crystal structure of FGFR1 in complex with AMP (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GQI">3GQI</a>). (C) Five regions of the ATP binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of reported irreversible FGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design of covalent FGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Modeled interactions of benzo[<i>b</i>]thiophene motifs with hydrophobic region I in FGFR4 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R6V">4R6V</a>): (A) <b>6c</b> with hydrophobic region I, (B) <b>6b</b> with hydrophobic region I.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>9g</b> effectively inhibits the phosphorylation of FGFR and the downstream effectors PLCγ and Erk in KG-1 (A), SNU-16 (B), and UMUC-14 (C). Cells treated with <b>9g</b> for 2 h at the indicated concentrations were lysed and subjected to Western blot analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>9g</b> irreversibly binds to FGFR1. Enzyme activity of FGFR1 was assayed by a Caliper EZ Reader under three different conditions: without the enzyme (background), without the compound (nonpreincubation control), and preincubated with the compound. “Conversion” here represents the enzyme activity and means “the percent of conversion of the substrate peptide”.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <b>9g</b> significantly inhibited FGFR-mediated tumor growth in vivo. (A) Tumor growth was inhibited upon <b>9g</b> treatment in NCI-H1581 xenografts. The RTVs are expressed as the mean ± SEM. Significant difference from the vehicle group was determined using a <i>t</i>-test, * <i>P</i> < 0.05, ** <i>P</i> < 0.01, *** <i>P</i> < 0.001. (B) Tumor weights are shown for day 14 after the mice were administered <b>9g</b>. (C) Body weight measurements during treatment. (D) Tumor growth was inhibited upon <b>9g</b> treatment in the SNU-16 xenografts. The RTVs are expressed as the mean ± SEM. Significant difference from the vehicle group was determined using a <i>t</i>-test, * <i>P</i> < 0.05, ** <i>P</i> < 0.01, *** <i>P</i> < 0.001. Tumor weights (E) are shown for day 21 after the mice were administered <b>9g</b>. (F) Body weight measurements during treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Proposed binding mode of <b>9g</b> with FGFR4 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R6V">4R6V</a>). (A) The docked protein structure of FGFR4 is shown on the surface. (B) The atoms of <b>9g</b> are colored as follows: carbon, green; oxygen, red; nitrogen, blue; sulfur, dark yellow. The protein is shown in the cartoon, and key residues are colored as follows: carbon, yellow; oxygen, red; nitrogen, blue, sulfur, dark yellow. H bonds are indicated by red dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Target Compounds <b>6a</b>–<b>l</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HO-linker-Boc, PPh<sub>3</sub>, DIAD, THF, 0 °C to rt or <i>tert</i>-butyl 2-bromoethylcarbamate, cesium carbonate, 80 °C; (b) ammonia (aq), 110 °C; (c) boronic acids or boronate esters, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 80 °C; (d) (i) HCl/dioxane, rt, (ii) acryloyl chloride, TEA, DCM, rt.</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Target Compounds <b>7a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HO-linker-Boc, PPh<sub>3</sub>, DIAD, THF, 0 °C to rt; (b) ammonia or methylamine (aq), 110 °C; (c) (7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl) boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 80 °C; (d) (i) HCl/dioxane, rt, (ii) acryloyl chloride, TEA, DCM, rt.</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/medium/jm-2017-01843j_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Target Compounds <b>8a</b>–<b>e</b>, <b>9a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01843&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (7-methoxy-5-methylbenzo[<i>b</i>]thiophen-2-yl) boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 80 °C; (b) (i) HCl/dioxane, rt, (ii) acyl chloride, TEA, DCM, rt or corresponding carboxylic acid, HATU, DMF, DIPEA, rt.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i125">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25400" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25400" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 44 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grose, R.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor signalling: from development to cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1038/nrc2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1038%2Fnrc2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=20094046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=116-129&author=N.+Turnerauthor=R.+Grose&title=Fibroblast+growth+factor+signalling%3A+from+development+to+cancer&doi=10.1038%2Fnrc2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signalling: from development to cancer</span></div><div class="casAuthors">Turner, Nicholas; Grose, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their receptors control a wide range of biol. functions, regulating cellular proliferation, survival, migration and differentiation.  Although targeting FGF signalling as a cancer therapeutic target has lagged behind that of other receptor tyrosine kinases, there is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumor types, and clin. reagents that specifically target the FGFs or FGF receptors are being developed.  Although FGF signalling can drive tumorigenesis, in different contexts FGF signalling can mediate tumor protective functions; the identification of the mechanisms that underlie these differential effects will be important to understand how FGF signalling can be most appropriately therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUBfz6uAu97bVg90H21EOLACvtfcHk0lhstLqHLcNMLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D&md5=7963bc75c149981560dffc8d91b4aaf1</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2780%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DGrose%26aufirst%3DR.%26atitle%3DFibroblast%2520growth%2520factor%2520signalling%253A%2520from%2520development%2520to%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fnrc2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fearon, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grose, R. P.</span></span> <span> </span><span class="NLM_article-title">Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2014.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2Fj.tcb.2014.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=25467007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2jtL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=221-233&author=E.+P.+Carterauthor=A.+E.+Fearonauthor=R.+P.+Grose&title=Careless+talk+costs+lives%3A+fibroblast+growth+factor+receptor+signalling+and+the+consequences+of+pathway+malfunction&doi=10.1016%2Fj.tcb.2014.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction</span></div><div class="casAuthors">Carter, Edward P.; Fearon, Abbie E.; Grose, Richard P.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">221-233</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Since its discovery 40 years ago, fibroblast growth factor (FGF) receptor (FGFR) signalling has been found to regulate fundamental cellular behaviors in a wide range of cell types.  FGFRs regulate development, homeostasis, and repair and are implicated in many disorders and diseases; and indeed, there is extensive potential for severe consequences, be they developmental, homeostatic, or oncogenic, should FGF-FGFR signalling go awry, so careful control of the pathway is critically important.  In this review, we discuss the recent developments in the FGF field, highlighting how FGFR signalling works in normal cells, how it can go wrong, how frequently it is compromised, and how it is being targeted therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJuJ0uV7rBFbVg90H21EOLACvtfcHk0lhstLqHLcNMLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2jtL%252FL&md5=d184f8f455ae220c2265070479309dee</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2014.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2014.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DE.%2BP.%26aulast%3DFearon%26aufirst%3DA.%2BE.%26aulast%3DGrose%26aufirst%3DR.%2BP.%26atitle%3DCareless%2520talk%2520costs%2520lives%253A%2520fibroblast%2520growth%2520factor%2520receptor%2520signalling%2520and%2520the%2520consequences%2520of%2520pathway%2520malfunction%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2015%26volume%3D25%26spage%3D221%26epage%3D233%26doi%3D10.1016%2Fj.tcb.2014.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Touat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ileana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postel-Vinay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">Targeting FGFR signaling in cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2684</span>– <span class="NLM_lpage">2694</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F1078-0432.CCR-14-2329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=26078430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2684-2694&author=M.+Touatauthor=E.+Ileanaauthor=S.+Postel-Vinayauthor=F.+Andreauthor=J.+C.+Soria&title=Targeting+FGFR+signaling+in+cancer&doi=10.1158%2F1078-0432.CCR-14-2329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FGFR Signaling in Cancer</span></div><div class="casAuthors">Touat, Mehdi; Ileana, Ecaterina; Postel-Vinay, Sophie; Andre, Fabrice; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2684-2694</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor signaling pathway (FGFR signaling) is an evolutionary conserved signaling cascade that regulates several basic biol. processes, including tissue development, angiogenesis, and tissue regeneration.  Substantial evidence indicates that aberrant FGFR signaling is involved in the pathogenesis of cancer.  Recent developments of deep sequencing technologies have allowed the discovery of frequent mol. alterations in components of FGFR signaling among several solid tumor types.  Moreover, compelling preclin. models have demonstrated the oncogenic potential of these aberrations in driving tumor growth, promoting angiogenesis, and conferring resistance mechanisms to anticancer therapies.  Recently, the field of FGFR targeting has exponentially progressed thanks to the development of novel agents inhibiting FGFs or FGFRs, which had manageable safety profiles in early-phase trials.  Promising treatment efficacy has been obsd. in different types of malignancies, particularly in tumors harboring aberrant FGFR signaling, thus offering novel therapeutic opportunities in the era of precision medicine.  The most exciting challenges now focus on selecting patients who are most likely to benefit from these agents, increasing the efficacy of therapies with the development of novel potent compds. and combination strategies, and overcoming toxicities assocd. with FGFR inhibitors.  After examn. of the basic and translational research studies that validated the oncogenic potential of aberrant FGFR signaling, this review focuses on recent data from clin. trials evaluating FGFR targeting therapies and discusses the challenges and perspectives for the development of these agents.  Clin Cancer Res; 21(12); 2684-94. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSZpKbvUn0hrVg90H21EOLACvtfcHk0lhstLqHLcNMLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfP&md5=3dbb11de3f3a7d25d3b4ccb56400fd4d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2329%26sid%3Dliteratum%253Aachs%26aulast%3DTouat%26aufirst%3DM.%26aulast%3DIleana%26aufirst%3DE.%26aulast%3DPostel-Vinay%26aufirst%3DS.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DTargeting%2520FGFR%2520signaling%2520in%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2684%26epage%3D2694%26doi%3D10.1158%2F1078-0432.CCR-14-2329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dieci, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnedos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">264</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F2159-8290.CD-12-0362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=23418312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=264-279&author=M.+V.+Dieciauthor=M.+Arnedosauthor=F.+Andreauthor=J.+C.+Soria&title=Fibroblast+growth+factor+receptor+inhibitors+as+a+cancer+treatment%3A+from+a+biologic+rationale+to+medical+perspectives&doi=10.1158%2F2159-8290.CD-12-0362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives</span></div><div class="casAuthors">Dieci, Maria Vittoria; Arnedos, Monica; Andre, Fabrice; Soria, Jean Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">264-279</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway plays a fundamental role in many physiol. processes, including embryogenesis, adult tissue homeostasis, and wound healing, by orchestrating angiogenesis.  Ligand-independent and ligand-dependent activation have been implicated in a broad range of human malignancies and promote cancer progression in tumors driven by FGF/FGFR oncogenic mutations or amplifications, tumor neoangiogenesis, and targeted treatment resistance, thereby supporting a strong rationale for anti-FGF/FGFR agent development.  Efforts are being pursued to develop selective approaches for use against this pathway by optimizing the management of emerging, class-specific toxicity profiles and correctly designing clin. trials to address these different issues.  Significance: FGF/FGFR pathway deregulations are increasingly recognized across different human cancers.  Understanding the mechanisms at the basis of these alterations and their multiple roles in cancer promotion and drug resistance is a fundamental step for further implementation of targeted therapies and research strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6bibZKwamTLVg90H21EOLACvtfcHk0ljhpA4TGWivvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D&md5=0e694a7641aa83c1540f745576f04bfa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0362%26sid%3Dliteratum%253Aachs%26aulast%3DDieci%26aufirst%3DM.%2BV.%26aulast%3DArnedos%26aufirst%3DM.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DFibroblast%2520growth%2520factor%2520receptor%2520inhibitors%2520as%2520a%2520cancer%2520treatment%253A%2520from%2520a%2520biologic%2520rationale%2520to%2520medical%2520perspectives%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D264%26epage%3D279%26doi%3D10.1158%2F2159-8290.CD-12-0362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Helsten, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomson, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span> <span> </span><span class="NLM_article-title">The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F1078-0432.CCR-14-3212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=26373574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVGqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=259-267&author=T.+Helstenauthor=S.+Elkinauthor=E.+Arthurauthor=B.+N.+Tomsonauthor=J.+Carterauthor=R.+Kurzrock&title=The+FGFR+landscape+in+cancer%3A+analysis+of+4%2C853+tumors+by+next-generation+sequencing&doi=10.1158%2F1078-0432.CCR-14-3212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing</span></div><div class="casAuthors">Helsten, Teresa; Elkin, Sheryl; Arthur, Elisa; Tomson, Brett N.; Carter, Jennifer; Kurzrock, Razelle</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">259-267</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Mol. profiling may have prognostic and predictive value, and is increasingly used in the clin. setting.  There are more than a dozen fibroblast growth factor receptor (FGFR) inhibitors in development.  Optimal therapeutic application of FGFR inhibitors requires knowledge of the rates and types of FGFR aberrations in a variety of cancer types.  Exptl. Design: We analyzed frequencies of FGFR aberrations in 4,853 solid tumors that were, on physician request, tested in a Clin. Lab.  Improvement Amendments (CLIA) lab. (Foundation Medicine) using next-generation sequencing (182 or 236 genes), and analyzed by N-of-One.  Results: FGFR aberrations were found in 7.1% of cancers, with the majority being gene amplification (66% of the aberrations), followed by mutations (26%) and rearrangements (8%).  FGFR1 (mostly amplification) was affected in 3.5% of 4,853 patients; FGFR2 in 1.5%; FGFR3 in 2.0%; and FGFR4 in 0.5%.  Almost every type of malignancy examd. showed some patients with FGFR aberrations, but the cancers most commonly affected were urothelial (32% FGFR-aberrant); breast (18%); endometrial (∼13%), squamous lung cancers (∼13%), and ovarian cancer (∼9%).  Among 35 unique FGFR mutations seen in this dataset, all but two are found in COSMIC.  Seventeen of the 35 are known to be activating, and 11 are transforming.  Conclusions: FGFR aberrations are common in a wide variety of cancers, with the majority being gene amplifications or activating mutations.  These data suggest that FGFR inhibition could be an important therapeutic option across multiple tumor types.  Clin Cancer Res; 22(1); 259-67. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_eQBJarU4mLVg90H21EOLACvtfcHk0lgA4fdMpUW_4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVGqs7Y%253D&md5=7172cbee01331fe0d3fac5dada295fc2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3212%26sid%3Dliteratum%253Aachs%26aulast%3DHelsten%26aufirst%3DT.%26aulast%3DElkin%26aufirst%3DS.%26aulast%3DArthur%26aufirst%3DE.%26aulast%3DTomson%26aufirst%3DB.%2BN.%26aulast%3DCarter%26aufirst%3DJ.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DThe%2520FGFR%2520landscape%2520in%2520cancer%253A%2520analysis%2520of%25204%252C853%2520tumors%2520by%2520next-generation%2520sequencing%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D259%26epage%3D267%26doi%3D10.1158%2F1078-0432.CCR-14-3212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Garcia, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natrajan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iorns, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">2085</span>– <span class="NLM_lpage">2094</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F0008-5472.CAN-09-3746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=20179196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2085-2094&author=N.+Turnerauthor=A.+Pearsonauthor=R.+Sharpeauthor=M.+Lambrosauthor=F.+Geyerauthor=M.+A.+Lopez-Garciaauthor=R.+Natrajanauthor=C.+Marchioauthor=E.+Iornsauthor=A.+Mackayauthor=C.+Gillettauthor=A.+Grigoriadisauthor=A.+Tuttauthor=J.+S.+Reis-Filhoauthor=A.+Ashworth&title=FGFR1+amplification+drives+endocrine+therapy+resistance+and+is+a+therapeutic+target+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-09-3746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer</span></div><div class="casAuthors">Turner, Nicholas; Pearson, Alex; Sharpe, Rachel; Lambros, Maryou; Geyer, Felipe; Lopez-Garcia, Maria A.; Natrajan, Rachael; Marchio, Caterina; Iorns, Elizabeth; Mackay, Alan; Gillett, Cheryl; Grigoriadis, Anita; Tutt, Andrew; Reis-Filho, Jorge S.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2085-2094</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Amplification of fibroblast growth factor receptor 1 (FGFR1) occurs in ∼10% of breast cancers and is assocd. with poor prognosis.  However, it is uncertain whether overexpression of FGFR1 is causally linked to the poor prognosis of amplified cancers.  Here, we show that FGFR1 overexpression is robustly assocd. with FGFR1 amplification in two independent series of breast cancers.  Breast cancer cell lines with FGFR1 overexpression and amplification show enhanced ligand-dependent signaling, with increased activation of the mitogen-activated protein kinase and phosphoinositide 3-kinase-AKT signaling pathways in response to FGF2, but also show basal ligand-independent signaling, and are dependent on FGFR signaling for anchorage-independent growth.  FGFR1-amplified cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1, suggesting that FGFR1 overexpression also promotes endocrine therapy resistance.  FGFR1 signaling suppresses progesterone receptor (PR) expression in vitro, and likewise, amplified cancers are frequently PR neg., identifying a potential biomarker for FGFR1 activity.  Furthermore, we show that amplified cancers have a high proliferative rate assessed by Ki67 staining and that FGFR1 amplification is found in 16% to 27% of luminal B-type breast cancers.  Our data suggest that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbsQ_wPmoftLVg90H21EOLACvtfcHk0lgp8XymeMITJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWis7s%253D&md5=d14ce3b47614b090c4f7bfa7e4ce8a38</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3746%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DPearson%26aufirst%3DA.%26aulast%3DSharpe%26aufirst%3DR.%26aulast%3DLambros%26aufirst%3DM.%26aulast%3DGeyer%26aufirst%3DF.%26aulast%3DLopez-Garcia%26aufirst%3DM.%2BA.%26aulast%3DNatrajan%26aufirst%3DR.%26aulast%3DMarchio%26aufirst%3DC.%26aulast%3DIorns%26aufirst%3DE.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DGillett%26aufirst%3DC.%26aulast%3DGrigoriadis%26aufirst%3DA.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DFGFR1%2520amplification%2520drives%2520endocrine%2520therapy%2520resistance%2520and%2520is%2520a%2520therapeutic%2520target%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D2085%26epage%3D2094%26doi%3D10.1158%2F0008-5472.CAN-09-3746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, P. M.</span></span> <span> </span><span class="NLM_article-title">Targeting mutant fibroblast growth factor receptors in cancer</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2011.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2Fj.molmed.2011.01.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=283-292&author=H.+Greulichauthor=P.+M.+Pollock&title=Targeting+mutant+fibroblast+growth+factor+receptors+in+cancer&doi=10.1016%2Fj.molmed.2011.01.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2011.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2011.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DPollock%26aufirst%3DP.%2BM.%26atitle%3DTargeting%2520mutant%2520fibroblast%2520growth%2520factor%2520receptors%2520in%2520cancer%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D283%26epage%3D292%26doi%3D10.1016%2Fj.molmed.2011.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, A. H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, B. T.</span></span> <span> </span><span class="NLM_article-title">Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.07.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2Fj.drudis.2013.07.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=23932951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyrsLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=51-62&author=H.+K.+Hoauthor=A.+H.+L.+Yeoauthor=T.+S.+Kangauthor=B.+T.+Chua&title=Current+strategies+for+inhibiting+FGFR+activities+in+clinical+applications%3A+opportunities%2C+challenges+and+toxicological+considerations&doi=10.1016%2Fj.drudis.2013.07.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations</span></div><div class="casAuthors">Ho, Han Kiat; Yeo, Angie Hui Ling; Kang, Tse Siang; Chua, Boon Tin</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-62</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Aberrations in fibroblast growth factor receptor (FGFR) signaling are instrumental to the pathophysiol. of several malignancies and disorders.  Hence, FGFR inhibitors are explored in therapeutics with early candidates developed as competitors for the ATP-binding pocket in the kinase domain.  More recent programs yielded compds. of diverse scaffolds with alternative binding modes.  Concurrently, monoclonal antibodies and peptide-based agents provide independent options for clin. development.  Notwithstanding this rapid progress, we contemplate the toxicol. impact of FGFR inhibition based on the defined role of FGFR family members in physiol. and homeostasis.  The high homol. among FGFR1-4 and also with other kinase subfamilies creates an addnl. challenge in developing selective inhibitors.  It orchestrates an ongoing conundrum of moderating a balance between synergism through multitargeting kinase inhibition and minimizing off-target toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonzqQ29AMdrbVg90H21EOLACvtfcHk0lgrtQUeg8GTbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyrsLrL&md5=2ff38789d72dbe11bfe053001e477ef7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.07.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.07.021%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DH.%2BK.%26aulast%3DYeo%26aufirst%3DA.%2BH.%2BL.%26aulast%3DKang%26aufirst%3DT.%2BS.%26aulast%3DChua%26aufirst%3DB.%2BT.%26atitle%3DCurrent%2520strategies%2520for%2520inhibiting%2520FGFR%2520activities%2520in%2520clinical%2520applications%253A%2520opportunities%252C%2520challenges%2520and%2520toxicological%2520considerations%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D51%26epage%3D62%26doi%3D10.1016%2Fj.drudis.2013.07.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiner, L. M.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1083</span>– <span class="NLM_lpage">1093</span>, <span class="refDoi"> DOI: 10.1038/onc.2014.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1038%2Fonc.2014.51" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=1083-1093&author=B.+Kimauthor=S.+Wangauthor=J.+M.+Leeauthor=Y.+Jeongauthor=T.+Ahnauthor=D.+S.+Sonauthor=H.+W.+Parkauthor=H.+S.+Yooauthor=Y.+J.+Songauthor=E.+Leeauthor=Y.+M.+Ohauthor=S.+B.+Leeauthor=J.+Choiauthor=J.+C.+Murrayauthor=Y.+Zhouauthor=P.+H.+Songauthor=K.+A.+Kimauthor=L.+M.+Weiner&title=Synthetic+lethal+screening+reveals+FGFR+as+one+of+the+combinatorial+targets+to+overcome+resistance+to+Met-targeted+therapy&doi=10.1038%2Fonc.2014.51"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fonc.2014.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2014.51%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DAhn%26aufirst%3DT.%26aulast%3DSon%26aufirst%3DD.%2BS.%26aulast%3DPark%26aufirst%3DH.%2BW.%26aulast%3DYoo%26aufirst%3DH.%2BS.%26aulast%3DSong%26aufirst%3DY.%2BJ.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DOh%26aufirst%3DY.%2BM.%26aulast%3DLee%26aufirst%3DS.%2BB.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DMurray%26aufirst%3DJ.%2BC.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DP.%2BH.%26aulast%3DKim%26aufirst%3DK.%2BA.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26atitle%3DSynthetic%2520lethal%2520screening%2520reveals%2520FGFR%2520as%2520one%2520of%2520the%2520combinatorial%2520targets%2520to%2520overcome%2520resistance%2520to%2520Met-targeted%2520therapy%26jtitle%3DOncogene%26date%3D2015%26volume%3D34%26spage%3D1083%26epage%3D1093%26doi%3D10.1038%2Fonc.2014.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morishima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukayama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefor, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niki, T.</span></span> <span> </span><span class="NLM_article-title">The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">82</span>, <span class="refDoi"> DOI: 10.1186/s12885-015-1065-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1186%2Fs12885-015-1065-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=82&author=S.+Saitoauthor=K.+Morishimaauthor=T.+Uiauthor=H.+Hoshinoauthor=D.+Matsubaraauthor=S.+Ishikawaauthor=H.+Aburataniauthor=M.+Fukayamaauthor=Y.+Hosoyaauthor=N.+Sataauthor=A.+K.+Leforauthor=Y.+Yasudaauthor=T.+Niki&title=The+role+of+HGF%2FMET+and+FGF%2FFGFR+in+fibroblast-derived+growth+stimulation+and+lapatinib-resistance+of+esophageal+squamous+cell+carcinoma&doi=10.1186%2Fs12885-015-1065-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-1065-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-1065-8%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DS.%26aulast%3DMorishima%26aufirst%3DK.%26aulast%3DUi%26aufirst%3DT.%26aulast%3DHoshino%26aufirst%3DH.%26aulast%3DMatsubara%26aufirst%3DD.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DFukayama%26aufirst%3DM.%26aulast%3DHosoya%26aufirst%3DY.%26aulast%3DSata%26aufirst%3DN.%26aulast%3DLefor%26aufirst%3DA.%2BK.%26aulast%3DYasuda%26aufirst%3DY.%26aulast%3DNiki%26aufirst%3DT.%26atitle%3DThe%2520role%2520of%2520HGF%252FMET%2520and%2520FGF%252FFGFR%2520in%2520fibroblast-derived%2520growth%2520stimulation%2520and%2520lapatinib-resistance%2520of%2520esophageal%2520squamous%2520cell%2520carcinoma%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D82%26doi%3D10.1186%2Fs12885-015-1065-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renhowe, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machajewski, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jazan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonios-McCrea, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapointe, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feucht, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warne, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heise, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aardalen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernette-Hammond, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. L.</span></span> <span> </span><span class="NLM_article-title">Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1021/jm800790t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800790t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Sl" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=278-292&author=P.+A.+Renhoweauthor=S.+Pecchiauthor=C.+M.+Shaferauthor=T.+D.+Machajewskiauthor=E.+M.+Jazanauthor=C.+Taylorauthor=W.+Antonios-McCreaauthor=C.+M.+McBrideauthor=K.+Frazierauthor=M.+Wiesmannauthor=G.+R.+Lapointeauthor=P.+H.+Feuchtauthor=R.+L.+Warneauthor=C.+C.+Heiseauthor=D.+Menezesauthor=K.+Aardalenauthor=H.+Yeauthor=M.+Heauthor=V.+Leauthor=J.+Voraauthor=J.+M.+Jansenauthor=M.+E.+Wernette-Hammondauthor=A.+L.+Harris&title=Design%2C+structure-activity+relationships+and+in+vivo+characterization+of+4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%3A+a+novel+class+of+receptor+tyrosine+kinase+inhibitors&doi=10.1021%2Fjm800790t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Structure-Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Renhowe, Paul A.; Pecchi, Sabina; Shafer, Cynthia M.; Machajewski, Timothy D.; Jazan, Elisa M.; Taylor, Clarke; Antonios-McCrea, William; McBride, Christopher M.; Frazier, Kelly; Wiesmann, Marion; Lapointe, Gena R.; Feucht, Paul H.; Warne, Robert L.; Heise, Carla C.; Menezes, Daniel; Aardalen, Kimberly; Ye, Helen; He, Molly; Le, Vincent; Vora, Jayesh; Jansen, Johanna M.; Wernette-Hammond, Mary Ellen; Harris, Alex L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-292</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The inhibition of key receptor tyrosine kinases (RTKs) that are implicated in tumor vasculature formation and maintenance, as well as tumor progression and metastasis, has been a major focus in oncol. research over the last several years.  Many potent small mol. inhibitors of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) kinases have been evaluated.  More recently, compds. that act through the complex inhibition of multiple kinase targets have been reported and may exhibit improved clin. efficacy.  We report herein a series of potent, orally efficacious 4-amino-3-benzimidazol-2-ylhydroquinolin-2-one analogs as inhibitors of VEGF, PDGF, and fibroblast growth factor (FGF) receptor tyrosine kinases.  Compds. in this class, such as TKI258 (I), are reversible ATP-competitive inhibitors of VEGFR-2, FGFR-1, and PDGFRβ with IC50 values <0.1 μM.  On the basis of its favorable in vitro and in vivo properties, compd. I was selected for clin. evaluation and is currently in phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUf3qVBfCr87Vg90H21EOLACvtfcHk0lgLpDUkhpi7PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Sl&md5=f20f564bb7dacb5a450a29dae9e04b50</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm800790t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800790t%26sid%3Dliteratum%253Aachs%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DMachajewski%26aufirst%3DT.%2BD.%26aulast%3DJazan%26aufirst%3DE.%2BM.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DAntonios-McCrea%26aufirst%3DW.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DLapointe%26aufirst%3DG.%2BR.%26aulast%3DFeucht%26aufirst%3DP.%2BH.%26aulast%3DWarne%26aufirst%3DR.%2BL.%26aulast%3DHeise%26aufirst%3DC.%2BC.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DVora%26aufirst%3DJ.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DWernette-Hammond%26aufirst%3DM.%2BE.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26atitle%3DDesign%252C%2520structure-activity%2520relationships%2520and%2520in%2520vivo%2520characterization%2520of%25204-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%253A%2520a%2520novel%2520class%2520of%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D278%26epage%3D292%26doi%3D10.1021%2Fjm800790t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarlato, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valbusa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Incalci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalletti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giavazzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camboni, G.</span></span> <span> </span><span class="NLM_article-title">E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1396</span>– <span class="NLM_lpage">1405</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F0008-5472.CAN-10-2700" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1396-1405&author=E.+Belloauthor=G.+Colellaauthor=V.+Scarlatoauthor=P.+Olivaauthor=A.+Berndtauthor=G.+Valbusaauthor=S.+C.+Serraauthor=M.+D%E2%80%99Incalciauthor=E.+Cavallettiauthor=R.+Giavazziauthor=G.+Damiaauthor=G.+Camboni&title=E-3810+is+a+potent+dual+inhibitor+of+VEGFR+and+FGFR+that+exerts+antitumor+activity+in+multiple+preclinical+models&doi=10.1158%2F0008-5472.CAN-10-2700"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2700%26sid%3Dliteratum%253Aachs%26aulast%3DBello%26aufirst%3DE.%26aulast%3DColella%26aufirst%3DG.%26aulast%3DScarlato%26aufirst%3DV.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DValbusa%26aufirst%3DG.%26aulast%3DSerra%26aufirst%3DS.%2BC.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DCavalletti%26aufirst%3DE.%26aulast%3DGiavazzi%26aufirst%3DR.%26aulast%3DDamia%26aufirst%3DG.%26aulast%3DCamboni%26aufirst%3DG.%26atitle%3DE-3810%2520is%2520a%2520potent%2520dual%2520inhibitor%2520of%2520VEGFR%2520and%2520FGFR%2520that%2520exerts%2520antitumor%2520activity%2520in%2520multiple%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D1396%26epage%3D1405%26doi%3D10.1158%2F0008-5472.CAN-10-2700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbatzky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handschuh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann-Lintz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontsch-Grunt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilberg, F.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4466</span>– <span class="NLM_lpage">4480</span>, <span class="refDoi"> DOI: 10.1021/jm900431g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900431g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntFygsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4466-4480&author=G.+J.+Rothauthor=A.+Heckelauthor=F.+Colbatzkyauthor=S.+Handschuhauthor=J.+Kleyauthor=T.+Lehmann-Lintzauthor=R.+Lotzauthor=U.+Tontsch-Gruntauthor=R.+Walterauthor=F.+Hilberg&title=Design%2C+synthesis%2C+and+evaluation+of+indolinones+as+triple+angiokinase+inhibitors+and+the+discovery+of+a+highly+specific+6-methoxycarbonyl-substituted+indolinone+%28BIBF+1120%29&doi=10.1021%2Fjm900431g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)</span></div><div class="casAuthors">Roth, Gerald J.; Heckel, Armin; Colbatzky, Florian; Handschuh, Sandra; Kley, Jorg; Lehmann-Lintz, Thorsten; Lotz, Ralf; Tontsch-Grunt, Ulrike; Walter, Rainer; Hilberg, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4466-4480</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a new treatment modality in oncol.  Preclin. findings suggest that blockade of addnl. pro-angiogenic kinases, such as fibroblast and platelet-derived growth factor receptors (FGFR and PDGFR), may improve the efficacy of pharmacol. cancer treatment.  Indolinones substituted in position 6 were identified as selective inhibitors of VEGF-, PDGF-, and FGF-receptor kinases.  In particular, 6-methoxycarbonyl-substituted indolinones showed a highly favorable selectivity profile.  Optimization identified potent inhibitors of VEGF-related endothelial cell proliferation with addnl. efficacy on pericyctes and smooth muscle cells.  In contrast, no direct inhibition of tumor cell proliferation was obsd.  Compds. 2 (BIBF 1000) and 3 (BIBF 1120) are orally available and display encouraging efficacy in in vivo tumor models while being well tolerated.  The triple angiokinase inhibitor 3 (I) is currently in phase III clin. trials for the treatment of nonsmall cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvvcX-_HYCS7Vg90H21EOLACvtfcHk0lifL803YopAUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntFygsL4%253D&md5=1b8af461631ae3117520fc4811130bb3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm900431g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900431g%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DHandschuh%26aufirst%3DS.%26aulast%3DKley%26aufirst%3DJ.%26aulast%3DLehmann-Lintz%26aufirst%3DT.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DWalter%26aufirst%3DR.%26aulast%3DHilberg%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520indolinones%2520as%2520triple%2520angiokinase%2520inhibitors%2520and%2520the%2520discovery%2520of%2520a%2520highly%2520specific%25206-methoxycarbonyl-substituted%2520indolinone%2520%2528BIBF%25201120%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4466%26epage%3D4480%26doi%3D10.1021%2Fjm900431g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gozgit, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F1535-7163.MCT-11-0450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=22238366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=690-699&author=J.+M.+Gozgitauthor=M.+J.+Wongauthor=L.+Moranauthor=S.+Wardwellauthor=Q.+K.+Mohemmadauthor=N.+I.+Narasimhanauthor=W.+C.+Shakespeareauthor=F.+Wangauthor=T.+Clacksonauthor=V.+M.+Rivera&title=Ponatinib+%28AP24534%29%2C+a+multitargeted+pan-FGFR+inhibitor+with+activity+in+multiple+FGFR-amplified+or+mutated+cancer+models&doi=10.1158%2F1535-7163.MCT-11-0450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models</span></div><div class="casAuthors">Gozgit, Joseph M.; Wong, Matthew J.; Moran, Lauren; Wardwell, Scott; Mohemmad, Qurish K.; Narasimhan, Narayana I.; Shakespeare, William C.; Wang, Frank; Clackson, Tim; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">690-699</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Members of the fibroblast growth factor receptor family of kinases (FGFR1-4) are dysregulated in multiple cancers.  Ponatinib (AP24534) is an oral multitargeted tyrosine kinase inhibitor being explored in a pivotal phase II trial in patients with chronic myelogenous leukemia due to its potent activity against BCR-ABL.  Ponatinib has also been shown to inhibit the in vitro kinase activity of all four FGFRs, prompting us to examine its potential as an FGFR inhibitor.  In Ba/F3 cells engineered to express activated FGFR1-4, ponatinib potently inhibited FGFR-mediated signaling and viability with IC50 values <40 nmol/L, with substantial selectivity over parental Ba/F3 cells.  In a panel of 14 cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon) and contg. FGFRs dysregulated by a variety of mechanisms, ponatinib inhibited FGFR-mediated signaling with IC50 values <40 nmol/L and inhibited cell growth with GI50 (concn. needed to reduce the growth of treated cells to half that of untreated cells) values of 7 to 181 nmol/L.  Daily oral dosing of ponatinib (10-30 mg/kg) to mice reduced tumor growth and inhibited signaling in all three tumor models examd.  Importantly, the potency of ponatinib in these models is similar to that previously obsd. in BCR-ABL-driven models and plasma levels of ponatinib that exceed the IC50 values for FGFR1-4 inhibition can be sustained in patients.  These results show that ponatinib is a potent pan-FGFR inhibitor and provide strong rationale for its evaluation in patients with FGFR-driven cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4-w5b7EPxLLVg90H21EOLACvtfcHk0lifL803YopAUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKis70%253D&md5=771979af1fba727510e073d19335ef5a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0450%26sid%3Dliteratum%253Aachs%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DWong%26aufirst%3DM.%2BJ.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPonatinib%2520%2528AP24534%2529%252C%2520a%2520multitargeted%2520pan-FGFR%2520inhibitor%2520with%2520activity%2520in%2520multiple%2520FGFR-amplified%2520or%2520mutated%2520cancer%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D690%26epage%3D699%26doi%3D10.1158%2F1535-7163.MCT-11-0450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavine, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilgour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span> <span> </span><span class="NLM_article-title">AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2045</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F0008-5472.CAN-11-3034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=22369928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2045-2056&author=P.+R.+Gavineauthor=L.+Mooneyauthor=E.+Kilgourauthor=A.+P.+Thomasauthor=K.+Al-Kadhimiauthor=S.+Beckauthor=C.+Rooneyauthor=T.+Colemanauthor=D.+Bakerauthor=M.+J.+Mellorauthor=A.+N.+Brooksauthor=T.+Klinowska&title=AZD4547%3A+an+orally+bioavailable%2C+potent%2C+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+tyrosine+kinase+family&doi=10.1158%2F0008-5472.CAN-11-3034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family</span></div><div class="casAuthors">Gavine, Paul R.; Mooney, Lorraine; Kilgour, Elaine; Thomas, Andrew P.; Al-Kadhimi, Katherine; Beck, Sarah; Rooney, Claire; Coleman, Tanya; Baker, Dawn; Mellor, Martine J.; Brooks, A. Nigel; Klinowska, Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2045-2056</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis and chemoresistance.  Several small-mol. FGF receptor (FGFR) kinase inhibitors are currently in clin. development; however, the predominant activity of the most advanced of these agents is against the kinase insert domain receptor (KDR), which compromises the FGFR selectivity.  Here, we report the pharmacol. profile of AZD4547, a novel and selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases.  AZD4547 inhibited recombinant FGFR kinase activity in vitro and suppressed FGFR signaling and growth in tumor cell lines with deregulated FGFR expression.  In a representative FGFR-driven human tumor xenograft model, oral administration of AZD4547 was well tolerated and resulted in potent dose-dependent antitumor activity, consistent with plasma exposure and pharmacodynamic modulation of tumor FGFR.  Importantly, at efficacious doses, no evidence of anti-KDR-related effects were obsd., confirming the in vivo FGFR selectivity of AZD4547.  Taken together, our findings show that AZD4547 is a novel selective small-mol. inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclin. models.  AZD4547 is under clin. investigation for the treatment of FGFR-dependent tumors.  Cancer Res; 72(8); 2045-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnpExryJc9xbVg90H21EOLACvtfcHk0lgVsqN0q8VZLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D&md5=cba90ad8f9b9e51cd10288868bbcc85e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3034%26sid%3Dliteratum%253Aachs%26aulast%3DGavine%26aufirst%3DP.%2BR.%26aulast%3DMooney%26aufirst%3DL.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DRooney%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DKlinowska%26aufirst%3DT.%26atitle%3DAZD4547%253A%2520an%2520orally%2520bioavailable%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2045%26epage%3D2056%26doi%3D10.1158%2F0008-5472.CAN-11-3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spanka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Douget, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brueggen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghausen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drueckes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graus Porta, D.</span></span> <span> </span><span class="NLM_article-title">Graus Porta, D. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7066</span>– <span class="NLM_lpage">7083</span>, <span class="refDoi"> DOI: 10.1021/jm2006222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2006222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7066-7083&author=V.+Guagnanoauthor=P.+Furetauthor=C.+Spankaauthor=V.+Bordasauthor=M.+Le+Dougetauthor=C.+Stammauthor=J.+Brueggenauthor=M.+R.+Jensenauthor=C.+Schnellauthor=H.+Schmidauthor=M.+Wartmannauthor=J.+Berghausenauthor=P.+Drueckesauthor=A.+Zimmerlinauthor=D.+Bussiereauthor=J.+Murrayauthor=D.+Graus+Porta&title=Graus+Porta%2C+D.+Discovery+of+3-%282%2C6-dichloro-3%2C5-dimethoxy-phenyl%29-1-%7B6-%5B4-%284-ethyl-piperazin-1-yl%29-phenylamino%5D-pyrimidin-4-yl%7D-1-methyl-urea+%28NVP-BGJ398%29%2C+a+potent+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+family+of+receptor+tyrosine+kinase&doi=10.1021%2Fjm2006222"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm2006222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2006222%26sid%3Dliteratum%253Aachs%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSpanka%26aufirst%3DC.%26aulast%3DBordas%26aufirst%3DV.%26aulast%3DLe%2BDouget%26aufirst%3DM.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DH.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DBerghausen%26aufirst%3DJ.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DGraus%2BPorta%26aufirst%3DD.%26atitle%3DGraus%2520Porta%252C%2520D.%2520Discovery%2520of%25203-%25282%252C6-dichloro-3%252C5-dimethoxy-phenyl%2529-1-%257B6-%255B4-%25284-ethyl-piperazin-1-yl%2529-phenylamino%255D-pyrimidin-4-yl%257D-1-methyl-urea%2520%2528NVP-BGJ398%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520family%2520of%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7066%26epage%3D7083%26doi%3D10.1021%2Fjm2006222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perera, T. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovcheva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mevellec, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vialard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lange, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhulst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulussen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van De Ven, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilissen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platero, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkera, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angibaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span> <span> </span><span class="NLM_article-title">Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1010</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F1535-7163.MCT-16-0589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=28341788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1010-1020&author=T.+P.+S.+Pereraauthor=E.+Jovchevaauthor=L.+Mevellecauthor=J.+Vialardauthor=D.+De+Langeauthor=T.+Verhulstauthor=C.+Paulussenauthor=K.+Van+De+Venauthor=P.+Kingauthor=E.+Freyneauthor=D.+C.+Reesauthor=M.+Squiresauthor=G.+Saxtyauthor=M.+Pageauthor=C.+W.+Murrayauthor=R.+Gilissenauthor=G.+Wardauthor=N.+T.+Thompsonauthor=D.+R.+Newellauthor=N.+Chengauthor=L.+Xieauthor=J.+Yangauthor=S.+J.+Plateroauthor=J.+D.+Karkeraauthor=C.+Moyauthor=P.+Angibaudauthor=S.+Laquerreauthor=M.+V.+Lorenzi&title=Discovery+and+pharmacological+characterization+of+JNJ-42756493+%28erdafitinib%29%2C+a+functionally+selective+small-molecule+FGFR+family+inhibitor&doi=10.1158%2F1535-7163.MCT-16-0589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor</span></div><div class="casAuthors">Perera, Timothy P. S.; Jovcheva, Eleonora; Mevellec, Laurence; Vialard, Jorge; De Lange, Desiree; Verhulst, Tinne; Paulussen, Caroline; Van De Ven, Kelly; King, Peter; Freyne, Eddy; Rees, David C.; Squires, Matthew; Saxty, Gordon; Page, Martin; Murray, Christopher W.; Gilissen, Ron; Ward, George; Thompson, Neil T.; Newell, David R.; Cheng, Na; Xie, Liang; Yang, Jennifer; Platero, Suso J.; Karkera, Jayaprakash D.; Moy, Christopher; Angibaud, Patrick; Laquerre, Sylvie; Lorenzi, Matthew V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1010-1020</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fibroblast growth factor (FGF) signaling plays crit. roles in key biol. processes ranging from embryogenesis to wound healing and has strong links to several hallmarks of cancer.  Genetic alterations in FGF receptor (FGFR) family members are assocd. with increased tumor growth, metastasis, angiogenesis, and decreased survival.  JNJ-42756493, erdafitinib, is an orally active small mol. with potent tyrosine kinase inhibitory activity against all four FGFR family members and selectivity vs. other highly related kinases.  JNJ-42756493 shows rapid uptake into the lysosomal compartment of cells in culture, which is assocd. with prolonged inhibition of FGFR signaling, possibly due to sustained release of the inhibitor.  In xenografts from human tumor cell lines or patient-derived tumor tissue with activating FGFR alterations, JNJ-42756493 administration results in potent and dose-dependent antitumor activity accompanied by pharmacodynamic modulation of phospho-FGFR and phospho-ERK in tumors.  The results of the current study provide a strong rationale for the clin. investigation of JNJ-42756493 in patients with tumors harboring FGFR pathway alterations.  Mol Cancer Ther; 16(6); 1010-20. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhJZ2AgFcI6LVg90H21EOLACvtfcHk0lhRa5s9xO-0-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D&md5=2cae21f09ad519925ab2a3c760284b02</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0589%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DT.%2BP.%2BS.%26aulast%3DJovcheva%26aufirst%3DE.%26aulast%3DMevellec%26aufirst%3DL.%26aulast%3DVialard%26aufirst%3DJ.%26aulast%3DDe%2BLange%26aufirst%3DD.%26aulast%3DVerhulst%26aufirst%3DT.%26aulast%3DPaulussen%26aufirst%3DC.%26aulast%3DVan%2BDe%2BVen%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DFreyne%26aufirst%3DE.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DSquires%26aufirst%3DM.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DPage%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DPlatero%26aufirst%3DS.%2BJ.%26aulast%3DKarkera%26aufirst%3DJ.%2BD.%26aulast%3DMoy%26aufirst%3DC.%26aulast%3DAngibaud%26aufirst%3DP.%26aulast%3DLaquerre%26aufirst%3DS.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26atitle%3DDiscovery%2520and%2520pharmacological%2520characterization%2520of%2520JNJ-42756493%2520%2528erdafitinib%2529%252C%2520a%2520functionally%2520selective%2520small-molecule%2520FGFR%2520family%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D1010%26epage%3D1020%26doi%3D10.1158%2F1535-7163.MCT-16-0589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span> <span> </span><span class="NLM_article-title">The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2547</span>– <span class="NLM_lpage">2558</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F1535-7163.MCT-14-0248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=25169980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2547-2558&author=Y.+Nakanishiauthor=N.+Akiyamaauthor=T.+Tsukaguchiauthor=T.+Fujiiauthor=K.+Sakataauthor=H.+Saseauthor=T.+Isobeauthor=K.+Morikamiauthor=H.+Shindohauthor=T.+Mioauthor=H.+Ebiikeauthor=N.+Takaauthor=Y.+Aokiauthor=N.+Ishii&title=The+fibroblast+growth+factor+receptor+genetic+status+as+a+potential+predictor+of+the+sensitivity+to+CH5183284%2FDebio+1347%2C+a+novel+selective+FGFR+inhibitor&doi=10.1158%2F1535-7163.MCT-14-0248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor</span></div><div class="casAuthors">Nakanishi, Yoshito; Akiyama, Nukinori; Tsukaguchi, Toshiyuki; Fujii, Toshihiko; Sakata, Kiyoaki; Sase, Hitoshi; Isobe, Takehito; Morikami, Kenji; Shindoh, Hidetoshi; Mio, Toshiyuki; Ebiike, Hirosato; Taka, Naoki; Aoki, Yuko; Ishii, Nobuya</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2547-2558</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The FGF receptors (FGFR) are tyrosine kinases that are constitutively activated in a subset of tumors by genetic alterations such as gene amplifications, point mutations, or chromosomal translocations/rearrangements.  Recently, small-mol. inhibitors that can inhibit the FGFR family as well as the VEGF receptor (VEGFR) or platelet-derived growth factor receptor (PDGFR) family displayed clin. benefits in cohorts of patients with FGFR genetic alterations.  However, to achieve more potent and prolonged activity in such populations, a selective FGFR inhibitor is still needed.  Here, we report the identification of CH5183284/Debio 1347, a selective and orally available FGFR1, FGFR2, and FGFR3 inhibitor that has a unique chem. scaffold.  By interacting with unique residues in the ATP-binding site of FGFR1, FGFR2, or FGFR3, CH5183284/Debio 1347 selectively inhibits FGFR1, FGFR2, and FGFR3 but does not inhibit kinase insert domain receptor (KDR) or other kinases.  Consistent with its high selectivity for FGFR enzymes, CH5183284/Debio 1347 displayed preferential antitumor activity against cancer cells with various FGFR genetic alterations in a panel of 327 cancer cell lines and in xenograft models.  Because of its unique binding mode, CH5183284/Debio 1347 can inhibit FGFR2 harboring one type of the gatekeeper mutation that causes resistance to other FGFR inhibitors and block FGFR2 V564F-driven tumor growth.  CH5183284/Debio 1347 is under clin. investigation for the treatment of patients harboring FGFR genetic alterations.  Mol Cancer Ther; 13(11); 2547-58. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGIBEnK21337Vg90H21EOLACvtfcHk0lhRa5s9xO-0-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73F&md5=35629d891a421582022b0f6ae0496479</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0248%26sid%3Dliteratum%253Aachs%26aulast%3DNakanishi%26aufirst%3DY.%26aulast%3DAkiyama%26aufirst%3DN.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DT.%26aulast%3DSakata%26aufirst%3DK.%26aulast%3DSase%26aufirst%3DH.%26aulast%3DIsobe%26aufirst%3DT.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DShindoh%26aufirst%3DH.%26aulast%3DMio%26aufirst%3DT.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DTaka%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DN.%26atitle%3DThe%2520fibroblast%2520growth%2520factor%2520receptor%2520genetic%2520status%2520as%2520a%2520potential%2520predictor%2520of%2520the%2520sensitivity%2520to%2520CH5183284%252FDebio%25201347%252C%2520a%2520novel%2520selective%2520FGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2547%26epage%3D2558%26doi%3D10.1158%2F1535-7163.MCT-14-0248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zia-Ebrahimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloem, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D. J.</span></span> <span> </span><span class="NLM_article-title">A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2200</span>– <span class="NLM_lpage">2210</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F1535-7163.MCT-11-0306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=21900693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2200-2210&author=G.+Zhaoauthor=W.+Y.+Liauthor=D.+Chenauthor=J.+R.+Henryauthor=H.+Y.+Liauthor=Z.+Chenauthor=M.+Zia-Ebrahimiauthor=L.+Bloemauthor=Y.+Zhaiauthor=K.+Hussauthor=S.+B.+Pengauthor=D.+J.+McCann&title=A+novel%2C+selective+inhibitor+of+fibroblast+growth+factor+receptors+that+shows+a+potent+broad+spectrum+of+antitumor+activity+in+several+tumor+xenograft+models&doi=10.1158%2F1535-7163.MCT-11-0306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models</span></div><div class="casAuthors">Zhao, Genshi; Li, Wei-ying; Chen, Daohong; Henry, James R.; Li, Hong-Yu; Chen, Zhaogen; Zia-Ebrahimi, Mohammad; Bloem, Laura; Zhai, Yan; Huss, Karen; Peng, Sheng-bin; McCann, Denis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2200-2210</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptors (FGFR) are tyrosine kinases that are present in many types of endothelial and tumor cells and play an important role in tumor cell growth, survival, and migration as well as in maintaining tumor angiogenesis.  Overexpression of FGFRs or aberrant regulation of their activities has been implicated in many forms of human malignancies.  Therefore, targeting FGFRs represents an attractive strategy for development of cancer treatment options by simultaneously inhibiting tumor cell growth, survival, and migration as well as tumor angiogenesis.  Here, we describe a potent, selective, small-mol. FGFR inhibitor, (R)-(E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)ethoxy)-1H-indazol-3yl)vinyl)-1H-pyrazol-1-yl)ethanol, designated as LY2874455.  This mol. is active against all 4 FGFRs, with a similar potency in biochem. assays.  It exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activity in several tumor xenograft models representing the major FGF/FGFR relevant tumor histologies including lung, gastric, and bladder cancers and multiple myeloma, and with a well-defined pharmacokinetic/pharmacodynamic relationship.  LY2874455 also exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.  Furthermore, LY2874455 did not show VEGF receptor 2-mediated toxicities such as hypertension at efficacious doses.  Currently, this mol. is being evaluated for its potential use in the clinic.  Mol Cancer Ther; 10(11); 2200-10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLrzAyZQK_grVg90H21EOLACvtfcHk0ljaeD8xk8rzLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N&md5=eaf08fd213a836f48da2055e01bd9c29</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0306%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DW.%2BY.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZia-Ebrahimi%26aufirst%3DM.%26aulast%3DBloem%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DPeng%26aufirst%3DS.%2BB.%26aulast%3DMcCann%26aufirst%3DD.%2BJ.%26atitle%3DA%2520novel%252C%2520selective%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptors%2520that%2520shows%2520a%2520potent%2520broad%2520spectrum%2520of%2520antitumor%2520activity%2520in%2520several%2520tumor%2520xenograft%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2200%26epage%3D2210%26doi%3D10.1158%2F1535-7163.MCT-11-0306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">476</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.11.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2Fj.ejmech.2016.11.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=27914362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFymu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=476-490&author=W.+Chengauthor=M.+Wangauthor=X.+Tianauthor=X.+Zhang&title=An+overview+of+the+binding+models+of+FGFR+tyrosine+kinases+in+complex+with+small+molecule+inhibitors&doi=10.1016%2Fj.ejmech.2016.11.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors</span></div><div class="casAuthors">Cheng, Weiyan; Wang, Mixiang; Tian, Xin; Zhang, Xiaojian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">476-490</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptor (FGFR) family receptor tyrosine kinase (RTK) includes four structurally related members, termed as FGFR1, FGFR2, FGFR3, and FGFR4.  Given its intimate role in the progression of several solid tumors, excessive FGFR signaling provides an opportunity for anticancer therapy.  Along with extensive pharmacol. studies validating the therapeutic potential of targeting the FGFRs for cancer treatment, co-crystal structures of FGFRs/inhibitors are continuously coming up to study the mechanism of actions and explore new inhibitors.  Herein, we review the reported co-crystals of FGFRs in complex with the corresponding inhibitors, main focusing our attention on the binding models and the pharmacol. activities of the inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP6Sw0C-AnwrVg90H21EOLACvtfcHk0ljaeD8xk8rzLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFymu7rF&md5=8f207cd73cd860fcb6ddedfad01dfdda</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.11.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.11.052%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DAn%2520overview%2520of%2520the%2520binding%2520models%2520of%2520FGFR%2520tyrosine%2520kinases%2520in%2520complex%2520with%2520small%2520molecule%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D476%26epage%3D490%26doi%3D10.1016%2Fj.ejmech.2016.11.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traxler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span> <span> </span><span class="NLM_article-title">Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(98)00044-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2FS0163-7258%2898%2900044-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10454197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1999&pages=195-206&author=P.+Traxlerauthor=P.+Furet&title=Strategies+toward+the+design+of+novel+and+selective+protein+tyrosine+kinase+inhibitors&doi=10.1016%2FS0163-7258%2898%2900044-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</span></div><div class="casAuthors">Traxler, Peter; Furet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 37 refs.  Protein tyrosine kinases play a fundamental role in signal transduction pathways.  Deregulated tyrosine kinase activity has been obsd. in many proliferative diseases (e.g., cancer, psoriasis, restenosis, etc.).  Tyrosine kinases are, therefore, attractive targets for the design of new therapeutic agents against cancer.  We have built up a pharmacophore model of the ATP-binding site of the epidermal growth factor receptor (EGFR) kinase and used it for the rational design of kinase inhibitors.  Several examples of the successful use of this model are presented in this review.  Amongst these, 4-substituted-pyrrolo[2,3-d]pyrimidines, a new class of highly potent and selective inhibitors of the EGFR kinase, have been identified and further optimized.  The most active derivs. inhibited the EGFR tyrosine kinase with IC50 values between 1 and 5 nM.  In EGF-dependent cellular systems, tyrosine phosphorylation, as well as c-fos mRNA expression, was inhibited with similar IC50 values.  Further successful application of this pharmacophore model led to the identification and optimization of phenylamino-pyrazolo[4,3-d]pyrimidines and substituted isoflavones and quinolones, other classes of potent, selective, and ATP competitive EGFR kinase inhibitors with IC50 values in the low nanomolar range.  Structure-activity relationships of both classes are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzTOVAYLwK77Vg90H21EOLACvtfcHk0ljaeD8xk8rzLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D&md5=26e5ed297e37b0cb188a0676e5b27f5b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2898%2900044-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252898%252900044-8%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DStrategies%2520toward%2520the%2520design%2520of%2520novel%2520and%2520selective%2520protein%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D1999%26volume%3D82%26spage%3D195%26epage%3D206%26doi%3D10.1016%2FS0163-7258%2898%2900044-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yosaatmadja, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squire, C. J.</span></span> <span> </span><span class="NLM_article-title">The 1.65 A° resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1107/S1399004714027539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1107%2FS1399004714027539" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=525-533&author=Y.+Yosaatmadjaauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=C.+J.+Squire&title=The+1.65+A%C2%B0+resolution+structure+of+the+complex+of+AZD4547+with+the+kinase+domain+of+FGFR1+displays+exquisite+molecular+recognition&doi=10.1107%2FS1399004714027539"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1107%2FS1399004714027539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS1399004714027539%26sid%3Dliteratum%253Aachs%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26atitle%3DThe%25201.65%2520A%25C2%25B0%2520resolution%2520structure%2520of%2520the%2520complex%2520of%2520AZD4547%2520with%2520the%2520kinase%2520domain%2520of%2520FGFR1%2520displays%2520exquisite%2520molecular%2520recognition%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2015%26volume%3D71%26spage%3D525%26epage%3D533%26doi%3D10.1107%2FS1399004714027539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunney, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiyagarajan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashford, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, C. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breeze, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orengo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katan, M.</span></span> <span> </span><span class="NLM_article-title">Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">24252</span>– <span class="NLM_lpage">24268</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.18632%2Foncotarget.8132" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=24252-24268&author=H.+Pataniauthor=T.+D.+Bunneyauthor=N.+Thiyagarajanauthor=R.+A.+Normanauthor=D.+Oggauthor=J.+Breedauthor=P.+Ashfordauthor=A.+Pottertonauthor=M.+Edwardsauthor=S.+V.+Williamsauthor=G.+S.+Thomsonauthor=C.+S.+M.+Pangauthor=M.+A.+Knowlesauthor=A.+L.+Breezeauthor=C.+Orengoauthor=C.+Phillipsauthor=M.+Katan&title=Landscape+of+activating+cancer+mutations+in+FGFR+kinases+and+their+differential+responses+to+inhibitors+in+clinical+use&doi=10.18632%2Foncotarget.8132"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8132%26sid%3Dliteratum%253Aachs%26aulast%3DPatani%26aufirst%3DH.%26aulast%3DBunney%26aufirst%3DT.%2BD.%26aulast%3DThiyagarajan%26aufirst%3DN.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DOgg%26aufirst%3DD.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DAshford%26aufirst%3DP.%26aulast%3DPotterton%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%2BV.%26aulast%3DThomson%26aufirst%3DG.%2BS.%26aulast%3DPang%26aufirst%3DC.%2BS.%2BM.%26aulast%3DKnowles%26aufirst%3DM.%2BA.%26aulast%3DBreeze%26aufirst%3DA.%2BL.%26aulast%3DOrengo%26aufirst%3DC.%26aulast%3DPhillips%26aufirst%3DC.%26aulast%3DKatan%26aufirst%3DM.%26atitle%3DLandscape%2520of%2520activating%2520cancer%2520mutations%2520in%2520FGFR%2520kinases%2520and%2520their%2520differential%2520responses%2520to%2520inhibitors%2520in%2520clinical%2520use%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D24252%26epage%3D24268%26doi%3D10.18632%2Foncotarget.8132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyohdoh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayase, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of [5-amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-(1<i>H</i>-indol-2-yl)methanone (CH5183284/Debio 1347), an orally available and selective fibroblast growth factor receptor (FGFR) inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10586</span>– <span class="NLM_lpage">10600</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01156</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01156" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10586-10600&author=H.+Ebiikeauthor=N.+Takaauthor=M.+Matsushitaauthor=M.+Ohmoriauthor=K.+Takamiauthor=I.+Hyohdohauthor=M.+Kohchiauthor=T.+Hayaseauthor=H.+Nishiiauthor=K.+Morikamiauthor=Y.+Nakanishiauthor=N.+Akiyamaauthor=H.+Shindohauthor=N.+Ishiiauthor=T.+Isobeauthor=H.+Matsuoka&title=Discovery+of+%5B5-amino-1-%282-methyl-3H-benzimidazol-5-yl%29pyrazol-4-yl%5D-%281H-indol-2-yl%29methanone+%28CH5183284%2FDebio+1347%29%2C+an+orally+available+and+selective+fibroblast+growth+factor+receptor+%28FGFR%29+inhibitor&doi=10.1021%2Facs.jmedchem.6b01156"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01156%26sid%3Dliteratum%253Aachs%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DTaka%26aufirst%3DN.%26aulast%3DMatsushita%26aufirst%3DM.%26aulast%3DOhmori%26aufirst%3DM.%26aulast%3DTakami%26aufirst%3DK.%26aulast%3DHyohdoh%26aufirst%3DI.%26aulast%3DKohchi%26aufirst%3DM.%26aulast%3DHayase%26aufirst%3DT.%26aulast%3DNishii%26aufirst%3DH.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DNakanishi%26aufirst%3DY.%26aulast%3DAkiyama%26aufirst%3DN.%26aulast%3DShindoh%26aufirst%3DH.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DIsobe%26aufirst%3DT.%26aulast%3DMatsuoka%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520%255B5-amino-1-%25282-methyl-3H-benzimidazol-5-yl%2529pyrazol-4-yl%255D-%25281H-indol-2-yl%2529methanone%2520%2528CH5183284%252FDebio%25201347%2529%252C%2520an%2520orally%2520available%2520and%2520selective%2520fibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10586%26epage%3D10600%26doi%3D10.1021%2Facs.jmedchem.6b01156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibition of fibroblast growth factor receptors in cancer</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">475</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2013.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2Fj.cytogfr.2013.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=23830577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKntrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=467-475&author=G.+Liangauthor=G.+Chenauthor=X.+Weiauthor=Y.+Zhaoauthor=X.+Li&title=Small+molecule+inhibition+of+fibroblast+growth+factor+receptors+in+cancer&doi=10.1016%2Fj.cytogfr.2013.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibition of fibroblast growth factor receptors in cancer</span></div><div class="casAuthors">Liang, Guang; Chen, Gaozhi; Wei, Xiaoyan; Zhao, Yunjie; Li, Xiaokun</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">467-475</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) signal through FGF receptors (FGFRs), which are a sub-family of the superfamily of receptor tyrosine kinases, to regulate human development and metab.  Uncontrolled FGF signaling is responsible for diverse array of developmental disorders, most notably skeletal syndromes due to FGFR gain-of-function mutations.  Studies in the last few years have provided significant evidence for the importance of FGF signaling in the pathogenesis of diverse cancers, including endometrial and bladder cancers.  FGFs are both potent mitogenic and angiogenic factors and can contribute to carcinogenesis by stimulating cell proliferation and tumor angiogenesis.  Gene knockout and pharmacol. inhibition of FGFRs in in vivo and in vitro models validate FGFRs as a target for cancer treatment.  Considerable efforts are being expended to develop specific, small-mol. inhibitors for treating FGFR-driven cancers.  Recent reviews on the FGF/FGFR system have focused primarily on signaling, pathophysiol., and functions in cancer.  In this article, we review the key roles of FGFR in cancer, provide an update on the status of clin. trials with small-mol. FGFR inhibitors, and discuss how the current structural data on FGFR kinases guide the design and characterization of new FGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbj2wCb5EOc7Vg90H21EOLACvtfcHk0liEVgbdf6oH9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKntrnO&md5=d372fecac21b7eb341c6944b433daa95</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2013.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2013.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DSmall%2520molecule%2520inhibition%2520of%2520fibroblast%2520growth%2520factor%2520receptors%2520in%2520cancer%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2013%26volume%3D24%26spage%3D467%26epage%3D475%26doi%3D10.1016%2Fj.cytogfr.2013.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the FGFR4/LY2874455 complex reveals insights into the pan-FGFR selectivity of LY2874455</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0162491</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0162491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1371%2Fjournal.pone.0162491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=27618313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFKjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0162491&author=D.+Wuauthor=M.+Guoauthor=M.+A.+Philipsauthor=L.+Quauthor=L.+Jiangauthor=J.+Liauthor=X.+Chenauthor=Z.+Chenauthor=L.+Chenauthor=Y.+Chen&title=Crystal+structure+of+the+FGFR4%2FLY2874455+complex+reveals+insights+into+the+pan-FGFR+selectivity+of+LY2874455&doi=10.1371%2Fjournal.pone.0162491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the FGFR4/LY2874455 complex reveals insights into the pan-FGFR selectivity of LY2874455</span></div><div class="casAuthors">Wu, Daichao; Guo, Ming; Philips, Michael A.; Qu, Lingzhi; Jiang, Longying; Li, Jun; Chen, Xiaojuan; Chen, Zhuchu; Chen, Lin; Chen, Yongheng</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0162491/1-e0162491/11</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Aberrant FGFR4 signaling has been documented abundantly in various human cancers.  The majority of FGFR inhibitors display significantly reduced potency toward FGFR4 compared to FGFR1-3.  However, LY2874455 has similar inhibition potency for FGFR1-4 with IC50 less than 6.4 nM.  To date, there is no published crystal structure of LY2874455 in complex with any kinase.  To better understand the pan-FGFR selectivity of LY2874455, we have detd. the crystal structure of the FGFR4 kinase domain bound to LY2874455 at a resoln. of 2.35 Å.  LY2874455, a type I inhibitor for FGFR4, binds to the ATP-binding pocket of FGFR4 in a DFG-in active conformation with three hydrogen bonds and a no. of van derWaals contacts.  After alignment of the kinase domain sequence of 4 FGFRs, and superposition of the ATP binding pocket of 4 FGFRs, our structural analyses reveal that the interactions of LY2874455 to FGFR4 are largely conserved in 4 FGFRs, explaining at least partly, the broad inhibitory activity of LY2874455 toward 4 FGFRs.  Consequently, our studies reveal new insights into the pan-FGFR selectivity of LY2874455 and provide a structural basis for developing novel FGFR inhibitors that target FGFR1-4 broadly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquH9zGVO6xArVg90H21EOLACvtfcHk0lgsd5aAdNVYdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFKjt74%253D&md5=444e0d350dac9196672923565b10f2ba</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0162491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0162491%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DPhilips%26aufirst%3DM.%2BA.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DCrystal%2520structure%2520of%2520the%2520FGFR4%252FLY2874455%2520complex%2520reveals%2520insights%2520into%2520the%2520pan-FGFR%2520selectivity%2520of%2520LY2874455%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0162491%26doi%3D10.1371%2Fjournal.pone.0162491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miduturu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stransky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodous, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shutes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T.</span></span> <span> </span><span class="NLM_article-title">First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-1029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F2159-8290.CD-14-1029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=25776529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVSrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=424-437&author=M.+Hagelauthor=C.+Miduturuauthor=M.+Sheetsauthor=N.+Rubinauthor=W.+Wengauthor=N.+Stranskyauthor=N.+Bifulcoauthor=J.+L.+Kimauthor=B.+Hodousauthor=N.+Brooijmansauthor=A.+Shutesauthor=C.+Winterauthor=C.+Lengauerauthor=N.+E.+Kohlauthor=T.+Guzi&title=First+selective+small+molecule+inhibitor+of+FGFR4+for+the+treatment+of+hepatocellular+carcinomas+with+an+activated+FGFR4+signaling+pathway&doi=10.1158%2F2159-8290.CD-14-1029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway</span></div><div class="casAuthors">Hagel, Margit; Miduturu, Chandra; Sheets, Michael; Rubin, Nooreen; Weng, Weifan; Stransky, Nicolas; Bifulco, Neil; Kim, Joseph L.; Hodous, Brian; Brooijmans, Natasja; Shutes, Adam; Winter, Christopher; Lengauer, Christoph; Kohl, Nancy E.; Guzi, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">424-437</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HCC cells with FGF19 gene amplification or overexpression and an intact FGFR4 signaling pathway are sensitive to potent and selective FGFR4 inhibition by the small mol. BLU9931 in vitro and in xenograft models.  Aberrant signaling through the fibroblast growth factor 19 (FGF19)/fibroblast growth factor receptor 4 (FGFR 4) signaling complex has been shown to cause hepatocellular carcinoma (HCC) in mice and has been implicated to play a similar role in humans.  We have developed BLU9931, a potent and irreversible small-mol. inhibitor of FGFR4, as a targeted therapy to treat patients with HCC whose tumors have an activated FGFR4 signaling pathway.  BLU9931 is exquisitely selective for FGFR4 vs. other FGFR family members and all other kinases.  BLU9931 shows remarkable antitumor activity in mice bearing an HCC tumor xenograft that overexpresses FGF19 due to amplification as well as a liver tumor xenograft that overexpresses FGF19 mRNA but lacks FGF19 amplification.  Approx. one third of patients with HCC whose tumors express FGF19 together with FGFR4 and its coreceptor klotho β (KLB) could potentially respond to treatment with an FGFR4 inhibitor.  These findings are the first demonstration of a therapeutic strategy that targets a subset of patients with HCC.  Significance: This article documents the discovery of BLU9931, a novel irreversible kinase inhibitor that specifically targets FGFR4 while sparing all other FGFR paralogs and demonstrates exquisite kinome selectivity.  BLU9931 is efficacious in tumors with an intact FGFR4 signaling pathway that includes FGF19, FGFR4, and KLB.  BLU9931 is the first FGFR4-selective mol. for the treatment of patients with HCC with aberrant FGFR4 signaling.  Cancer Discov; 5(4); 424-37. cpr2015 AACR.  See related commentary by Packer and Pollock, p. 355 This article is highlighted in the In This Issue feature, p.  333.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcHNr-1ZnG7Vg90H21EOLACvtfcHk0lgsd5aAdNVYdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVSrtL8%253D&md5=4a69439aee01a3c090c14851a785362e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-1029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-1029%26sid%3Dliteratum%253Aachs%26aulast%3DHagel%26aufirst%3DM.%26aulast%3DMiduturu%26aufirst%3DC.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DRubin%26aufirst%3DN.%26aulast%3DWeng%26aufirst%3DW.%26aulast%3DStransky%26aufirst%3DN.%26aulast%3DBifulco%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DHodous%26aufirst%3DB.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DShutes%26aufirst%3DA.%26aulast%3DWinter%26aufirst%3DC.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DGuzi%26aufirst%3DT.%26atitle%3DFirst%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520FGFR4%2520for%2520the%2520treatment%2520of%2520hepatocellular%2520carcinomas%2520with%2520an%2520activated%2520FGFR4%2520signaling%2520pathway%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D424%26epage%3D437%26doi%3D10.1158%2F2159-8290.CD-14-1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A structure-guided approach to creating covalent FGFR inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+S.+Gray&title=A+structure-guided+approach+to+creating+covalent+FGFR+inhibitors&doi=10.1016%2Fj.chembiol.2010.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0ljVBcDJlLcimg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520structure-guided%2520approach%2520to%2520creating%2520covalent%2520FGFR%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D285%26epage%3D295%26doi%3D10.1016%2Fj.chembiol.2010.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">E4869</span>– <span class="NLM_lpage">E4877</span>, <span class="refDoi"> DOI: 10.1073/pnas.1403438111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1073%2Fpnas.1403438111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=25349422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=E4869-E4877&author=L.+Tanauthor=J.+Wangauthor=J.+Tanizakiauthor=Z.+Huangauthor=A.+R.+Arefauthor=M.+Rusanauthor=S.+J.+Zhuauthor=Y.+Zhangauthor=D.+Ercanauthor=R.+G.+Liaoauthor=M.+Capellettiauthor=W.+Zhouauthor=W.+Hurauthor=N.+Kimauthor=T.+Simauthor=S.+Gaudetauthor=D.+A.+Barbieauthor=J.+R.+J.+Yehauthor=C.+H.+Yunauthor=P.+S.+Hammermanauthor=M.+Mohammadiauthor=P.+A.+Janneauthor=N.+S.+Gray&title=Development+of+covalent+inhibitors+that+can+overcome+resistance+to+first-generation+FGFR+kinase+inhibitors&doi=10.1073%2Fpnas.1403438111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</span></div><div class="casAuthors">Tan, Li; Wang, Jun; Tanizaki, Junko; Huang, Zhifeng; Aref, Amir R.; Rusan, Maria; Zhu, Su-Jie; Zhang, Yiyun; Ercan, Dalia; Liao, Rachel G.; Capelletti, Marzia; Zhou, Wenjun; Hur, Wooyoung; Kim, NamDoo; Sim, Taebo; Gaudet, Suzanne; Barbie, David A.; Yeh, Jing-Ruey Joanna; Yun, Cai-Hong; Hammerman, Peter S.; Mohammadi, Moosa; Janne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">E4869-E4877</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The human FGF receptors (FGFRs) play crit. roles in various human cancers, and several FGFR inhibitors are currently under clin. investigation.  Resistance usually results from selection for mutant kinases that are impervious to the action of the drug or from up-regulation of compensatory signaling pathways.  Preclin. studies have demonstrated that resistance to FGFR inhibitors can be acquired through mutations in the FGFR gatekeeper residue, as clin. obsd. for FGFR4 in embryonal rhabdomyosarcoma and neuroendocrine breast carcinomas.  Here the authors report on the use of a structure-based drug design to develop two selective, next-generation covalent FGFR inhibitors, the FGFR irreversible inhibitors I and II.  To our knowledge, I and II are the first inhibitors that can potently inhibit the proliferation of cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2, which confer resistance to first-generation clin. FGFR inhibitors such as NVP-BGJ398 and AZD4547.  Because of the conformational flexibility of the reactive acrylamide substituent, II has the unprecedented ability to inhibit both the EGF receptor (EGFR) and FGFR covalently by targeting two distinct cysteine residues.  The authors report the cocrystal structure of FGFR4 with I, which unexpectedly exhibits a "DFG-out" covalent binding mode.  The structural basis for dual FGFR and EGFR targeting by FIIN3 also is illustrated by crystal structures of II bound with FGFR4 V550L and EGFR L858R.  These results have important implications for the design of covalent FGFR inhibitors that can overcome clin. resistance and provide the first example, to the knowledge, of a kinase inhibitor that covalently targets cysteines located in different positions within the ATP-binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmCbTDKPA32LVg90H21EOLACvtfcHk0ljVBcDJlLcimg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsL%252FP&md5=fd4a7eac1e0c17e7c9f2651dd2d76ac7</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1403438111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1403438111%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DRusan%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DR.%2BG.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGaudet%26aufirst%3DS.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DYeh%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520covalent%2520inhibitors%2520that%2520can%2520overcome%2520resistance%2520to%2520first-generation%2520FGFR%2520kinase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3DE4869%26epage%3DE4877%26doi%3D10.1073%2Fpnas.1403438111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. K.</span></span> <span> </span><span class="NLM_article-title">Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2096</span>– <span class="NLM_lpage">2106</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F1535-7163.MCT-16-0136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=27371729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCnsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2096-2106&author=W.+S.+Brownauthor=L.+Tanauthor=A.+Smithauthor=N.+S.+Grayauthor=M.+K.+Wendt&title=Covalent+targeting+of+fibroblast+growth+factor+receptor+inhibits+metastatic+breast+cancer&doi=10.1158%2F1535-7163.MCT-16-0136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer</span></div><div class="casAuthors">Brown, Wells S.; Tan, Li; Smith, Andrew; Gray, Nathanael S.; Wendt, Michael K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2096-2106</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Therapeutic targeting of late-stage breast cancer is limited by an inadequate understanding of how tumor cell signaling evolves during metastatic progression and by the currently available small mol. inhibitors capable of targeting these processes.  Herein, we demonstrate that both β3 integrin and fibroblast growth factor receptor-1 (FGFR1) are part of an epithelial-mesenchymal transition (EMT) program that is required to facilitate metastatic outgrowth in response to fibroblast growth factor-2 (FGF2).  Mechanistically, β3 integrin phys. disrupts an interaction between FGFR1 and E-cadherin, leading to a dramatic redistribution of FGFR1 subcellular localization, enhanced FGF2 signaling and increased three-dimensional (3D) outgrowth of metastatic breast cancer cells.  This ability of β3 integrin to drive FGFR signaling requires the enzymic activity of focal adhesion kinase (FAK).  Consistent with these mechanistic data, we demonstrate that FGFR, β3 integrin, and FAK constitute a mol. signature capable of predicting decreased survival of patients with the basal-like subtype of breast cancer.  Importantly, covalent targeting of a conserved cysteine in the P-loop of FGFR1-4 with our newly developed small mol., FIIN-4, more effectively blocks 3D metastatic outgrowth as compared with currently available FGFR inhibitors.  In vivo application of FIIN-4 potently inhibited the growth of metastatic, patient-derived breast cancer xenografts and murine-derived metastases growing within the pulmonary microenvironment.  Overall, the current studies demonstrate that FGFR1 works in concert with other EMT effector mols. to drive aberrant downstream signaling, and that these events can be effectively targeted using our novel therapeutics for the treatment of the most aggressive forms of breast cancer.  Mol Cancer Ther; 15(9); 2096-106. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQFBxSpCHYZ7Vg90H21EOLACvtfcHk0ljVBcDJlLcimg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCnsLvI&md5=f58566c7181197b10a9dcc3c203ef13e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0136%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DW.%2BS.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWendt%26aufirst%3DM.%2BK.%26atitle%3DCovalent%2520targeting%2520of%2520fibroblast%2520growth%2520factor%2520receptor%2520inhibits%2520metastatic%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2096%26epage%3D2106%26doi%3D10.1158%2F1535-7163.MCT-16-0136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venetsanakos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughhead, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span> <span> </span><span class="NLM_article-title">Discovery of the irreversible covalent FGFR inhibitor 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (PRN1371) for the treatment of solid tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6516</span>– <span class="NLM_lpage">6527</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00360</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00360" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6516-6527&author=K.+A.+Brameldauthor=T.+D.+Owensauthor=E.+Vernerauthor=E.+Venetsanakosauthor=J.+M.+Bradshawauthor=V.+T.+Phanauthor=D.+Tamauthor=K.+Leungauthor=J.+Shuauthor=J.+LaStantauthor=D.+G.+Loughheadauthor=T.+Tonauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=D.+M.+Goldsteinauthor=J.+O.+Funk&title=Discovery+of+the+irreversible+covalent+FGFR+inhibitor+8-%283-%284-acryloylpiperazin-1-yl%29propyl%29-6-%282%2C6-dichloro-3%2C5-dimethoxyphenyl%29-2-%28methylamino%29pyrido%5B2%2C3-d%5Dpyrimidin-7%288H%29-one+%28PRN1371%29+for+the+treatment+of+solid+tumors&doi=10.1021%2Facs.jmedchem.7b00360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors</span></div><div class="casAuthors">Brameld, Ken A.; Owens, Timothy D.; Verner, Erik; Venetsanakos, Eleni; Bradshaw, J. Michael; Phan, Vernon T.; Tam, Danny; Leung, Kwan; Shu, Jin; LaStant, Jacob; Loughhead, David G.; Ton, Tony; Karr, Dane E.; Gerritsen, Mary E.; Goldstein, David M.; Funk, Jens Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6516-6527</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors.  Clin. validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers.  Our goal was to develop an irreversible covalent inhibitor of FGFR1-4 for use in oncol. indications.  An irreversible covalent binding mechanism imparts many desirable pharmacol. benefits including high potency, selectivity, and prolonged target inhibition.  Herein we report the structure-based design, medicinal chem. optimization, and unique ADME assays of our irreversible covalent drug discovery program which culminated in the discovery of compd. 34 (PRN1371), a highly selective and potent FGFR1-4 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpklTuvm1niy7Vg90H21EOLACvtfcHk0liEtqCFvA-z7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK&md5=987069b645d5e0e36ccda5e5c81520b9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00360%26sid%3Dliteratum%253Aachs%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DLaStant%26aufirst%3DJ.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26atitle%3DDiscovery%2520of%2520the%2520irreversible%2520covalent%2520FGFR%2520inhibitor%25208-%25283-%25284-acryloylpiperazin-1-yl%2529propyl%2529-6-%25282%252C6-dichloro-3%252C5-dimethoxyphenyl%2529-2-%2528methylamino%2529pyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-one%2520%2528PRN1371%2529%2520for%2520the%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6516%26epage%3D6527%26doi%3D10.1021%2Facs.jmedchem.7b00360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib: a first in class covalent inhibitor of bruton’s tyrosine kinase</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.2217/fon.14.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.2217%2Ffon.14.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=24941982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=957-967&author=M.+S.+Davidsauthor=J.+R.+Brown&title=Ibrutinib%3A+a+first+in+class+covalent+inhibitor+of+bruton%E2%80%99s+tyrosine+kinase&doi=10.2217%2Ffon.14.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase</span></div><div class="casAuthors">Davids, Matthew S.; Brown, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">957-967</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Ibrutinib (formerly PCI-32765) is a potent, covalent inhibitor of Bruton's tyrosine kinase, a kinase downstream of the B-cell receptor that is crit. for B-cell survival and proliferation.  In preclin. studies, ibrutinib bound to Bruton's tyrosine kinase with high affinity, leading to inhibition of B-cell receptor signaling, decreased B-cell activation and induction of apoptosis.  In clin. studies, ibrutinib has been well-tolerated and has demonstrated profound anti-tumor activity in a variety of hematol. malignancies, most notably chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), leading to US FDA approval for relapsed CLL and MCL.  Ongoing studies are evaluating ibrutinib in other types of non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and Waldenstroem's macrogobulinemia, in larger Phase III studies in CLL and MCL, and in combination studies with monoclonal antibodies and chemotherapy.  Future studies will combine ibrutinib with other promising novel agents currently in development in hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3o_pMnFVskLVg90H21EOLACvtfcHk0lgCFI9d_xMrxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D&md5=345b4e839a830be822d474f62755a022</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.51%26sid%3Dliteratum%253Aachs%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DIbrutinib%253A%2520a%2520first%2520in%2520class%2520covalent%2520inhibitor%2520of%2520bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DFuture%2520Oncol.%26date%3D2014%26volume%3D10%26spage%3D957%26epage%3D967%26doi%3D10.2217%2Ffon.14.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, G. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8249</span>– <span class="NLM_lpage">8267</span>, <span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+V.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+potent+and+selective+EGFR+inhibitor+%28AZD9291%29+of+both+sensitizing+and+T790M+resistance+mutations+that+spares+the+wild+type+form+of+the+receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0lgCFI9d_xMrxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520EGFR%2520inhibitor%2520%2528AZD9291%2529%2520of%2520both%2520sensitizing%2520and%2520T790M%2520resistance%2520mutations%2520that%2520spares%2520the%2520wild%2520type%2520form%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Developing irreversible inhibitors of the protein kinase cysteinome</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&author=Q.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+irreversible+inhibitors+of+the+protein+kinase+cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0lhLYY5FiD81Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520irreversible%2520inhibitors%2520of%2520the%2520protein%2520kinase%2520cysteinome%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almaden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behenna, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho-Schultz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemkens, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson-Fisher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalaie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kephart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafontaine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ornelas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planken, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinrich, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-{(3<i>R</i>,4<i>R</i>)-3-[({5-chloro-2-[(1-methyl-1<i>H</i>-pyrazol-4-yl)amino]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a potent, wt sparing, irreversible inhibitor of T790M-containing EGFR mutants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2024</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01633</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01633" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2005-2024&author=H.+Chengauthor=S.+K.+Nairauthor=B.+W.+Murrayauthor=C.+Almadenauthor=S.+Baileyauthor=S.+Baxiauthor=D.+Behennaauthor=S.+Cho-Schultzauthor=D.+Dalvieauthor=D.+M.+Dinhauthor=M.+P.+Edwardsauthor=J.+L.+Fengauthor=R.+A.+Ferreauthor=K.+S.+Gajiwalaauthor=M.+D.+Hemkensauthor=A.+Jackson-Fisherauthor=M.+Jalaieauthor=T.+O.+Johnsonauthor=R.+S.+Kaniaauthor=S.+Kephartauthor=J.+Lafontaineauthor=B.+Lunneyauthor=K.+K.+C.+Liuauthor=Z.+Liuauthor=J.+Matthewsauthor=A.+Nagataauthor=S.+Niessenauthor=M.+A.+Ornelasauthor=S.+T.+M.+Orrauthor=M.+Pairishauthor=S.+Plankenauthor=S.+Renauthor=D.+Richterauthor=K.+Ryanauthor=N.+Sachauthor=H.+Shenauthor=T.+Smealauthor=J.+Solowiejauthor=S.+Suttonauthor=K.+Tranauthor=E.+Tsengauthor=W.+Vernierauthor=M.+Wallsauthor=S.+Wangauthor=S.+L.+Weinrichauthor=S.+Xinauthor=H.+Xuauthor=M.+J.+Yinauthor=M.+Zientekauthor=R.+Zhouauthor=J.+C.+Kath&title=Discovery+of+1-%7B%283R%2C4R%29-3-%5B%28%7B5-chloro-2-%5B%281-methyl-1H-pyrazol-4-yl%29amino%5D-7H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%7Doxy%29methyl%5D-4-methoxypyrrolidin-1-yl%7Dprop-2-en-1-one+%28PF-06459988%29%2C+a+potent%2C+wt+sparing%2C+irreversible+inhibitor+of+T790M-containing+EGFR+mutants&doi=10.1021%2Facs.jmedchem.5b01633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants</span></div><div class="casAuthors">Cheng, Hengmiao; Nair, Sajiv K.; Murray, Brion W.; Almaden, Chau; Bailey, Simon; Baxi, Sangita; Behenna, Doug; Cho-Schultz, Sujin; Dalvie, Deepak; Dinh, Dac M.; Edwards, Martin P.; Feng, Jun Li; Ferre, Rose Ann; Gajiwala, Ketan S.; Hemkens, Michelle D.; Jackson-Fisher, Amy; Jalaie, Mehran; Johnson, Ted O.; Kania, Robert S.; Kephart, Susan; Lafontaine, Jennifer; Lunney, Beth; Liu, Kevin K.-C.; Liu, Zhengyu; Matthews, Jean; Nagata, Asako; Niessen, Sherry; Ornelas, Martha A.; Orr, Suvi T. M.; Pairish, Mason; Planken, Simon; Ren, Shijian; Richter, Daniel; Ryan, Kevin; Sach, Neal; Shen, Hong; Smeal, Tod; Solowiej, Jim; Sutton, Scott; Tran, Khanh; Tseng, Elaine; Vernier, William; Walls, Marlena; Wang, Shuiwang; Weinrich, Scott L.; Xin, Shuibo; Xu, Haiwei; Yin, Min-Jean; Zientek, Michael; Zhou, Ru; Kath, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2005-2024</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">First generation EGFR TKIs (gefitinib, erlotinib) provide significant clin. benefit for NSCLC cancer patients with oncogenic EGFR mutations.  Ultimately, these patients' disease progresses, often driven by a second-site mutation in the EGFR kinase domain (T790M).  Another liability of the first generation drugs is severe adverse events driven by inhibition of WT EGFR.  As such, our goal was to develop a highly potent irreversible inhibitor with the largest selectivity ratio between the drug-resistant double mutants (L858R/T790M, Del/T790M) and WT EGFR.  A unique approach to develop covalent inhibitors, optimization of reversible binding affinity, served as a cornerstone of this effort.  PF-06459988 was discovered as a novel, third generation irreversible inhibitor, which demonstrates (i) high potency and specificity to the T790M-contg. double mutant EGFRs, (ii) minimal intrinsic chem. reactivity of the electrophilic warhead, (iii) greatly reduced proteome reactivity relative to earlier irreversible EGFR inhibitors, and (iv) minimal activity against WT EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfRspJvDDNKrVg90H21EOLACvtfcHk0lh6agKlE1vnwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslChtQ%253D%253D&md5=b8c07b22033543305964c9e8771f3db5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DNair%26aufirst%3DS.%2BK.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBaxi%26aufirst%3DS.%26aulast%3DBehenna%26aufirst%3DD.%26aulast%3DCho-Schultz%26aufirst%3DS.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DFeng%26aufirst%3DJ.%2BL.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DHemkens%26aufirst%3DM.%2BD.%26aulast%3DJackson-Fisher%26aufirst%3DA.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKephart%26aufirst%3DS.%26aulast%3DLafontaine%26aufirst%3DJ.%26aulast%3DLunney%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMatthews%26aufirst%3DJ.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DOrnelas%26aufirst%3DM.%2BA.%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DPlanken%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DK.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DVernier%26aufirst%3DW.%26aulast%3DWalls%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWeinrich%26aufirst%3DS.%2BL.%26aulast%3DXin%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DM.%2BJ.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%25201-%257B%25283R%252C4R%2529-3-%255B%2528%257B5-chloro-2-%255B%25281-methyl-1H-pyrazol-4-yl%2529amino%255D-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%257Doxy%2529methyl%255D-4-methoxypyrrolidin-1-yl%257Dprop-2-en-1-one%2520%2528PF-06459988%2529%252C%2520a%2520potent%252C%2520wt%2520sparing%252C%2520irreversible%2520inhibitor%2520of%2520T790M-containing%2520EGFR%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2005%26epage%3D2024%26doi%3D10.1021%2Facs.jmedchem.5b01633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, C. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panek, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klohs, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, A. M.</span></span> <span> </span><span class="NLM_article-title">Discovery and structure-activity studies of a novel series of pyrido[2,3-<i>d</i>]pyrimidine tyrosine kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2415</span>– <span class="NLM_lpage">2420</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(97)00445-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1016%2FS0960-894X%2897%2900445-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=2415-2420&author=C.+J.+C.+Connollyauthor=J.+M.+Hambyauthor=M.+C.+Schroederauthor=M.+Barvianauthor=G.+H.+Luauthor=R.+L.+Panekauthor=A.+Amarauthor=C.+Shenauthor=A.+J.+Krakerauthor=D.+W.+Fryauthor=W.+D.+Klohsauthor=A.+M.+Doherty&title=Discovery+and+structure-activity+studies+of+a+novel+series+of+pyrido%5B2%2C3-d%5Dpyrimidine+tyrosine+kinase+inhibitors&doi=10.1016%2FS0960-894X%2897%2900445-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2897%2900445-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252897%252900445-9%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DC.%2BJ.%2BC.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DBarvian%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DAmar%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DC.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DKlohs%26aufirst%3DW.%2BD.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26atitle%3DDiscovery%2520and%2520structure-activity%2520studies%2520of%2520a%2520novel%2520series%2520of%2520pyrido%255B2%252C3-d%255Dpyrimidine%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1997%26volume%3D7%26spage%3D2415%26epage%3D2420%26doi%3D10.1016%2FS0960-894X%2897%2900445-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, C. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boushelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartl, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amar, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinkampf, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patmore, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klohs, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Showalter, H. D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span> <span> </span><span class="NLM_article-title">3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4200</span>– <span class="NLM_lpage">4211</span>, <span class="refDoi"> DOI: 10.1021/jm000161d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000161d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4200-4211&author=A.+M.+Thompsonauthor=C.+J.+C.+Connollyauthor=J.+M.+Hambyauthor=S.+Boushelleauthor=B.+G.+Hartlauthor=A.+M.+Amarauthor=A.+J.+Krakerauthor=D.+L.+Driscollauthor=R.+W.+Steinkampfauthor=S.+J.+Patmoreauthor=P.+W.+Vincentauthor=B.+J.+Robertsauthor=W.+L.+Elliottauthor=W.+Klohsauthor=W.+R.+Leopoldauthor=H.+D.+H.+Showalterauthor=W.+A.+Denny&title=3-%283%2C5-Dimethoxyphenyl%29-1%2C6-naphthyridine-2%2C7-diamines+and+related+2-urea+derivatives+are+potent+and+selective+inhibitors+of+the+FGF+receptor-1+tyrosine+kinase&doi=10.1021%2Fjm000161d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm000161d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000161d%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DConnolly%26aufirst%3DC.%2BJ.%2BC.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DBoushelle%26aufirst%3DS.%26aulast%3DHartl%26aufirst%3DB.%2BG.%26aulast%3DAmar%26aufirst%3DA.%2BM.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DDriscoll%26aufirst%3DD.%2BL.%26aulast%3DSteinkampf%26aufirst%3DR.%2BW.%26aulast%3DPatmore%26aufirst%3DS.%2BJ.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DKlohs%26aufirst%3DW.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3D3-%25283%252C5-Dimethoxyphenyl%2529-1%252C6-naphthyridine-2%252C7-diamines%2520and%2520related%25202-urea%2520derivatives%2520are%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520FGF%2520receptor-1%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4200%26epage%3D4211%26doi%3D10.1021%2Fjm000161d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoon, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crean, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Showalter, H. D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4628</span>– <span class="NLM_lpage">4653</span>, <span class="refDoi"> DOI: 10.1021/jm0500931</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0500931" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4628-4653&author=A.%0AM.+Thompsonauthor=A.+M.+Delaneyauthor=J.+M.+Hambyauthor=M.+C.+Schroederauthor=T.+A.+Spoonauthor=S.+M.+Creanauthor=H.+D.+H.+Showalterauthor=W.+A.+Denny&title=Synthesis+and+structure-activity+relationships+of+soluble+7-substituted+3-%283%2C5-dimethoxyphenyl%29-1%2C6-naphthyridin-2-amines+and+related+ureas+as+dual+inhibitors+of+the+fibroblast+growth+factor+receptor-1+and+vascular+endothelial+growth+factor+receptor-2+tyrosine+kinases&doi=10.1021%2Fjm0500931"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm0500931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0500931%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DSpoon%26aufirst%3DT.%2BA.%26aulast%3DCrean%26aufirst%3DS.%2BM.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520soluble%25207-substituted%25203-%25283%252C5-dimethoxyphenyl%2529-1%252C6-naphthyridin-2-amines%2520and%2520related%2520ureas%2520as%2520dual%2520inhibitors%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor-1%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4628%26epage%3D4653%26doi%3D10.1021%2Fjm0500931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of substituted 1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine derivatives as potent and selective FGFR kinase inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">634</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsVamsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=629-634&author=B.+Zhaoauthor=Y.+Liauthor=P.+Xuauthor=Y.+Daiauthor=C.+Luoauthor=Y.+Sunauthor=J.+Aiauthor=M.+Gengauthor=W.+Duan&title=Discovery+of+substituted+1H-pyrazolo%5B3%2C4-b%5Dpyridine+derivatives+as+potent+and+selective+FGFR+kinase+inhibitors&doi=10.1021%2Facsmedchemlett.6b00066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives as Potent and Selective FGFR Kinase Inhibitors</span></div><div class="casAuthors">Zhao, Bin; Li, Yixuan; Xu, Pan; Dai, Yang; Luo, Cheng; Sun, Yiming; Ai, Jing; Geng, Meiyu; Duan, Wenhu</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">629-634</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fibroblast growth factor receptors (FGFRs) are important targets for cancer therapy.  Herein, we describe the design, synthesis, and biol. evaluation of a novel series of 1H-pyrazolo[3,4-b]pyridine derivs. as potent and selective FGFR kinase inhibitors.  On the basis of its excellent in vitro potency and favorable pharmacokinetic properties, compd. I was selected for in vivo evaluation and showed significant antitumor activity in a FGFR1-driven H1581 xenograft model.  These results indicated that I would be a promising candidate for further drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt1RCtnNDMAbVg90H21EOLACvtfcHk0liZWHR7pg0hKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsVamsb0%253D&md5=08cf7f710e2dfa738c7904965fae0630</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00066%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDuan%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520substituted%25201H-pyrazolo%255B3%252C4-b%255Dpyridine%2520derivatives%2520as%2520potent%2520and%2520selective%2520FGFR%2520kinase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D629%26epage%3D634%26doi%3D10.1021%2Facsmedchemlett.6b00066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schott, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudge, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. G.</span></span> <span> </span><span class="NLM_article-title">Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5003</span>– <span class="NLM_lpage">5012</span>, <span class="refDoi"> DOI: 10.1021/jm3004043</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3004043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5003-5012&author=R.+A.+Normanauthor=A.+K.+Schottauthor=D.+M.+Andrewsauthor=J.+Breedauthor=K.+M.+Footeauthor=A.+P.+Garnerauthor=D.+Oggauthor=J.+P.+Ormeauthor=J.+H.+Pinkauthor=K.+Robertsauthor=D.+A.+Rudgeauthor=A.+P.+Thomasauthor=A.+G.+Leach&title=Protein-ligand+crystal+structures+can+guide+the+design+of+selective+inhibitors+of+the+FGFR+tyrosine+kinase&doi=10.1021%2Fjm3004043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm3004043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3004043%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DSchott%26aufirst%3DA.%2BK.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DGarner%26aufirst%3DA.%2BP.%26aulast%3DOgg%26aufirst%3DD.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DRudge%26aufirst%3DD.%2BA.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26atitle%3DProtein-ligand%2520crystal%2520structures%2520can%2520guide%2520the%2520design%2520of%2520selective%2520inhibitors%2520of%2520the%2520FGFR%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5003%26epage%3D5012%26doi%3D10.1021%2Fjm3004043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richters, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getlik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomassi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Termathe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Wrangowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruetter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlenbrock, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaumann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eppmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kibies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffgaard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menninger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Cuaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinnefeld, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kast, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Targeting drug resistance in EGFR with covalent inhibitors: a structure-based design approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6844</span>– <span class="NLM_lpage">6863</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01082</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6844-6863&author=J.+Engelauthor=A.+Richtersauthor=M.+Getlikauthor=S.+Tomassiauthor=M.+Keulauthor=M.+Termatheauthor=J.+Lategahnauthor=C.+Beckerauthor=S.+Mayer-Wrangowskiauthor=C.+Gruetterauthor=N.+Uhlenbrockauthor=J.+Kruellauthor=N.+Schaumannauthor=S.+Eppmannauthor=P.+Kibiesauthor=F.+Hoffgaardauthor=J.+Heilauthor=S.+Menningerauthor=S.+Ortiz-Cuaranauthor=J.+M.+Heuckmannauthor=V.+Tinnefeldauthor=R.+P.+Zahediauthor=M.+L.+Sosauthor=C.+Schultz-Fademrechtauthor=R.+K.+Thomasauthor=S.+M.+Kastauthor=D.+Rauh&title=Targeting+drug+resistance+in+EGFR+with+covalent+inhibitors%3A+a+structure-based+design+approach&doi=10.1021%2Facs.jmedchem.5b01082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach</span></div><div class="casAuthors">Engel, Julian; Richters, Andre; Getlik, Matthaeus; Tomassi, Stefano; Keul, Marina; Termathe, Martin; Lategahn, Jonas; Becker, Christian; Mayer-Wrangowski, Svenja; Gruetter, Christian; Uhlenbrock, Niklas; Kruell, Jasmin; Schaumann, Niklas; Eppmann, Simone; Kibies, Patrick; Hoffgaard, Franziska; Heil, Jochen; Menninger, Sascha; Ortiz-Cuaran, Sandra; Heuckmann, Johannes M.; Tinnefeld, Verena; Zahedi, Rene P.; Sos, Martin L.; Schultz-Fademrecht, Carsten; Thomas, Roman K.; Kast, Stefan M.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6844-6863</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases represent one of the prime targets in cancer therapy, as the dysregulation of these elementary transducers of extracellular signals, like the epidermal growth factor receptor (EGFR), contributes to the onset of cancer, such as non-small cell lung cancer (NSCLC).  Strong efforts were directed to the development of irreversible inhibitors and led to compd. CO-1686, which takes advantage of increased residence time at EGFR by alkylating Cys797 and thereby preventing toxic effects.  Here, the authors present a structure-based approach, rationalized by subsequent computational anal. of conformational ligand ensembles in soln., to design novel and irreversible EGFR inhibitors based on a screening hit that was identified in a phenotype screen of 80 NSCLC cell lines against approx. 1500 compds.  Using protein x-ray crystallog., the authors deciphered the binding mode in engineered cSrc (T338M/S345C), a validated model system for EGFR-T790M, which constituted the basis for further rational design approaches.  Chem. synthesis led to further compd. collections that revealed increased biochem. potency and, in part, selectivity toward mutated (L858R and L858R/T790M) vs. nonmutated EGFR.  Further cell-based and kinetic studies were performed to substantiate the authors initial findings.  Utilizing proteolytic digestion and nano-LC-MS/MS anal., the authors confirmed the alkylation of Cys797.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNGJPIuqoVObVg90H21EOLACvtfcHk0lisEG6A4WpdNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsrvM&md5=d5264a2a99d7752af0e587f23aeb7723</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01082%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DTermathe%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DGruetter%26aufirst%3DC.%26aulast%3DUhlenbrock%26aufirst%3DN.%26aulast%3DKruell%26aufirst%3DJ.%26aulast%3DSchaumann%26aufirst%3DN.%26aulast%3DEppmann%26aufirst%3DS.%26aulast%3DKibies%26aufirst%3DP.%26aulast%3DHoffgaard%26aufirst%3DF.%26aulast%3DHeil%26aufirst%3DJ.%26aulast%3DMenninger%26aufirst%3DS.%26aulast%3DOrtiz-Cuaran%26aufirst%3DS.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DTinnefeld%26aufirst%3DV.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DKast%26aufirst%3DS.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DTargeting%2520drug%2520resistance%2520in%2520EGFR%2520with%2520covalent%2520inhibitors%253A%2520a%2520structure-based%2520design%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6844%26epage%3D6863%26doi%3D10.1021%2Facs.jmedchem.5b01082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingipalli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sha, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span> <span> </span><span class="NLM_article-title">Utilization of structure-based design to identify novel, irreversible inhibitors of EGFR harboring the T790M mutation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=514-519&author=E.+J.+Hennessyauthor=C.+Chuaquiauthor=S.+Ashtonauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=J.+E.+Debreczeniauthor=C.+Eberleinauthor=L.+Gingipalliauthor=T.+C.+M.+Klinowskaauthor=J.+P.+Ormeauthor=L.+Shaauthor=X.+Wu&title=Utilization+of+structure-based+design+to+identify+novel%2C+irreversible+inhibitors+of+EGFR+harboring+the+T790M+mutation&doi=10.1021%2Facsmedchemlett.6b00058"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00058%26sid%3Dliteratum%253Aachs%26aulast%3DHennessy%26aufirst%3DE.%2BJ.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DGingipalli%26aufirst%3DL.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%2BM.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSha%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DX.%26atitle%3DUtilization%2520of%2520structure-based%2520design%2520to%2520identify%2520novel%252C%2520irreversible%2520inhibitors%2520of%2520EGFR%2520harboring%2520the%2520T790M%2520mutation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D514%26epage%3D519%26doi%3D10.1021%2Facsmedchemlett.6b00058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truesdale, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennisi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alligood, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L.</span></span> <span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">6652</span>– <span class="NLM_lpage">6659</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells&doi=10.1158%2F0008-5472.CAN-04-1168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0lg4-ioq6ZSBpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659%26doi%3D10.1158%2F0008-5472.CAN-04-1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahleda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dienstmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Italiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platero, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuyckens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee-Kishore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peddareddigari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">3401</span>– <span class="NLM_lpage">3408</span>, <span class="refDoi"> DOI: 10.1200/JCO.2014.60.7341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=10.1200%2FJCO.2014.60.7341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=26324363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFGrtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=3401-3408&author=J.+Taberneroauthor=R.+Bahledaauthor=R.+Dienstmannauthor=J.+R.+Infanteauthor=A.+Mitaauthor=A.+Italianoauthor=E.+Calvoauthor=V.+Morenoauthor=B.+Adamoauthor=A.+Gazzahauthor=B.+Zhongauthor=S.+J.+Plateroauthor=J.+W.+Smitauthor=K.+Stuyckensauthor=M.+Chatterjee-Kishoreauthor=J.+Rodonauthor=V.+Peddareddigariauthor=F.+R.+Luoauthor=J.+C.+Soria&title=Phase+I+dose-escalation+study+of+JNJ-42756493%2C+an+oral+pan-fibroblast+growth+factor+receptor+inhibitor%2C+in+patients+with+advanced+solid+tumors&doi=10.1200%2FJCO.2014.60.7341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation study of JNJ-42756493, an oral Pan-Fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors</span></div><div class="casAuthors">Tabernero, Josep; Bahleda, Rastislav; Dienstmann, Rodrigo; Infante, Jeffrey R.; Mita, Alain; Italiano, Antoine; Calvo, Emiliano; Moreno, Victor; Adamo, Barbara; Gazzah, Anas; Zhong, Bob; Platero, Suso J.; Smit, Johan W.; Stuyckens, Kim; Chatterjee-Kishore, Moitreyee; Radon, Jordi; Peddareddigari, Vijay; Luo, Feng R.; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3401-3408</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: JNJ-42756493 is an orally administered pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.  This first-in-human study evaluates the safety, pharmacokinetics, and pharmaco-dynamics and defines the recommended phase II dose (RP2D) of JNJ-42756493.  Patients and Methods: Eligible patients with advanced solid tumors received escalating doses of JNJ-42756493 from 0.5 to 12 mg administered continuously daily or JNJ-42756493 10 or 12 mg administered intermittently (7 days on/7 days off).  Results: Sixty-five patients were enrolled.  The most common treatment-emergent adverse events included hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), constipation (34%), decreased appetite (32%), and dysgeusia (31%).  Twenty-seven patients (42%) experi- enced grade ≥ 3 treatment-emergent adverse events, and one dose-limiting toxicity of grade 3 ALT elevation was obsd. at 12 mg daily.  Maximum-tolerated dose was not defined.  Nine milligrams daily was considered as the initial RP2D; however, tolerability was improved with intermittent schedules, and 10 mg administered on a 7-days-on/7-days-off schedule was considered the final RP2D.  Pharmacokinetics were linear, dose proportional, and predictable, with a half-life of 50 to 60 h.  Dose-dependent elevations in serum phosphate, a manifestation of pharmacodynamic effect, occurred in all patients starting at 4 mg daily.  Among 23 response- evaluable patients with tumor FGFR pathway alterations, four confirmed responses and one unconfirmed partial response were obsd. in patients with glioblastoma and urothelial and endometrial cancer (all with FGFR2 or FGFR3 translocations); 16 patients had stable disease.  Conclusion: JNJ-42756493 administered at 10 mg on a 7-days-on/7-days-off schedule achieved exposures at which clin. responses were obsd., demonstrated pharmacodynamic biomarker activity, and had a manageable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo08TfKyvsabVg90H21EOLACvtfcHk0lg4-ioq6ZSBpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFGrtb4%253D&md5=6d4a6b3c2f06f3d5d1a490cf9ffe44c5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.60.7341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.60.7341%26sid%3Dliteratum%253Aachs%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DBahleda%26aufirst%3DR.%26aulast%3DDienstmann%26aufirst%3DR.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMita%26aufirst%3DA.%26aulast%3DItaliano%26aufirst%3DA.%26aulast%3DCalvo%26aufirst%3DE.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DAdamo%26aufirst%3DB.%26aulast%3DGazzah%26aufirst%3DA.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DPlatero%26aufirst%3DS.%2BJ.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DStuyckens%26aufirst%3DK.%26aulast%3DChatterjee-Kishore%26aufirst%3DM.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DPeddareddigari%26aufirst%3DV.%26aulast%3DLuo%26aufirst%3DF.%2BR.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DPhase%2520I%2520dose-escalation%2520study%2520of%2520JNJ-42756493%252C%2520an%2520oral%2520pan-fibroblast%2520growth%2520factor%2520receptor%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D3401%26epage%3D3408%26doi%3D10.1200%2FJCO.2014.60.7341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GQI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GQI','PDB','3GQI'); return false;">PDB: 3GQI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R6V" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R6V','PDB','4R6V'); return false;">PDB: 4R6V</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i120"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01843">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_38761"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01843">10.1021/acs.jmedchem.7b01843</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthesis of requisite boronic acids <b>23a</b>–<b>h</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01843/suppl_file/jm7b01843_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01843/suppl_file/jm7b01843_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01843/suppl_file/jm7b01843_si_001.csv">jm7b01843_si_001.csv (3.24 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01843/suppl_file/jm7b01843_si_002.pdf">jm7b01843_si_002.pdf (646.87 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R6V">4R6V</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01843&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-20%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01843%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01843" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994e8639133d12","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
